---
document_datetime: 2023-09-21 20:55:21
document_pages: 111
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-003820-ii-0108-epar-assessment-report-variation_en.pdf
document_name: keytruda-h-c-003820-ii-0108-epar-assessment-report-variation_en.pdf
version: success
processing_time: 247.7213257
conversion_datetime: 2026-01-01 22:36:16.435017
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

16 December 2021 EMA/33031/2022 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Keytruda

International non-proprietary name: pembrolizumab

Procedure No. EMEA/H/C/003820/II/0108

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 6                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................7                                                 |
| 2. Scientific discussion................................................................................                   | 7                                                                                                         |
| 2.1. Introduction                                                                                                          | ........................................................................................................7 |
| 2.1.1. Problem statement                                                                                                   | ............................................................................................7             |
| 2.1.2. About the product                                                                                                   | .............................................................................................8            |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific                                                  | advice........9                                                                                           |
| 2.1.4. General comments on compliance with GCP........................................................                     | 10                                                                                                        |
| 2.2. Non-clinical aspects............................................................................................      | 10                                                                                                        |
| 2.2.1. Ecotoxicity/environmental risk assessment.........................................................                  | 10                                                                                                        |
| 2.3. Clinical aspects                                                                                                      | .................................................................................................. 10     |
| 2.3.1. Introduction....................................................................................................    | 10                                                                                                        |
| 2.3.2. Clinical Pharmacology                                                                                               | ...................................................................................... 13                 |
| 2.3.3. Discussion and Conclusions on clinical pharmacology                                                                 | ........................................... 13                                                            |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 13     |
| 2.4.1. Dose response study(ies) .................................................................................          | 13                                                                                                        |
| 2.4.2. Main study(ies)                                                                                                     | ............................................................................................... 13        |
| 2.4.3. Discussion on clinical efficacy............................................................................         | 70                                                                                                        |
| 2.4.1. Conclusions on the clinical efficacy ....................................................................           | 73                                                                                                        |
| 2.5. Clinical safety                                                                                                       | .................................................................................................... 73   |
| 2.5.1. Discussion on clinical safety............................................................................           | 101                                                                                                       |
| 2.5.2. Conclusions on clinical safety..........................................................................            | 103                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                          | ................................................................................................... 104   |
| 2.6. Risk management plan                                                                                                  | ..................................................................................... 104                 |
| 2.7. Update of the Product information......................................................................               | 106                                                                                                       |
| 2.7.1. User consultation ..........................................................................................        | 106                                                                                                       |
| 2.7.2. Additional monitoring.....................................................................................          | 107                                                                                                       |
| 3. Benefit-Risk Balance...........................................................................                         | 107                                                                                                       |
| 3.1. Therapeutic Context .........................................................................................         | 107                                                                                                       |
| 3.1.1. Disease or condition ......................................................................................         | 107                                                                                                       |
| 3.1.2. Available therapies and unmet medical need.....................................................                     | 107                                                                                                       |
| 3.1.3. Main clinical studies.......................................................................................        | 108                                                                                                       |
| 3.2. Favourable effects............................................................................................        | 108                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects...........................................                     | 108                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................         | 108                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | ....................................... 109                                                               |
| 3.6. Effects Table....................................................................................................     | 109                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................                 | 110                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects............................................                       | 110                                                                                                       |
| 3.7.2. Balance of benefits and risks                                                                                       | .......................................................................... 110                            |
| 3.7.3. Additional considerations on the benefit-risk balance                                                               | ......................................... 110                                                             |
| 3.8. Conclusions                                                                                                           | ..................................................................................................... 110 |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations  ............................................................................... 110

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| ADA           | antidrug antibodies                                                                                  |
|---------------|------------------------------------------------------------------------------------------------------|
| ApaT          | all participants as treated                                                                          |
| BICR          | blinded independent central review                                                                   |
| cHL           | classic Hodgkin lymphoma                                                                             |
| CI            | confidence interval                                                                                  |
| COVID-19      | Coronavirus disease caused by severe acute respiratory syndrome                                      |
| CPS           | combined positive score                                                                              |
| CSR           | clinical study report                                                                                |
| CT            | computed tomography                                                                                  |
| DFS           | disease-free survival                                                                                |
| DRSS          | disease recurrence-specific survival                                                                 |
| ECOG PS       | Eastern Cooperative Oncology Group performance status                                                |
| EDR           | early discrepancy rate                                                                               |
| EFS           | event-free survival                                                                                  |
| eDMC          | external Data Monitoring Committee                                                                   |
| EORTC QLQ-C30 | European Organization for the Research and Treatment of Cancer Quality of life Questionnaire Core 30 |
| EQ-5D-5L      | EuroQoL 5 Dimensions 5 Levels                                                                        |
| E-R           | exposure-response                                                                                    |
| ESMO          | European Society of Medical Oncology                                                                 |
| FKSI-DRS      | Functional Assessment of Cancer Therapy Kidney Symptom index - Disease- related Symptoms             |
| GC            | gastric carcinoma                                                                                    |
| HCC           | hepatocellular carcinoma                                                                             |
| HR            | hazard ratio                                                                                         |
| HNSCC         | head and neck squamous cell carcinoma                                                                |
| IA1           | first interim analysis                                                                               |
| ITT           | intent-to-treat                                                                                      |
| KM            | Kaplan-Meier                                                                                         |
| LDR           | late discrepancy rate                                                                                |
| MRI           | magnetic resonance imaging                                                                           |
| MSI-H         | microsatellite instability-high                                                                      |
| NCCN          | National Comprehensive Cancer Network                                                                |

<div style=\"page-break-after: always\"></div>

| NED         | no evidence of disease                      |
|-------------|---------------------------------------------|
| OS          | overall survival                            |
| PD-1        | programmed cell death 1                     |
| PD-L1       | programmed cell death ligand 1              |
| PFS2        | progression-free survival 2                 |
| PK          | pharmacokinetic                             |
| PMBCL       | primary mediastinal large B-cell lymphoma   |
| PRO         | patient-reported outcome                    |
| Q2W/Q3W/Q6W | every 2/3/6 weeks                           |
| QoL         | quality of life                             |
| RCC         | renal cell carcinoma                        |
| sSAP        | supplemental statistical analysis plan      |
| UC          | urothelial carcinoma                        |
| US          | United States                               |
| VEGF        | vascular endothelial growth factor          |
| VEGFR       | vascular endothelial growth factor receptor |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Merck Sharp &amp; Dohme B.V. submitted to the European Medicines Agency on 25 June 2021 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Update of sections 4.1, 4.2 and 5.1 of the SmPC in order to extend the existing therapeutic indications for Keytruda to include the adjuvant treatment in monotherapy of adults with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.  The Package Leaflet are updated accordingly. The RMP version 35.1 has also been submitted

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  (an)  EMA  Decision(s) P/0043/2018 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP (EMEA-001474-PIP01-13-M01) covering the condition 'Treatment of all  conditions  included  in  the  category  of  malignant  neoplasms  (except  nervous  system, haematopoietic and lymphoid tissue) was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Derogation(s) of market exclusivity

NA

## Scientific advice

The Applicant consulted CHMP on the clinical development program for adjuvant RCC (EMEA/H/SA/2437/16/2016/II).

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Co-Rapporteur appointed by the CHMP was:

Co-Rapporteur:

Jan Mueller-Berghaus

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 25 June 2021      |
| Start of procedure:                                  | 17 July 2021      |
| CHMP Co-Rapporteur Assessment Report                 | 13 September 2021 |
| CHMP RapporteurAssessmentReport(comments)            | 10 October 2021   |
| PRAC RapporteurAssessment Report                     | 14 September 2021 |
| PRAC Outcome                                         | 30 September 2021 |
| CHMPmemberscomments                                  | 04October 2021    |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 07October 2021    |
| Request for supplementary information (RSI)          | 14October2021     |
| CHMP Co-Rapporteur Assessment Report                 | 22 November 2021  |
| PRAC Rapporteur Assessment Report                    | 23 November 2021  |
| PRAC members comments                                | n/a               |
| Updated PRAC Rapporteur Assessment Report            | n/a               |
| PRAC Outcome                                         | 02 December 2021  |
| CHMP members comments                                | 06 December2021   |
| Updated CHMP Rapporteur Assessment Report            | 09 December 2021  |
| Opinion                                              | 16 December 2021  |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1.Problem statement

This application concerns an extension of indication for pembrolizumab (Keytruda) to include the adjuvant treatment in monotherapy of adults with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastaticlesions.

## Diseaseor condition,Epidemiology,Biological Feature

Renal cell carcinoma(RcC)represents the sixthmost common cancerinmen and the eighth most common cancer in women, accounting for 3%-4% of all adult malignancies in the US (Siegel et al. CA A Cancer J Clin.2019). In 2020, an estimated 138,611 new cases of kidney cancer were expected to be

<div style=\"page-break-after: always\"></div>

diagnosed in Europe with approximately 54,054 people expected to die from the disease (GLOBOCAN, 2020).

Well-known risk factors for RCC are cigarette smoking, obesity and hypertension (Chow et al. 2010).

Renal cell carcinoma generally resists both traditional chemotherapy and radiation therapy. Surgical resection can be curative for patients presenting with localized disease. However, one third of patients present with regional or distant metastases and the 5-year survival rate for metastatic disease is approximately 12%. Of patients with localized RCC treated with nephrectomy with curative intent, approximately one quarter relapse at distant sites. The prognosis in these cases is poor (Choueiri and Motzer 2017). Advanced RCC entails both locally advanced disease that is not amenable to local therapy, i.e. curative surgery or radiation therapy, as well as metastatic disease. Advanced RCC thus requires systemic treatment. There are currently no approved adjuvant treatments for RCC and observation remains the standard of care after nephrectomy.

## State the claimed therapeutic indication

The proposed new indication for Keytruda in this procedure is:

'KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with RCC at intermediatehigh or high-risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.'

## Management

Patients diagnosed with renal cancer are usually managed with nephron-sparing or total nephrectomy. However, a significant percentage of patients will develop recurrent disease and eventually die of RCC. Most patients with intermediate-high or high-risk lesions will experience recurrence within 2 to 3 years following surgery. These patients have a higher incidence of metastasis at the time of disease recurrence. The estimated 5-year survival of patients with localized low-, intermediate-, and high-risk RCC is approximately 92%, 67%, and 44% (respectively), and decreases to 12% in metastatic RCC patients.

Currently, there is no globally accepted standard of care in adjuvant RCC, including patients with resected metastatic disease (M1 NED). NCCN and ESMO guidelines recommend a clinical trial as an alternative adjuvant option, while post-nephrectomy surveillance (category 2A) and adjuvant sunitinib (category 3) are also recommended in the 2021 NCCN guidelines. The EMA, however, has not approved adjuvant therapy with sunitinib. Therefore, novel treatments in the adjuvant setting are needed to prevent disease recurrence in patients with RCC at intermediate-high or high risk of recurrence.

## 2.1.2. About the product

Pembrolizumab is a humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to inhibit the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and, ultimately, immune rejection.

Currently, Keytruda is approved in the EU (SmPC Keytruda):

- as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.
- as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.
- as monotherapy is indicated for the first line treatment of metastatic non-small cell lung

<div style=\"page-break-after: always\"></div>

carcinoma in adults whose tumours express PD L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.

- in combination with pemetrexed and platinum chemotherapy, is indicated for the first line treatment of metastatic non squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations.
- in combination with carboplatin and either paclitaxel or nab paclitaxel, is indicated for the first line treatment of metastatic squamous non-small cell lung carcinoma in adults.
- as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma in adults whose tumours express PD L1 with a ≥ 1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA.
- as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.
- as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma
- as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin containing chemotherapy and whose tumours express PD L1 with a combined positive score (CPS) ≥ 10.
- as monotherapy or in combination with platinum and 5 fluorouracil (5 FU) chemotherapy, is indicated for the first line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD L1 with a CPS ≥ 1.
- as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD L1 with a ≥ 50% TPS and progressing on or after platinum containing chemotherapy.
- in combination with axitinib, is indicated for the first line treatment of advanced renal cell carcinoma in adults.
- in combination with lenvatinib first line treatment of adults with advanced renal cell carcinoma (RCC)
- as monotherapy is indicated for the first line treatment of metastatic microsatellite instability high (MSI H) or mismatch repair deficient (dMMR) colorectal cancer in adults.
- in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the firstline treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PDL1 with a CPS ≥ 10.
- in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease
- in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

Scientific Advice was sought from CHMP on the adequacy of the design and statistical analysis of a

<div style=\"page-break-after: always\"></div>

phase 3 study to support the proposed indication. The overall design and statistical plan of the pivotal study for the adjuvant treatment of RCC (KEYNOTE-564) were generally agreed to. As part of the discussion, it was noted that the proposed eligibility criteria were considered to result in a heterogeneous patient population with regard to prognosis and risk of relapse due to inclusion of M1 NED patients, and that data to support a filing should be sufficiently mature.

## 2.1.4. General comments on compliance with GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

According to the Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00) proteins are exempted from the submission of ERA studies because they are unlikely to result in significant risk to the environment. Pembrolizumab is a protein, therefore an ERA has not been submitted by the MAH. This is acceptable.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

Table 1 Overview of the KEYTRUDA RCC Clinical Development Program

| Study Number Status NCT Number                     | Design                                                                                                                                                 | Population                                            | Dosage Regimen                                                                                                                | Primary Endpoint(s)                       |
|----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| KEYNOTE-035 (Study A4061079) Completed NCT02133742 | Phase 1b, open-label, dose- finding study to evaluate the safety, pharmacokinetics, and pharmacodynamics of axitinib in combination with pembrolizumab | Participants with previously untreated advanced ccRCC | Dose-finding: Axitinib: 5 mg BID a + pembrolizumab 2 mg/kg Q3W Dose Expansion Axitinib 5 mg BID b + pembrolizumab 2 mg/kg Q3W | Determinatio n of MTD for axitinib Safety |

<div style=\"page-break-after: always\"></div>

| Study Number Status NCT Number                         | Design                                                                                                                                                                        | Population                                                                                                                                                                                                                                                            | Dosage Regimen                                                                                                                                              | Primary Endpoint(s)                                            |
|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| KEYNOTE-146 Ongoing; closed to enrollment NCT02501096  | Phase 1b/2, open-label, multicenter study to evaluate pembrolizumab and lenvatinib in selected solid tumors                                                                   | Phase 1b: Participants with predominantly ccRCC who have progressed after treatment with approved therapies or for which there are no standard therapies available Phase 2: Participants with predominantly ccRCC who have received up to 2 lines of systemic therapy | Cohort 2 (RCC): Phase 1b: Pembrolizumab 200 mg Q3W + lenvatinib 24 mg/day c Phase 2: Pembrolizumab 200 mg Q3W + lenvatinib 20 mg/day d                      | Determinatio n of MTD (Phase 1b) ORR using irRECIST at Week 24 |
| KEYNOTE-426 Ongoing; closed for enrollment NCT02853331 | Phase 3, open-label, multicenter, global study to evaluate the efficacy and safety of pembrolizumab in combination with axitinib versus sunitinib monotherapy                 | Treatment-naïve participants with advanced ccRCC                                                                                                                                                                                                                      | Arm 1: Pembrolizumab 200 mg Q3W + axitinib 5 mg BID Arm 2: Sunitinib 50 mg QD; 4 weeks on and 2 weeks off                                                   | PFS, OS                                                        |
| KEYNOTE-427 Ongoing; closed for enrollment NCT02853344 | Phase 2, open-label, multicenter, global study to evaluate the efficacy and safety of pembrolizumab in locally advanced/metastatic RCC                                        | Treatment-naïve participants with advanced ccRCC (Cohort A) or nccRCC (Cohort B)                                                                                                                                                                                      | Pembrolizumab 200 mg Q3W                                                                                                                                    | ORR                                                            |
| KEYNOTE-564 Ongoing; closed to enrollment NCT03142334  | Phase 3, randomized, double-blind, placebo- controlled, multicenter, global study to evaluate the efficacy and safety of pembrolizumab as adjuvant treatment post nephrectomy | Participants with RCC at intermediate-high risk or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic disease                                                                                                         | Arm 1: Pembrolizumab 200 mg Q3W Arm 2: Placebo (normal saline) Q3W                                                                                          | DFS                                                            |
| KEYNOTE-581 Ongoing; closed to enrollment NCT02811861  | Phase 3, open-label, multicenter, global study to evaluate the efficacy and safety of lenvatinib + pembrolizumab or lenvatinib + everolimus versus sunitinib                  | Treatment-naïve participants with advanced ccRCC                                                                                                                                                                                                                      | Arm A: lenvatinib 18 mg QD + everolimus 5 mg QD Arm B: lenvatinib 20 mg QD + pembrolizumab 200 mg Q3W Arm C: Sunitinib 50 mg QD; 4 weeks on and 2 weeks off | PFS                                                            |
| KEYNOTE-679                                            | Phase 3, randomized, open-                                                                                                                                                    | Participants with                                                                                                                                                                                                                                                     | Group 1: Pembrolizumab                                                                                                                                      | ORR                                                            |

<div style=\"page-break-after: always\"></div>

| Study Number Status NCT Number             | Design                                                                                                                                 | Population                                                                                                                                                                  | Dosage Regimen                                                                                                                                                                                                                                                                                                                                                                                                               | Primary Endpoint(s)                                       |
|--------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|
| Ongoing, enrollment terminated NCT03260894 | label, parallel-group study to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared with sunitinib or pazopanib | locally advanced/metastatic ccRCC who have not received prior systemic therapy                                                                                              | 200 mg Q3W + epacadostat 100 mg BID Group 2: Sunitinib 50 mg QD; 4 weeks on and 2 weeks off or pazopanib 800 mg QD                                                                                                                                                                                                                                                                                                           |                                                           |
| MK-3475- U03A Ongoing NCT04626479          | Phase 1b/2 parallel, rolling- arm study of immune and targeted combination therapies                                                   | Treatment-naïve participants with advanced ccRCC                                                                                                                            | Arm 1: MK-1308A (coformulation of 25 mg of MK- 1308 and 400 mg of pembrolizumab) Q6W and 20 mg of lenvatinib QD Arm 2: MK-4280A (coformulation of 800 mg MK- 4280 and 200 mg of pembrolizumab) Q3W and 20 mg of lenvatinib QD Arm 4: 120 mg of belzutifan QD, 400 mg of pembrolizumab Q6W, and 20 mg lenvatinib QD Reference arm: 400 mg of pembrolizumab Q6W and 20 mg lenvatinib QD                                        | DLTs, AEs, discontinuati ons of treatment due to AEs, ORR |
| MK-3475- U03B Ongoing NCT04626518          | Phase 1b/2 parallel, rolling- arm study of immune and targeted combination therapies                                                   | Participants who experienced disease progression on or after receiving systemic treatment for advanced disease with PD-(L)1 checkpoint inhibitors and a VEGF- TKI (2L+ RCC) | Arm 1: MK-1308A (coformulation of 25 mg of MK- 1308 and 400 mg of pembrolizumab) Q6W Arm 2: MK-4280A (coformulation of 800 mg MK- 4280 and 200 mg of pembrolizumab) Q3W Arm 3: 800 mg of MK-4830 and 200 mg of pembrolizumab Q3W Arm 4: 120 mg of belzutifan QD and 400 mg of pembrolizumab Q6W Arm 5: 120 mg of belzutifan QD and 20 mg of lenvatinib QD Reference arm: 400 mg of pembrolizumab Q6W and 20 mg lenvatinib QD | DLTs, AEs, discontinuati ons of treatment due to AEs, ORR |

<div style=\"page-break-after: always\"></div>

| Study             |        |            |                | Primary     |
|-------------------|--------|------------|----------------|-------------|
| Status NCT Number | Design | Population | Dosage Regimen | Endpoint(s) |

2L=second-line; AE=adverse event; BID=twice daily; cc=clear cell; DFS=disease-free survival; DLT=dose-limiting toxicity; irRECIST=immune-related Response Evaluation Criteria for Solid Tumors; MTD=maximum tolerated dose; ncc=nonclear cell; ORR=objective response rate; OS=overall survival; PD-(L)1=programmed cell death (ligand) 1; PFS=progression-free survival; Q3W=every 3 weeks; Q6W=every 6 weeks; QD=once daily; RCC=renal cell carcinoma; TKI=tyrosine kinase inhibitor; VEGF=vascular endothelial growth factor.

- a The starting dose of axitinib was 5 mg but could be reduced based on dose-limiting toxicities.
- b The MTD was determined to be 5 mg BID.
- c Phase 1b was a dose-finding phase to determine the MTD. The starting dose of lenvatinib was 24 mg but could be reduced based on dose-limiting toxicities.
- d The MTD was determined to be 20 mg/day.

## 2.3.2. Clinical Pharmacology

No new pharmacology data were submitted in support of this application.

## 2.3.3. Discussion and Conclusions on clinical pharmacology

No additional data have been provided with this submission which is considered acceptable as the clinical pharmacology properties of pembrolizumab were described in detail in the original marketing application and previous supplemental applications with new clinical data are consistent with results in the original marketing application. Available clinical pharmacology data are considered sufficient to support this application

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

No formal dose-response studies have been carried out for the adjuvant RCC indication. Pembrolizumab dose and regimen used in the pivotal KEYNOTE-564 study 200 mg Q3W IV is the dosage currently approved in combination with chemotherapy for other indications (NSCLC, HNSCC).

## 2.4.2. Main study(ies)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Study Design

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Methods

## Study participants

## Key inclusion criteria:

- Histologically confirmed diagnosis of RCC with clear cell component with or without sarcomatoid features by local review
- Had intermediate-high risk, high-risk, or M1 NED RCC as defined by the following pathological tumor-node-metastasis and Fuhrman grading status:
- Intermediate-high risk RCC
- pT2, Grade 4 or sarcomatoid, N0, M0
- pT3, any grade , N0, M0
- High-risk RCC
- pT4, any grade, N0, M0
- pT any stage, any grade, N+, M0
- M1 NED RCC participants who presented not only with the primary kidney tumor, but also solid, isolated, soft tissue metastases that could be completely resected at one of the following:
- the time of nephrectomy (synchronous) or,

<div style=\"page-break-after: always\"></div>

◦ ≤ 1 year from nephrectomy (metachronous)

- Have no prior systemic therapy for advanced RCC
- Have ECOG PS 0 or 1
- Underwent a partial nephroprotective or radical complete nephrectomy (and complete resection of solid, isolated, soft tissue metastatic lesion(s) in M1 NED participants) with negative surgical margins ≥ 4 weeks prior to the time of screening
- Was tumor free (CT or MRI of the brain, chest, abdomen, and pelvis, and a bone scan ≤ 28 days from randomization) as assessed by the investigator

## Exclusion Criteria

Participants were excluded from the study if they had any of the following:

- Major surgery, other than nephrectomy and/or resection of pre-existing metastases for M1 NED participants, within 12 weeks prior to randomization
- Received prior radiotherapy for RCC.
- Have pre-existing brain or bone metastatic lesion.
- Have residual thrombus post nephrectomy in the vena renalis or vena cava.
- Have other medical conditions or history that would interfere with the participant's participation for the full duration of the study, or was not in the best interest of the participant to participate

## Treatments

Pembrolizumab 200 mg or matching placebo (saline 200 mg infusion) were administered intravenously Q3W for a total of 17 cycles or 1 year.

## Objectives/Endpoints

Study objectives are summarized in the Table 1

Table 2 Study objectives and endpoints

<div style=\"page-break-after: always\"></div>

| Objective/Hypothesis                                                                                                                                                                                  | Endpoint(s)                                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                             |
| Objective: To compare DFS as assessed by the investigator for participants treated with pembrolizumab vs those receiving placebo Hypothesis: Pembrolizumab is superior to placebo with respect to DFS | DFS as assessed by the investigator: time from randomization to the first documented local recurrence, or occurrence of distant kidney cancer metastasis(es), or death due to any cause, whichever occurs first                                                                                                                                                             |
| Secondary                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                             |
| Key Secondary                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                             |
| Objective: To compare OS for participants treated with pembrolizumab vs those receiving placebo Hypothesis: Pembrolizumab is superior to placebo with respect to OS                                   | OS: time from randomization to death due to any cause                                                                                                                                                                                                                                                                                                                       |
| Other Secondary                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                             |
| To compare the safety and tolerability profiles for participants treated with pembrolizumab vs those receiving placebo                                                                                | AEs, SAEs, AEs leading to discontinuation, deaths, laboratory values, and vital signs                                                                                                                                                                                                                                                                                       |
| To compare measures of DRSS as assessed by the investigator, in participants treated with pembrolizumab vs those receiving placebo                                                                    | DRSSl as assessed by the investigator: time from randomization to the first documented local recurrence of RCC DRSS2 as assessed by the investigator: time from randomization to the first documented local recurrence with visceral lesion or occurrence of distant kidney cancer metastasis(es) with visceral lesion, whichever occurs first                              |
| To compare EFS as assessed by the blinded independent radiology review for participants treated with pembrolizumab vs those receiving placebo                                                         | EFS is to be assessed by BICR. EFSis defined as time from randomization to the first documented local recurrence or occurrence of distant kidney cancer metastasis(es) among participants, which by BICR were considered M0/M1 NED: or disease progression among participants, which by BICR were considered to have Ml, or death due to any cause, whichever occurs first. |

<div style=\"page-break-after: always\"></div>

| Objective/Hypothesis                                                                                                                                                                                               | Endpoint(s)                                                                                                                                                                                                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To compare DFS and OS according to participants' PD-L1 expression status (positive, negative) for participants treated with pembrolizumab vs those receiving placebo                                               | DFS as assessed by the investigator: time from randomization to the first documented local recurrence, or occurrence of distant kidney cancer metastasis(es), or death due to any cause, whichever occurs first OS: time from randomization to death due to any cause |
| To evaluate PROs with EORTC-QLQ-C30 and the FKSI-DRS                                                                                                                                                               | Mean change from baseline in EORTC QLQ-C30 global health status/quality of life scores Mean change from baseline in EORTC QLQ-C30 functional subscales: physical functioning Mean change from baseline in FKSI-DRS                                                    |
| Tertiary/Exploratory                                                                                                                                                                                               |                                                                                                                                                                                                                                                                       |
| To evaluate PK parameters and the presence of ADA                                                                                                                                                                  | PK parameters (clearance and volume of distribution) ADA to pembrolizumab                                                                                                                                                                                             |
| To identify molecular (genomic, metabolic. and/or proteomic) biomarkers that may be indicati ve of clinical response/resistance. safety, pharmacodynamic activity, and/or the mechanism of action of pembrolizumab | Biomarker analyses may include germline genetic variation, genetic (DNA) mutations from tumor, tumor and blood RNA variation, proteomics and immunohistochemistry, and other blood-derived biomarkers.                                                                |
| To evaluate PROs with the EORTC QLQ-C30 and FKSI-DRS and to characterize utilities with the EQ-5D-5L                                                                                                               | Scales and subscales for select endpoints of the EORTC QLQ-C30, FKSI-DRS, and EQ-5D-5L (refer to Section 3.4.3.2 of the sSAP [16.1.9] for details)                                                                                                                    |

## Sample size

Sample size calculation for primary endpoint DFS and key-secondary endpoint OS:

The study was initially planned to randomize 950 subjects in a 1:1 ratio between the pembrolizumab and the placebo group (495:495). To be more in line with the actual final number of randomized subjects, power calculation in Amendment 03 was changed to be based on 994 subjects.

The study was event-driven with minimum follow-up (calendar time) requirement at first interim analysis. For primary DFS and key-secondary OS endpoint, a Lan-DeMets O'Brien-Fleming alpha-spending function was constructed to implement group sequential efficacy boundaries to control the Type I error and a Hwang-Shih-DeCani spending function with gamma = -6 to derive futility boundaries.

<div style=\"page-break-after: always\"></div>

The power calculation of the primary endpoint DFS was based on the following assumptions: 1) DFS follows a Poisson mixture cure rate model (de Castro, M., et al 2010) with assumed cure rate of 0.3 (Leibovich, B. C., et al 2003) and with a median of 45 months for those not cured in the placebo group; 2) An enrollment period of 27 months; 3) A yearly drop-out rate of 2%; 4) the true HR was 0.67.

With 265 DFS events, there was approximately 84% power at IA1 to detect a hazard ratio of 0.67 (pembrolizumab versus placebo) with one-sided alpha spending of 1.22% under the DFS assumptions (see above). At IA2 of the study (final DFS analysis), with 332 DFS events there was 95% power to detect a hazard ratio of 0.67 at a one-sided alpha bound of 2.14% level. Overall, based on a target total number of 332 DFS events and one IA at approximately 80% of the target number of events (I.e. 265 DFS events), the study has approximately 95% power to detect a hazard ratio of 0.67 at an overall alpha level of 2.5% (1-sided).

For the key-secondary OS endpoint , the power was conditional on the null hypothesis of DFS being rejected. The power calculation was based on the following assumptions: 1) OS follows an exponential distribution with a median of 145 months in the placebo group; 2) An enrollment period of 27 months ; 3) A yearly dropout rate of 1%; 4) the true HR is 0.67 for OS.

With 200 OS events at final analysis and three interim analyses at approximately 47%, 66%, and 86% of the target number of events, there was approximately 79% power to detect a HR of 0.67 or approximately 88% power to detect a HR of 0.635 at one-sided 2.5% alpha level. This hypothesis may only be tested if primary endpoint DFS was supported when the hypothesis testing of DFS met statistical significance criterion.

## Randomisation

990 subjects were planned to be randomized in a 1:1 ratio into pembrolizumab group or placebo group using the IVRS/IWRS. Treatment allocation/randomization was planned to be stratified according to metastasis status (M0 versus M1 NED) and within M0 group additionally by ECOG PS (0 versus 1) and US participant (YES versus NO).

Table 3 Subjects Characteristics (ITT population)

|                                   | Pembrolizumab   | Pembrolizumab   | Placebo   | Placebo   | Total   | Total   |
|-----------------------------------|-----------------|-----------------|-----------|-----------|---------|---------|
|                                   | n               | (%)             | n         | (%)       | n       | (%)     |
| Metastatic Staging                |                 |                 |           |           |         |         |
| M0                                | 467             | (94.2)          | 469       | (94.2)    | 936     | (94.2)  |
| MI NED                            | 29              | (5.8)           | 29        | (5.8)     | 58      | (5.8)   |
| RCC Risk Category                 |                 |                 |           |           |         |         |
| MO-Intermediate-High Risk         | 422             | (85.1)          | 433       | (86.9)    | 855     | (86.0)  |
| M0-High Risk                      | 40              | (8.1)           | 36        | (7.2)     | 76      | (7.6)   |
| M0-Others                         | 5               | (1.0)           | 0         | (0.0)     | 5       | (0.5)   |
| MINED                             | 29              | (5.8)           | 29        | (5.8)     | 58      | (5.8)   |
| ECOGPerformanceScale              |                 |                 |           |           |         |         |
| 0                                 | 421             | (84.9)          | 426       | (85.5)    | 847     | (85.2)  |
| 1                                 | 75              | (15.1)          | 72        | (14.5)    | 147     | (14.8)  |
| Geographic Regionof EnrollingSite |                 |                 |           |           |         |         |
| North America                     | 133             | (26.8)          | 125       | (25.1)    | 258     | (26.0)  |
| European Union                    | 188             | (37.9)          | 187       | (37.6)    | 375     | (37.7)  |
| Rest of World                     | 175             | (35.3)          | 186       | (37.3)    | 361     | (36.3)  |
| Region                            |                 |                 |           |           |         |         |
| US                                | 114             | (23.0)          | 117       | (23.5)    | 231     | (23.2)  |
| Non-US                            | 382             | (77.0)          | 381       | (76.5)    | 763     | (76.8)  |

<div style=\"page-break-after: always\"></div>

## Blinding (masking)

The study was planned to be double-blind. Pembrolizumab and placebo were to be prepared and/or administered in a blinded fashion by an unblinded pharmacist or qualified trial site personnel. The participant and the investigator who were involved in the study treatment administration or clinical evaluation of the participants were to remain unaware of the group assignments.

An external Data Monitoring Committee (eDMC) had access to unblinded patient treatment assignment.

## Statistical methods

## Study populations

The primary and key secondary efficacy analyses were performed on the Intention-to-Treat (ITT) population, which includes all randomized participants. Participants were analyzed in the treatment group to which they were randomized. The safety analysis was performed on the All Participants as Treated population (APaT), including all randomized participants who received at least one dose of study treatment. The Patient reported outcomes (PRO) analyses were performed on the PRO full analysis set (FAS), defined as participants who received at least one study treatment and completed at least one PRO assessment. Efficacy data from participants in ITT population were analyzed in the treatment group to which they were randomized. Safety data from participants in APaT population were analyzed in the treatment group they actually received, which is the same as the treatment group to which they were randomized in this study.

## Statistical methods

The primary endpoint was planned to be DFS assessed by investigator, defined as time from randomization to the first documented local recurrence, or occurrence of distant kidney cancer metastasis(es), or death due to any cause, whichever occurs first. The time of recurrence was defined by the first documented recurrence, regardless of discontinuation of study treatment.

Key-secondary endpoint was planned to be OS, defined as time from randomization to death due to any cause.

Treatment differences in the primary and key-secondary endpoint were assessed by the stratified logrank test. Hazard ratios (HR) and 95% confidence intervals from stratified Cox Model with Efron's tie handling method were reported. The stratification factors used in the randomisation were used as stratification factors in the primary and key-secondary analysis.

Further secondary endpoints were DRSS1 and DRSS2. Curves in each treatment group were estimated by nonparametric cumulative incidence estimator. EFS was analysed by Kaplan-Meier method. The ITT population was used for analysing those secondary endpoints.

Patient reported outcomes (PRO) were assessed by visit. A constrained longitudinal data analysis (cLDA) was performed for the analysis of change from baseline in PROs using the PRO FAS.

## Sensitivity analyses for primary endpoint

One sensitivity analysis with different censoring rules for DFS was planned to be performed for the primary analysis, see Table below. The sensitivity analysis was the same as the primary analysis except that events immediately after 2 consecutive missed disease assessments or after new anticancer therapy, if any, should be censored at last disease assessment prior to the earlier date of ≥2 consecutive missed disease assessments and new anticancer therapy.

<div style=\"page-break-after: always\"></div>

The censoring rules for primary and sensitivity analysis are summarized as follows:

Table 4 censoring Rules for Primary and Sensitivity Analysis of Disease-Free Survival

| Situation                                                                                                                              | Primary Analysis                               | Sensitivity Analysis                                                                                                                               |
|----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| No recuirence and no death; new anticancer treatment is not initiated                                                                  | Censored at last disease assessment            | Censored at last disease assessment                                                                                                                |
| No recurrence and no death: new anticancer treatment is initiated                                                                      | Censored at last disease assessment            | Censored at last disease assessment before new anticancer treatment                                                                                |
| Recuirence or death documented after ≤1 missed disease assessment and before new anticancer treatment, if any                          | Event at date of documented recurence or death | Event at date of documented recurence or death                                                                                                     |
| Recuirence or death documented immediately after ≥2 consecutive missed disease assessiments, or after new anticancer treatment, if any | Event at date of documented recurence or death | Censored at the last disease assessment prior to the earlier date of≥2 consecutive missed disease assessments and new anticancer treatment, if any |

To evaluate the robustness of the results from the primary analysis method after adjusting the potential confounding effect of baseline disease status, the following sensitivity analyses were added resulting from Amendment 03 and 04. DFS by investigator assessment was evaluated using stratification factors for randomization with baseline disease status as assessed by BICR (no evidence of disease [ie, NED] vs. evidence of disease [ie, non-NED]) as an additional stratum. In addition, DFS by BICR were analyzed as a sensitivity analysis in which participants enrolled with baseline disease by BICR will be censored at randomization date.

## Interim analyses

Three interim analyses were planned for the study. Results were planned to be reviewed by an external DMC. The timing for the interim analyses and final analysis were defined as follows:

Table 5 Boundary Properties for Planned Interim and Final Analyses for DFS

| Analysis                                            | Value                                               | Efficacy                                            | Futilityt                                           |
|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| IA1: 80%(First Interim for DFS)                     | Z                                                   | 2.2504                                              | -0.5476                                             |
| N: 990                                              | p (1-sided)                                         | 0.0122                                              | 0.7080                                              |
| Events: 265                                         | HR at bound                                         | 0.7584                                              | 1.0696                                              |
| Month: 39                                           | P(Cross)ifHR=1                                      | 0.0122                                              | 0.2920                                              |
|                                                     | P(Cross)if HR=0.67                                  | 0.8402                                              | 0.0001                                              |
| IA2: (Final Analysis for DFS)                       | Z                                                   | 2.0249                                              | 2.0249                                              |
| N: 990                                              | p (1-sided)                                         | 0.0214                                              | 0.0214                                              |
| Events:332                                          | HR at bound                                         | 0.8005                                              | 0.8005                                              |
| Month: 50                                           | P(Cross)if HR=1                                     | 0.0250                                              | 0.9750                                              |
|                                                     | P(Cross) if HR=0.67                                 | 0.9490                                              | 0.0510                                              |
| IA=Interim.Analysis t:Futilityboundaryisnon-binding | IA=Interim.Analysis t:Futilityboundaryisnon-binding | IA=Interim.Analysis t:Futilityboundaryisnon-binding | IA=Interim.Analysis t:Futilityboundaryisnon-binding |

Table 6 Boundary Properties for Planned Interim and Final Analyses for OS

<div style=\"page-break-after: always\"></div>

| Analysis                                                                                     | Value                                                                      | Efficacy                                  | Futilityt                                   |
|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|-------------------------------------------|---------------------------------------------|
| IA1: 47% (First Interim for OS) N: 990 Events:94 Month:39                                    | Z p (1-sided) HR at bound P(Cross) if HR=1 P(Cross) if HR=0.67             | 3.0679 0.0011 0.5305 0.0011 0.1280        | -1.7717 0.9618 1.4421 0.0382 0.0001         |
| IA2: 66% (Second Interim for OS) N: 990 Events: 132 Month: 50 IA3: 86%(Third Interim for OS) | Z p (1-sided) HR at bound P(Cross)if HR=1 P(Cross) if HR=0.67 Z            | 2.5455 0.0055 0.6416 0.0058 0.4033        | -1.1786 0.8807 1.2281 0.1247 0.0003 -0.2090 |
| N: 990 Events: 172 Month: 63 Final N: 990                                                    | p (1-sided) HR at bound P(Cross) if HR=1 P(Cross) if HR=0.67 Z p (1-sided) | 2.2023 0.0138 0.7143 0.0157 0.6688 2.0534 | 0.5828 1.0324 0.4195 0.0025                 |
| Events:200 Month. 72                                                                         | HR at bound P(Cross) if HR=1 P(Cross) if HR=0.67                           | 0.0200 0.7476 0.0250 0.7930               | 2.0534 0.0200 0.7476 0.9750 0.2070          |

One interim analysis of DFS after approximately 265 events (80% information fraction) and a minimum follow-up of at least 12 months and a final analysis of DFS after 332 events were planned to be performed. Four analyses of OS were planned, where the final analysis of OS was planned to be conducted based on 200 events, and interim analyses were planned at the time of interim and final DFS analysis (47%, i.e. 94 OS events, and 66%, i.e. 132 OS events, of information fraction expected) and one year thereafter (86%, i.e. 172 OS events, of information fraction expected). The first IA was always to be driven by the number of DFS events. The second IA was to be driven by DFS events unless DFS was to be rejected in the first IA. In this case, it was to be driven by the number of OS events.

For primary DFS and key-secondary OS endpoint, a Lan-DeMets O'Brien-Fleming alpha-spending function was constructed to implement group sequential efficacy boundaries to control the Type I error and a Hwang-Shih-DeCani spending function with gamma = -6 to derive non-binding futility boundaries. Bounds were planned to be adjusted according to the actual number of events at each analysis.

The alpha-reallocation was pre-specified in advance, see paragraph on Multiplicity below.

As the information fraction is based on sample sizes (number of events) that were estimated, the alphas may change according to the available information (observed data).

## Multiplicity

The family-wise type-I error was planned to be controlled on the one-sided 2.5% level, covering the primary and key-secondary hypotheses. If the DFS null hypothesis would be rejected at the 2.5% level, then the OS null hypothesis was planned to be formally evaluated for statistical significance at the 2.5% level. For each endpoint, group sequential methods were planned to be used to adjust for the interim and final analyses planned. If the DFS null hypothesis would be rejected at an interim or final analysis, each OS interim and final analysis test was planned to be compared to its rejection boundary for formal testing. For instance, the OS hypothesis would not be formally evaluated for statistical significance until the DFS null hypothesis would be rejected.

## Safety analysis

<div style=\"page-break-after: always\"></div>

The analysis of safety results were performed by tiered approach. Summary statistics for baseline, ontreatment, and change from baseline values were provided by treatment group. For Tier 2 endpoints, point estimates and 95% Cis were provided for between-treatment differences; only point estimates by treatment group were provided for Tier 3 safety parameters in percentage of subjects with events using the Miettinen and Nurminen method. Additionally, exploratory analyses were performed for time to first Grade 3-5 AEs by Kaplan-Meier method and Cox proportional hazard model with Efron's method of tie handling.

## Results

## Participant flow

<!-- image -->

Note:Theparticipant forwhom study treatment was reported as ongoing at the time of the data cutoff date for IAl hadreceived thelast dose of study treatmentbuthad not completed the study treatment discontinuationvisit at the time of the data cutoff date.

Table 7 Disposition of Participants (ITT Population)

<div style=\"page-break-after: always\"></div>

994

984

663

(67.4)

320

(32.5)

115

(11.7)

152

(15.4)

5

(0.5)

16

(1.6)

2

(0.2)

1

(0.1)

31

(3.2)

6

(0.6)

1

(0.1)

77

(7.7)

51

(5.1)

26

(2.6)

1

(0.1)

25

(2.5)

917

|                                                                                         | Pembrolizumab      | Pembrolizumab   | Placebo   | Placebo   | Total   | Total   |
|-----------------------------------------------------------------------------------------|--------------------|-----------------|-----------|-----------|---------|---------|
|                                                                                         | n                  | (%)             | n         | (%)       | n       | (%)     |
| Participants in population                                                              | 496                |                 | 498       |           | 994     |         |
| Status for Study Treatment                                                              |                    |                 |           |           |         |         |
| Started Completed Discontinued                                                          | 488 51 3 10 0 1 21 |                 | 496       |           | 984     |         |
|                                                                                         | 298                | (61.1)          | 365       | (73.6)    | 663     | (67.4)  |
|                                                                                         | 190                | (38.9)          | 130       | (26.2)    | 320     | (32.5)  |
| Adverse Event                                                                           | 104                | (21.3)          | 11        | (2.2)     | 115     | (11.7)  |
| Disease Relapse                                                                         |                    | (10.5)          | 101       | (20.4)    | 152     | (15.4)  |
| Non-Compliance With Protocol                                                            |                    | (0.6)           | 2         | (0.4)     | 5       | (0.5)   |
| Physician Decision                                                                      |                    | (2.0)           | 6         | (1.2)     | 16      | (1.6)   |
| Associated With Covid-19                                                                |                    | (0.0)           | 2         | (0.4)     | 2       | (0.2)   |
| Protocol Violation                                                                      |                    | (0.2)           | 0         | (0.0)     | 1       | (0.1)   |
| Withdrawal By Subject                                                                   |                    | (4.3)           | 10        | (2.0)     | 31      | (3.2)   |
| Associated With Covid-19                                                                | 2                  | (0.4)           | 4         | (0.8)     | 6       | (0.6)   |
| Participants Ongoing                                                                    |                    | (0.0)           | 1         |           |         | (0.1)   |
| Status for Trial                                                                        | 0                  |                 |           | (0.2)     | 1       |         |
| Discontinued                                                                            |                    |                 |           |           |         |         |
| Death                                                                                   | 33                 | (6.7)           | 44        | (8.8)     | 77      | (7.7)   |
|                                                                                         | 18                 | (3.6)           | 33        | (6.6)     | 51      | (5.1)   |
| Withdrawal By Subject                                                                   | 15                 | (3.0)           | 11        | (2.2)     | 26      | (2.6)   |
| Associated With Covid-19, No Further Information Association With Covid-19 Unspecified, | 1                  | (0.2)           | 0         | (0.0)     | 1       | (0.1)   |
| No Further Information                                                                  | 14                 | (2.8)           | 11        | (2.2)     | 25      | (2.5)   |
| Participants Ongoing                                                                    | 463                | (93.3)          | 454       | (91.2)    | 917     | (92.3)  |

(92.3)

If the overall count of participants is calculated and displayed within a section in the first row, then it is used as the denominator for the percentage calculation. Otherwise, participants in population is used as the denominator for the percentage calculation.

Database Cutoff Date: 14DEC2020

## Recruitment

A total of 1406 participants were screened and 994 were randomly allocated across 212 global study sites in 21 countries.

The first patient, first visit was done on 30-JUN-2017 while the last patient, last visit was done on 14DEC-2020: data cut-off for IA1. The median follow-up time was 23.9 months (range 2.5 to 41.5 months).

## Conduct of the study

## Protocol amendments

## The key changes introduced by the protocol amendments are summarized below

| Protocol Amendment   | Most relevant changes   |
|----------------------|-------------------------|

<div style=\"page-break-after: always\"></div>

| #01 (02 Nov 2017)   | -To include metachronous and synchronous M1 NED post-operative nephrectomy ≤ 1 year. Since study inception, the inclusion of metachronous and synchronous M1 NED patients was intended; however, during protocol finalization metachronous was inadvertently removed. -Collection of PK and ADA revised from '30 days after treatment discontinuation (or until participant starts new anticancer treatment)' to 'at Safety Follow up'                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| #2 (4 Sep 2019)     | - Deleted PK/ADA objective The PK/ADA objective is now exploratory, not a secondary objective. - Changed from 4 to 3 interim analyses may be conducted. Removed IA1 due to insufficient duration of minimum follow-up resulting from prolonged enrollment period. - Updated the total number of DFS events expected at 48 months with at least 91.7% power to detect an HR of 0.67 when the study enrollment is extended from 18 months to 25 months. - Updated the censoring rules for DFS. Updated the censoring rules per the most recent oncology standard. - Updated analysis strategy for safety parameters, ie, updated the criterion for Tier 2 safety events and updated the list of additional events to be considered as Tier 2 or Tier 3 safety events. Subjects enrolled in this study usually experience various adverse events of similar types, adverse events reported less frequent than in 10%, or SAE, Grade 3-5 events reported in less than 5% of subjects would obscure the assessment of overall safety profile and add little to meaningful interpretation. |
| # 3 (11 May 2020)   | - Added secondary endpoint to compare event-free survival (EFS) as assessed by the blinded independent radiology review for participants treated with pembrolizumab versus those receiving placebo. - Changed duration of trial required to achieve the primary objective from 48 months to approximately 50 months. Projected duration of trial extended due to increased total targeted number of DFS events at IA2. (1) Changed the timing of interim analyses and final analysis. (2) Changed α -spending function for primary DFS from Hwang-Shih- DeCani (HSD) spending function with γ = -15 to Lan-DeMets O'Brien- Fleming spending approximation α -spending function.                                                                                                                                                                                                                                                                                                                                                                                                      |
| #4 (13 Oct 2020)    | - Removed PK/ADA sample collection. - Updated censoring rules for the primary analysis and the sensitivity analysis. The new primary analysis is the old sensitivity analysis 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

## Protocol deviations

Table 8 Summary of Important Protocol Deviations Considered to be Clinically Important (All Randomized Subjects)

|                                                                                                                                          | Pembrolizumab                                                                                       | Pembrolizumab                                                                                       | Placcbo                                                                                             | Placcbo                                                                                             | Total                                                                                               | Total                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
|                                                                                                                                          | n                                                                                                   | (%)                                                                                                 | n                                                                                                   | (%)                                                                                                 | n                                                                                                   | (%)                                                                                                 |
| Participants in population                                                                                                               | 496                                                                                                 |                                                                                                     | 498                                                                                                 |                                                                                                     | 994                                                                                                 |                                                                                                     |
| with one ormoreclinicallyimportant protocol deviations                                                                                   | 2                                                                                                   | (0.4)                                                                                               | 3                                                                                                   | (0.6)                                                                                               | 5                                                                                                   | (0.5)                                                                                               |
| withnoclinicallyimportantprotocol deviations                                                                                             | 494                                                                                                 | (99.6)                                                                                              | 495                                                                                                 | (99.4)                                                                                              | 989                                                                                                 | (99.5)                                                                                              |
| Inclusion/ExclusionCriteria                                                                                                              | 2                                                                                                   | (0.4)                                                                                               | 2                                                                                                   | (0.4)                                                                                               | 4                                                                                                   | (0.4)                                                                                               |
| Participantwasrandomizedwithpre-existingbrain orbonemetastatic lesion(s).                                                                | 1                                                                                                   | (0.2)                                                                                               | 1                                                                                                   | (0.2)                                                                                               | 2                                                                                                   | (0.2)                                                                                               |
| Participantwasrandomizedwithresidual thrombuspost-nephrectomyin the venarenalis orvenacava.                                              |                                                                                                     | (0.2)                                                                                               |                                                                                                     | (0.2)                                                                                               | 2                                                                                                   | (0.2)                                                                                               |
| SafetyReporting                                                                                                                          | 0                                                                                                   | (0.0)                                                                                               |                                                                                                     | (0.2)                                                                                               |                                                                                                     | (0.1)                                                                                               |
| Participant hadareportableSafetyEvent and/orfollowupSafetyEvent information that was notreportedper thetimelinesoutlinedin the protocol. | 0                                                                                                   | (0.0)                                                                                               |                                                                                                     | (0.2)                                                                                               |                                                                                                     | (0.1)                                                                                               |
| Everyparticipantiscounted asingletimeforeach applicablerow andcolumn. DatabaseCutoffDate:14DEC2020.                                      | Everyparticipantiscounted asingletimeforeach applicablerow andcolumn. DatabaseCutoffDate:14DEC2020. | Everyparticipantiscounted asingletimeforeach applicablerow andcolumn. DatabaseCutoffDate:14DEC2020. | Everyparticipantiscounted asingletimeforeach applicablerow andcolumn. DatabaseCutoffDate:14DEC2020. | Everyparticipantiscounted asingletimeforeach applicablerow andcolumn. DatabaseCutoffDate:14DEC2020. | Everyparticipantiscounted asingletimeforeach applicablerow andcolumn. DatabaseCutoffDate:14DEC2020. | Everyparticipantiscounted asingletimeforeach applicablerow andcolumn. DatabaseCutoffDate:14DEC2020. |

Table 9 Summary of Protocol Deviations Associated With COVID-19 (All Randomized Subjects)

|                                                                                                        | Pembrolizumab   | Pembrolizumab   | Placebo   | Placebo   | Total   | Total   |
|--------------------------------------------------------------------------------------------------------|-----------------|-----------------|-----------|-----------|---------|---------|
|                                                                                                        |                 | (%)             | n         | (%)       | n       | (%)     |
| Participants in population                                                                             | 496             |                 | 498       |           | 994     |         |
| with one or more protocoldeviations associatedwith COVID-19                                            | 127             | (25.6)          | 117       | (23.5)    | 244     | (24.5)  |
| withnoprotocol deviations associatedwith COVID-19                                                      | 369             | (74.4)          | 381       | (76.5)    | 750     | (75.5)  |
| Informed Consent                                                                                       | 6               | (1.2)           | 5         | (1.0)     | 11      | (1.1)   |
| Not Important Infomed Consent deviation                                                                | 6               | (1.2)           | 5         | (1.0)     | 11      | (1.1)   |
| Safety Reporting                                                                                       | 0               | (0.0)           | 1         | (0.2)     | 1       | (0.1)   |
| NotImportantSafetyReporting deviation                                                                  | 0               | (0.0)           |           | (0.2)     |         | (0.1)   |
| StudyIntervention                                                                                      | 3               | (0.0)           | 3         | (0.6)     | 6       | (0.0)   |
| NotImportantStudyInterventiondeviation                                                                 | 3               | (0.6)           | 3         | (0.6)     | 6       | (0.6)   |
| Trial Procedures                                                                                       | 125             | (25.2)          | 113       | (22.7)    | 238     | (23.9)  |
| Not Important Trial Proceduresdeviation                                                                | 125             | (25.2)          | 113       | (22.7)    | 238     | (23.9)  |
| Everyparticipant iscounteda single timefor each applicablerowandcolumn. Database CutoffDate:14DEC2020. |                 |                 |           |           |         |         |

## Baseline data

Table 10 Demographic and Baseline Characteristics

Source:[P564V01MK3475:adam-adsl][P564V01MK3475:sdtm-dv;suppdv]

and new sensitivity analysis is the old primary analysis. The old sensitivity analysis 2 is removed. -

<div style=\"page-break-after: always\"></div>

|                                  | Pembrolizumab   | Pembrolizumab   | Placebo   | Placebo   | Total    | Total   |
|----------------------------------|-----------------|-----------------|-----------|-----------|----------|---------|
|                                  | n               | (%)             |           | (%)       | n        | (%)     |
| Participants in population       | 496             |                 | 498       |           | t66      |         |
| Sex                              |                 |                 |           |           |          |         |
| Male                             | 347             | (70.0)          | 359       | (72.1)    | 706      | (71.0)  |
| Female                           | 149             | (30.0)          | 139       | (27.9)    | 288      | (29.0)  |
| Age (Years)                      |                 |                 |           |           |          |         |
| <65                              | 338             | (68.1)          | 326       | (65.5)    | 664      | (66.8)  |
| >=65                             | 158             | (31.9)          | 172       | (34.5)    | 330      | (33.2)  |
| Mean                             | 58.3            |                 | 58.6      |           | 58.4     |         |
| SD                               | 10.6            |                 | 11.0      |           | 10.8     |         |
| Median                           | 60.0            |                 | 60.0      |           | 60.0     |         |
| Range                            | 27 to 81        |                 | 25 to 84  |           | 25 to 84 |         |
| Race                             |                 |                 |           |           |          |         |
| American Indian Or Alaska Native | 10              | (2.0)           | 2         | (0.4)     | 12       | (1.2)   |
| Asian                            | 63              | (12.7)          | 75        | (15.1)    | 138      | (13.9)  |
| BlackOrAfricanAmerican           | 7               | (1.4)           |           | (1.0)     | 12       | (1.2)   |

|                                                     | Pembrolizimab   | Pembrolizimab   | Placebo   | Placebo   | Total   | Total   |
|-----------------------------------------------------|-----------------|-----------------|-----------|-----------|---------|---------|
|                                                     | n               | (%)             | n         | (%)       | n       | (%)     |
| Multiple                                            | 8               | (1.6)           | 5         | (1.0)     | 13      | (1.3)   |
| AmericanIndian OrAlaskaNativeBlackOrAfricanAmerican | 2               | (0.4)           | 0         | (0.0)     | 2       | (0.2)   |
| American Indian Or Alaska Native White              | 3               | (0.6)           | 2         | (0.4)     | 5       | (0.5)   |
| Black Or African American White                     | 2               | (0.4)           | 3         | (0.6)     |         | (0.5)   |
| White Asian                                         | 1               | (0.2)           | 0         | (0.0)     | 1       | (0.1)   |
| White                                               | 372             | (75.0)          | 377       | (75.7)    | 749     | (75.4)  |
| Missing                                             | 36              | (7.3)           | 34        | (6.8)     | 70      | (7.0)   |
| Ethnicity                                           |                 |                 |           |           |         |         |
| Hispanic Or Latino                                  | 72              | (14.5)          | 62        | (12.4)    | 134     | (13.5)  |
| Not Hispanic Or Latino                              | 381             | (76.8)          | 394       | (79.1)    | 775     | (78.0)  |
| Not Reported                                        | 21              | (4.2)           | 20        | (4.0)     | 41      | (4.1)   |
| Unknown                                             | 21              | (4.2)           | 21        | (4.2)     | 42      | (4.2)   |
| Missing                                             | 1               | (0.2)           | 1         | (0.2)     | 2       | (0.2)   |
| GeographicRegion of EnrollingSite                   |                 |                 |           |           |         |         |
| North America                                       | 133             | (26.8)          | 125       | (25.1)    | 258     | (26.0)  |
| European Union                                      | 188             | (37.9)          | 187       | (37.6)    | 375     | (37.7)  |
| Restof World                                        | 175             | (35.3)          | 186       | (37.3)    | 361     | (36.3)  |

|                       | Pembrolizmab   | Pembrolizmab   | Placebo   | Placebo   | Total   | Total   |
|-----------------------|----------------|----------------|-----------|-----------|---------|---------|
|                       | n              | (%)            | n         | (%)       | n       | (%)     |
| Region                |                |                |           |           |         |         |
| US                    | 114            | (23.0)         | 117       | (23.5)    | 231     | (23.2)  |
| Non-US                | 382            | (77.0)         | 381       | (76.5)    | 763     | (76.8)  |
| ECOGPerformance Scale |                |                |           |           |         |         |
| 0                     | 421            | (84.9)         | 426       | (85.5)    | 847     | (85.2)  |
| 1                     | 75             | (15.1)         | 72        | (14.5)    | 147     | (14.8)  |
| Type of nephrectomy   |                |                |           |           |         |         |
| Partial               | 37             | (7.5)          | 38        | (7.6)     | 75      | (7.5)   |
| Radical               | 459            | (92.5)         | 460       | (92.4)    | 919     | (92.5)  |
| PD-L1 Status          |                |                |           |           |         |         |
| CPS<1                 | 124            | (25.0)         | 113       | (22.7)    | 237     | (23.8)  |
| CPS >= 1              | 365            | (73.6)         | 383       | (76.9)    | 748     | (75.3)  |
| Missing               | 7              | (1.4)          | 2         | (0.4)     | 9       | (0.9)   |
| Primary Tumor         |                |                |           |           |         |         |

<div style=\"page-break-after: always\"></div>

|                    | Pembrolizimab   | Pembrolizimab   | Placebo   | Placebo   | Total   | Total   |
|--------------------|-----------------|-----------------|-----------|-----------|---------|---------|
|                    | n               | (%)             |           | (%)       | n       | (%)     |
| T1                 | 11              | (2.2)           | 15        | (3.0)     | 26      | (2.6)   |
| T2                 | 27              | (5.4)           | 33        | (6.6)     | 60      | (6.0)   |
| T3                 | 444             | (89.5)          | 437       | (87.8)    | 881     | (88.6)  |
| T4                 | 14              | (2.8)           | 13        | (2.6)     | 27      | (2.7)   |
| Tumor Grade        |                 |                 |           |           |         |         |
| Grade 1            | 19              | (3.8)           | 16        | (3.2)     | 35      | (3.5)   |
| Grade 2            | 153             | (30.8)          | 150       | (30.1)    | 303     | (30.5)  |
| Grade 3            | 219             | (44.2)          | 213       | (42.8)    | 432     | (43.5)  |
| Grade 4            | 103             | (20.8)          | 119       | (23.9)    | 222     | (22.3)  |
| Missing            | 2               | (0.4)           | 0         | (0.0)     | 2       | (0.2)   |
| SarcomatoidFeature |                 |                 |           |           |         |         |
| Presence           | 52              | (10.5)          | 59        | (11.8)    | 111     | (11.2)  |
| Absence            | 417             | (84.1)          | 415       | (83.3)    | 832     | (83.7)  |
| Unknown            | 27              | (5.4)           | 24        | (4.8)     | 51      | (5.1)   |
| Lymph Nodes Stage  |                 |                 |           |           |         |         |
| NO                 | 465             | (93.8)          | 467       | (93.8)    | 932     | (93.8)  |

|                          | Pembrolizumab   | Pembrolizumab   | Placebo   | Placebo   | Total   | Total   |
|--------------------------|-----------------|-----------------|-----------|-----------|---------|---------|
|                          |                 | (%)             |           | (%)       |         | (%)     |
| N1                       | 31              | (6.3)           | 31        | (6.2)     | 62      | (6.2)   |
| Metastatic Staging       |                 |                 |           |           |         |         |
| M0                       | 467             | (94.2)          | 469       | (94.2)    | 936     | (94.2)  |
| MI NED                   | 29              | (5.8)           | 29        | (5.8)     | 58      | (5.8)   |
| RCCRiskCategory          |                 |                 |           |           |         |         |
| M0-Intermediate-HighRisk | 422             | (85.1)          | 433       | (86.9)    | 855     | (86.0)  |
| M0-High Risk             | 40              | (8.1)           | 36        | (7.2)     | 76      | (7.6)   |
| M0-Others                | 5               | (1.0)           | 0         | (0.0)     | 5       | (0.5)   |
| M1 NED                   | 29              | (5.8)           | 29        | (5.8)     | 58      | (5.8)   |

Participants in M0-Intermediate-highriskarepT2(Grade4or sarcomatoid),N0,M0orpT3(AnyGrade),N0,M0.Participants inM0-highrisk arepT4(Any Grade),N0,M0 or pT Any(Any Grade),N1or greater,M0.Participants in M1 NED areparticipants whopresent not onlywith the primarykidney tumor but alsosolid,isolated,softtissuemetastasesthatwerecompletelyresected atthetimeofnephrectomy（synchronous)or&lt;=1yearfromnephrectomy (metachronous).ParticipantsinM0-OthersareT2(grade&lt;=3)N0M0orT1 N0M0.

DatabaseCutoffDate:14DEC2020.

## Numbers analysed

For IA1, efficacy analyses were conducted using the intention-to-treat (ITT) population, and safety analyses were conducted using the All Participants as Treated (APaT) population, which included all randomized participants who received at least 1 dose of study intervention.

## Outcomes and estimation

## Disease free survival (DFS)

As of the data cutoff for IA1, a total of 260 DFS events (78% of the total planned events at the final analysis) were observed in the 2 treatment groups (109 in the pembrolizumab group and 151 in the placebo group). At the prespecified 2.5% overall alpha level (one-sided), pembrolizumab demonstrated a statistically significant improvement in DFS compared with placebo (median DFS was not reached in either treatment group; HR: 0.68 [95% CI: 0.53, 0.87]; and log-rank test p-value 0.0010, p-value boundary: 0.0114) Table 11 . The KM curve separated from the outset in favour of pembrolizumab. The difference in the DFS rates between treatment groups at 12, 18, and 24 months ranged from 9.2% to 9.6%.

<div style=\"page-break-after: always\"></div>

Table 11. Analysis of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment (ITT Population) Database Cutoff Date: 14DEC2020

151 (30.3)

2 (0.4)

149 (29.9)

347 (69.7)

344 (69.1)

3 (0.6)

NR (NR, NR)

[13.8, NR]

9241.1

1.6

76.2 (72.2, 79.7)

71.9 (67.7, 75.7)

68.1 (63.5, 72.2)

|                                                            | Pembrolizumab (N=496)                      | Placebo (N=498)                     |
|------------------------------------------------------------|--------------------------------------------|-------------------------------------|
| Number of Events (%)                                       | 109 (22.0) 6 (1.2)                         | 151 (30.3) 2 (0.4)                  |
| Death                                                      |                                            |                                     |
| Disease Recurrence                                         | 103 (20.8)                                 | 149 (29.9)                          |
| Number of Censored (%)                                     | 387 (78.0)                                 | 347 (69.7)                          |
| Last Tumor Assessment Showing No Disease Recurrence        | 375 (75.6)                                 | 344 (69.1)                          |
| No Post-Baseline Disease Status Assessment                 | 12 (2.4)                                   | 3 (0.6)                             |
| Kaplan-Meier Estimates (months) a Median (95% CI) [Q1, Q3] | NR (NR, NR) [25.8, NR]                     | NR (NR, NR) [13.8, NR]              |
| person-months                                              | 9759.0                                     | 9241.1                              |
| Event Rate / 100 person-months                             | 1.1                                        | 1.6                                 |
| vs Placebo Hazard Ratio (95% CI) b p-value c               | 0.68 (0.53, 0.87) 0.0010 85.7 (82.2, 88.5) | 76.2 (72.2, 79.7)                   |
| DFS Rate at month 12 (%) (95% CI)                          |                                            |                                     |
| DFS Rate at month 18 (%) (95% CI)                          | 81.5 (77.7, 84.8)                          | 71.9 (67.7, 75.7) 68.1 (63.5, 72.2) |
| DFS Rate at month 24 (%) (95% CI)                          | 77.3 (72.8, 81.1)                          |                                     |

a  From product-limit (Kaplan-Meier) method for censored data.

b  Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastasis status (M0 versus M1 NED by investigator) and ECOG PS (0 versus 1),US participant (Yes versus No) within M0 group by investigator.

c  One-sided p-value based on log-rank test stratified by metastasis status (M0 versus M1 NED by investigator) and ECOG PS (0 versus 1),US participant (Yes versus No) within M0 group by investigator.

NR = Not reached.

Database Cutoff Date: 14DEC2020

<div style=\"page-break-after: always\"></div>

Figure 1 Kaplan-Meier Plot of Disease-Free Survival (Primary Censoring Rule)

<!-- image -->

Updated efficacy results (data cut-off date 14JUN2021) with a median follow-up time of 29.7 months are summarised in Table 12 and Figure 2.

Table 12 Efficacy results in KEYNOTE-564 (data cut-off date 14JUN2021)

| Endpoint                          | Pembrolizumab 200 mg every 3 weeks n=496   | Placebo n=498     |
|-----------------------------------|--------------------------------------------|-------------------|
| DFS                               |                                            |                   |
| Number (%) of patients with event | 114 (23%)                                  | 169 (34%)         |
| Median in months (95% CI)         | NR (NR, NR)                                | NR (40.5, NR)     |
| Hazard ratio * (95% CI)           | 0.63 (0.50, 0.80)                          | 0.63 (0.50, 0.80) |
| p-Value †                         | < 0.0001                                   | < 0.0001          |

NR = not reached

<div style=\"page-break-after: always\"></div>

Figure 2 Kaplan-Meier curve for disease-free survival by treatment arm in KEYNOTE-564 (intent to treat population) (Data cut-off date 14JUN2021)

<!-- image -->

## Secondary endpoints

## Overall survival (OS)

The OS data were immature at IA1 with 51 deaths (26% of total planned OS events at the final analysis). For OS, the HR was 0.54 (95% CI: 0.30, 0.96) (p=0.0164037) and the median OS was not reached in either group. The p-value did not cross the statistical hypothesis testing p-value boundary of 9.3×10 -6  at IA1. The upper bound of 95% CI for the OS HR was below 1.0, with nearly twice as many deaths in the placebo group (33) compared with the pembrolizumab group (18).

Table 13 Analysis of Overall Survival  (ITT Population)

|                                                   | Pembrolizumab (N=496)   | Placebo (N=498)   |
|---------------------------------------------------|-------------------------|-------------------|
| Number of Events (%)                              | 18 (3.6)                | 33 (6.6)          |
| Kaplan-Meier Estimates (months) a Median (95% CI) | NR (NR, NR)             | NR (NR, NR)       |
| [Q1, Q3]                                          | [NR, NR]                | [NR, NR]          |
| person-months                                     | 12195.5                 | 12096.2           |

33 (6.6)

NR (NR, NR)

[NR, NR]

12096.2

<div style=\"page-break-after: always\"></div>

0.3

.0164037

98.0 (96.3, 98.9)

96.8 (94.8, 98.0)

93.5 (90.5, 95.6)

| Event Rate / 100 person-months   | 0.1               | 0.3               |
|----------------------------------|-------------------|-------------------|
| vs Placebo                       |                   |                   |
| Hazard Ratio (95% CI) b          | 0.54 (0.30, 0.96) |                   |
| p-value c                        | .0164037          |                   |
| OS Rate at month 12 (%) (95% CI) | 98.6 (97.0, 99.3) | 98.0 (96.3, 98.9) |
| OS Rate at month 18 (%) (95% CI) | 97.9 (96.1, 98.9) | 96.8 (94.8, 98.0) |
| OS Rate at month 24 (%) (95% CI) | 96.6 (94.3, 98.0) | 93.5 (90.5, 95.6) |

NR = Not reached.

Database Cutoff Date: 14DEC2020

Figure 3. Kaplan-Meier Plot of Overall Survival (ITT Population )

<!-- image -->

Updated OS results were not yet mature at the updated data cut-off date of 14JUN2021 and are summarised below.

Table 14 Analysis of Overall Survival (ITT Population)  (data cut-off date 14JUN2021

<div style=\"page-break-after: always\"></div>

|                                  | Pembrolizumab (N=496)      | Placebo (N=498)   |
|----------------------------------|----------------------------|-------------------|
| Number of Events (%)             | 23 (4.6)                   | 43 (8.6)          |
| Kaplan-Meier Estimates (months)a |                            |                   |
| Median (95% CI)                  | NR (NR, NR)                | NR (NR, NR)       |
| [Q1, Q3]                         | [NR, NR]                   | [NR, NR]          |
| person-months                    | 14948.1                    | 14797.1           |
| Event Rate / 100 person-months   | 0.2                        | 0.3               |
| vs Placebo                       |                            |                   |
| Hazard Ratio (95% C1)b p-valuec  | 0.52 (0.31, 0.86) .0047677 |                   |
| OS Rate at month 12 (%) (95% CI) | 98.6 (97.0, 99.3)          | 98.0 (96.3, 98.9) |
| OS Rate at month 18 (%) (95% CI) | 97.8 (96.0, 98.8)          | 96.8 (94.8, 98.0) |
| OS Rate at month 24 (%) (95% CI) | 96.2 (94.1, 97.6)          | 93.8 (91.3, 95.6) |

a From product-limit (Kaplan-Meier) method for censored data.

b Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastasis status (MO versus M1 NED by investigator) and ECOG PS (O versus 1),US participant (Yes versus No) within M0 group by investigator.

One-sided p-value based on log-rank test stratified by metastasis status (M0 versus M1 NED by investigator) and ECOG PS (O versus 1),US participant (Yes versus No) within M0 group by investigator.

NR = Not reached.

Database Cutoff Date: 14JUN2021

<div style=\"page-break-after: always\"></div>

Figure 4 Kaplan-Meier Plot of Overall Survival (ITT Population )

<!-- image -->

## Other Secondary Efficacy Endpoint:

## Disease Recurrence-specific Survival

The cumulative incidences of the event of interest in the pembrolizumab group were consistently lower compared with the placebo group over time for both DRSS1 and DRSS2, showing a favourable numeric trend in DRSS1 and DRSS2 for pembrolizumab compared with placebo.

Table 15 Analysis of Disease Recurrence Specific Survival 1  Based on Investigator Assessment  (ITT Population

|                                  | Pembrolizumab (N=496)   | Placebo (N=498)   |
|----------------------------------|-------------------------|-------------------|
| Number of Events (%) a           | 17 (3.4)                | 32 (6.4)          |
| Number of Competing Events (%) b | 92 (18.5)               | 119 (23.9)        |
| Number of Censored (%)           | 387 (78.0)              | 347 (69.7)        |

<div style=\"page-break-after: always\"></div>

| Cumulative Incidence of Event at month 12 (%) (95% C1)   | 1.9 (0.9, 3.4)   | 5.5 (3.7, 7.8)   |
|----------------------------------------------------------|------------------|------------------|
| Cumulative Incidence of Event at month 18 (%) (95% C1)   | 2.8 (1.6, 4.6)   | 5.9 (4.1, 8.3)   |
| CumulativeIncidenceof Event atmonth 24(%)(95% C1)        | 3.4 (2.0, 5.4)   | 6.6 (4.6, 9.2)   |

Cumulativeincidenceestimatesatspecifiedtimepointsarebasedonnonparametricestimationof cumulativeincidenceoftheeventofinterestaccountingforcompetingriskevents.

DatabaseCutoffDate:14DEC2020

Figure5CumulativeIncidencePlotofDiseaseRecurrenceSpecificSurvival1

<!-- image -->

Table16Analysis of Disease RecurrenceSpecificSurvival 2Based onInvestigator Assessment(ITT Population)

|                       | Pembrolizumab (N=496)   | Placebo (N=498)   |
|-----------------------|-------------------------|-------------------|
| Number of Events (%)a | 94 (19.0)               | 134 (26.9)        |

<div style=\"page-break-after: always\"></div>

| Number of Competing Events (%)b                        | 15 (3.0)   | 17 (3.4)                           |
|--------------------------------------------------------|------------|------------------------------------|
| Number of Censored (%)                                 | 387 (78.0) | 347 (69.7)                         |
| CumulativeIncidence of Event atmonth 12(%）(95% CI)     |            | 12.8 (10.0, 16.0)21.2 (17.7,24.9)  |
| CumulativeIncidenceof Event atmonth 18(%）(95% CI)      |            | 16.3 (13.1, 19.8)25.0 (21.2, 28.9) |
| Cumulative Incidence of Event at month 24 (%) (95% CI) |            | 19.8 (16.1, 23.9)28.2 (24.1, 32.5) |

Cumulativeincidence estimatesatspecified timepoints arebased onnonparametric estimation of cumulativeincidenceoftheeventofinterestaccountingforcompetingriskevents.

DatabaseCutoffDate:14DEC2020

Figure 6 Cumulative Incidence Plot of Disease Recurrence Specific Survival 2 based on Investigator Assessment (ITT population)

<!-- image -->

## Event-FreeSurvival(EFS)byBICR

EFS was defined as time from randomization to the first disease recurrence by BICR among participants who were assessed by BICR with no evidence of disease (ie, NED) at baseline, or disease progression

<div style=\"page-break-after: always\"></div>

among participants who were assessed by BICR with evidence of disease (ie, non-NED) at baseline, or death due to any cause, whichever occurs first. The baseline disease status by BICR determined whether disease recurrence or disease progression was tracked for a participant.

Table 17 Analysis of Event-Free Survival  Based on BICR (Baseline Disease Status Based on BICR Review of Baseline Scan Only)  (ITT Population)

155 (31.1)

2 (0.4)

25 (5.0)

128 (25.7)

343 (68.9)

340 (68.3)

3 (0.6)

NR (NR, NR)

[10.9, NR]

8613.8

1.8

73.0 (68.9, 76.8)

70.9 (66.7, 74.8)

66.5 (61.8, 70.8)

|                                                                 | Pembrolizumab (N=496)   | Placebo (N=498)   |
|-----------------------------------------------------------------|-------------------------|-------------------|
| Number of Events (%)                                            | 116 (23.4)              | 155 (31.1)        |
| Death                                                           | 7 (1.4)                 | 2 (0.4)           |
| Disease Progression                                             | 14 (2.8)                | 25 (5.0)          |
| Disease Recurrence                                              | 95 (19.2)               | 128 (25.7)        |
| Number of Censored (%)                                          | 380 (76.6)              | 343 (68.9)        |
| Last Tumor Assessment Showing No Disease Recurrence/Progression | 368 (74.2)              | 340 (68.3)        |
| No Post-Baseline Tumor Status Assessment                        | 12 (2.4)                | 3 (0.6)           |
| Kaplan-Meier Estimates (months) a Median (95% CI)               | NR (NR, NR)             | NR (NR, NR)       |
| [Q1, Q3]                                                        | [25.7, NR]              | [10.9, NR]        |
| person-months                                                   | 9216.3                  | 8613.8            |
| Event Rate / 100 person-months                                  | 1.3                     | 1.8               |
| vs Placebo                                                      |                         |                   |
| Hazard Ratio (95% CI) b                                         | 0.72 (0.56, 0.91)       |                   |
| p-value c                                                       | 0.0035                  |                   |
| EFS Rate at month 12 (%) (95% CI)                               | 81.6 (77.8, 84.8)       | 73.0 (68.9, 76.8) |
| EFS Rate at month 18 (%) (95% CI)                               | 77.7 (73.5, 81.2)       | 70.9 (66.7, 74.8) |

a  From product-limit (Kaplan-Meier) method for censored data.

b  Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by baseline disease status by BICR (NED by BICR versus Non-NED by BICR), then within NED by BICR further stratified by randomization strata: M0 versus M1 NED by investigator and ECOG PS (0 versus 1),US participant (Yes versus No) within M0 group by investigator..

c  One-sided p-value based on log-rank test stratified by baseline disease status by BICR (NED by BICR versus Non-NED by BICR), then within NED by BICR further stratified by randomization strata: M0 versus M1 NED by investigator and ECOG PS (0 versus 1),US participant (Yes versus No) within M0 group by investigator..

NR = Not reached.

<div style=\"page-break-after: always\"></div>

For participants who were assessed as baseline NED based on BICR review of baseline scan only but had a post-baseline scan that triggered retrospective assessment of the baseline disease, the date of that scan is used as the event date.

Database Cutoff Date: 14DEC2020

Figure 7 Kaplan-Meier Plot of Event-Free Survival Based on BICR (Baseline Disease Status Based on BICR Review of Baseline Scan Only) (ITT Population)

<!-- image -->

Consistent results were obtained based on a sensitivity analysis of EFS by BICR without the additional stratum of baseline disease status by BICR (stratified on randomization strata only) (HR 0.71, 95% CI: 0.55, 0.90).

## Disease-Free Survival (DFS) by BICR ( Cutoff Date: 14JUN2021)

Table 18 Analysis of Disease-Free Survival Based on BICR  (Participants with Baseline Non-NED Based on BICR Review of Baseline Scan Only are Censored at Baseline)  (ITT Population)

141 (28.3)

2 (0.4)

139 (27.9)

|                      | Pembrolizumab (N=496)   | Placebo (N=498)   |
|----------------------|-------------------------|-------------------|
| Number of Events (%) | 117 (23.6)              | 141 (28.3)        |
| Death                | 6 (1.2)                 | 2 (0.4)           |
| Disease Recurrence   | 111 (22.4)              | 139 (27.9)        |

<div style=\"page-break-after: always\"></div>

357 (71.7)

29 (5.8)

328 (65.9)

NR (NR, NR)

[13.8, NR]

10132.4

1.4

75.6 (71.4, 79.3)

73.6 (69.3, 77.4)

70.3 (65.8, 74.3)

| Number of Censored (%)                              | 379 (76.4)        | 357 (71.7)        |
|-----------------------------------------------------|-------------------|-------------------|
| Censored At Baseline                                | 19 (3.8)          | 29 (5.8)          |
| Last Tumor Assessment Showing No Disease Recurrence | 360 (72.6)        | 328 (65.9)        |
| Kaplan-Meier Estimates (months) a                   |                   |                   |
| Median (95% CI)                                     | NR (NR, NR)       | NR (NR, NR)       |
| [Q1, Q3]                                            | [25.9, NR]        | [13.8, NR]        |
| person-months                                       | 10746.4           | 10132.4           |
| Event Rate / 100 person-months                      | 1.1               | 1.4               |
| vs Placebo                                          |                   |                   |
| Hazard Ratio (95% CI) b                             | 0.78 (0.61, 0.99) |                   |
| p-value c                                           | 0.0212            |                   |
| DFS Rate at month 12 (%) (95% CI)                   | 82.4 (78.6, 85.6) | 75.6 (71.4, 79.3) |
| DFS Rate at month 18 (%) (95% CI)                   | 78.8 (74.7, 82.3) | 73.6 (69.3, 77.4) |
| DFS Rate at month 24 (%) (95% CI)                   | 76.1 (71.8, 79.8) | 70.3 (65.8, 74.3) |

a  From product-limit (Kaplan-Meier) method for censored data.

b  Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastasis status (M0 versus M1 NED by investigator) and ECOG PS (0 versus 1),US participant (Yes versus No) within M0 group by investigator.

c  One-sided p-value based on log-rank test stratified by metastasis status (M0 versus M1 NED by investigator) and ECOG PS (0 versus 1),US participant (Yes versus No) within M0 group by investigator.

NR = Not reached.

Baseline Non-NED was assessed by BICR review of baseline scan only.

Database Cutoff Date: 14JUN2021

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Exploratory Endpoint:

## Progression-Free Survival 2

A post hoc exploratory analysis of PFS2 based on investigator assessment was conducted. PFS2 was defined as the time from randomization to disease progression on next-line anticancer drug therapy, or death from any cause, whichever occurred first. A total of 63 participants in the pembrolizumab group and 86 participants in the placebo group received subsequent anticancer drug therapy.

<div style=\"page-break-after: always\"></div>

|                                                  | Pembrolizumab (N=496)    | Placebo (N=498)      |
|--------------------------------------------------|--------------------------|----------------------|
| Number of Events (%)                             | 30 (6.0)                 | 56 (11.2)            |
| Death                                            | 11 (2.2)                 | 13 (2.6)             |
| Progression After Next-Line Therapy              | 19 (3.8)                 | 43 (8.6)             |
| Number of Censored (%)                           | 466 (94.0)               | 442 (88.8)           |
| Last Known Alive Date                            | 458 (92.3)               | 439 (88.2)           |
| Second Next-Line Therapy Start Date              | 8 (1.6)                  | 3 (0.6)              |
| Kaplan-Meier Estimates (months)a Median (95% CI) | NR (NR, NR)              | NR (NR, NR) [NR, NR] |
| [Q1, Q3]                                         | [NR, NR] 11941.6         | 11683.9              |
| person-months Event Rate / 100 person-months     | 0.3                      | 0.5                  |
| vs Placebo                                       |                          |                      |
| Hazard Ratio (95% C1)b p-valuec                  | 0.52 (0.34, 0.81) 0.0018 |                      |
| PFS2 Rate at month 12 (%) (95% C1)               | 98.4 (96.8, 99.2)        | 95.3 (93.1, 96.9)    |
| PFS2 Rate at month 18 (%) (95% CI)               | 95.2 (92.8, 96.8)        | 92.2 (89.5, 94.3)    |
| PFS2 Rate at month 24 (%) (95% CI)               | 93.6 (90.7, 95.5)        | 88.3 (84.7. 91.0)    |
| PFS2 Rate at month 30 (%) (95% CI)               | 93.1 (90.1, 95.2)        | 85.7 (81.2, 89.1)    |

b Based on Cox regression model with Efron's method of tie handling with treatment as a covariate.

c One-sided p-value based on log-rank test.

NR = Not reached.

Database Cutoff Date: 14DEC2020

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Patient-Reported Outcomes

PROs were assessed at Cycles 1, 5, 9, 13, and 17, as well as at discontinuation, 30-day follow-up, and annually during post-treatment follow-up until disease recurrence or new anticancer treatment was initiated.

The 3 prespecified PRO endpoints were mean change from baseline in FKSI-DRS score, EORTC-QLQC30 global health status/quality of life scores, and EORTC-QLQ-C30 physical functioning scale . Nominal p-values were computed for between-treatment group comparisons. Results were not adjusted for multiplicity, and therefore should be interpreted with caution.

Completion rates for FKSI-DRS by visit at baseline through Week 52 were generally high (90.4% at baseline, 64.3% at Week 52) as were compliance rates overall (90.4% at baseline, 85.0% at Week 52), and were similar in both treatment groups.

The completion and compliance rates for EORTC QLQC30 and EQ-5D-5L were similar to those for the FKSI-DRS.

## Key PRO Endpoints

Change from Baseline in FKSI-DRS and EORTC QLQ-C30 Global Health Status/Quality of Life

A change in FKSIDRS score of ≥3 and a change in EORTC QLQ -C30 score of ≥10 were considered to be clinically meaningful.

<div style=\"page-break-after: always\"></div>

For both FKSI-DRS and EORTC QLQ-C30 global health status/QoL score, no clinically meaningful decreases from baseline to Week 52 were observed in either the pembrolizumab or placebo groups.

Table 20 Analysis of Change from Baseline in EORTC QLQ-C30 Global Health Status/QoL to Week 52 (PRO FAS Population)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Week 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | ChangefromBaselinetoWeek52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | ChangefromBaselinetoWeek52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | ChangefromBaselinetoWeek52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | LSMean(95%CI)*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Pembrolizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 438                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 79.22 (18.46)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 301                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 74.92 (18.26)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 484                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | -4.25(-6.32,-2.19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | -4.25(-6.32,-2.19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 450                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 77.04 (17.61)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 325                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 76.82 (19.56)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 492                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | -1.68(-3.69.0.32)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | -1.68(-3.69.0.32)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| PairwiseComparison                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Difference in LS Means (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | p-Valuea                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Pembrolizumabvs.Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | -2.57 (-5.22.0.08)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.0571                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| BasedonacLDAmodelwiththePROscoresastheresponsevariablewithcovariatesfortreatmentbystudyvisitinteraction,stratificationfactorsmetastasisstatus(MOversus M1NED).andwithinMOgroupfurther stratifiedbyECOGPS(Oversus1)and USparticipant(YesversusNo)ascovariates. Forbaseline andWeek52.Nis thenumberof subjectsineach treatmentgroupwithnon-missingassessments at thespecific timepoint;forchangefrombaseline.Nisthe numberofsubjectsintheanalysispopulationineachtreatmentgroup. DatabaseCutoffDate:14DEC2020 | BasedonacLDAmodelwiththePROscoresastheresponsevariablewithcovariatesfortreatmentbystudyvisitinteraction,stratificationfactorsmetastasisstatus(MOversus M1NED).andwithinMOgroupfurther stratifiedbyECOGPS(Oversus1)and USparticipant(YesversusNo)ascovariates. Forbaseline andWeek52.Nis thenumberof subjectsineach treatmentgroupwithnon-missingassessments at thespecific timepoint;forchangefrombaseline.Nisthe numberofsubjectsintheanalysispopulationineachtreatmentgroup. DatabaseCutoffDate:14DEC2020 | BasedonacLDAmodelwiththePROscoresastheresponsevariablewithcovariatesfortreatmentbystudyvisitinteraction,stratificationfactorsmetastasisstatus(MOversus M1NED).andwithinMOgroupfurther stratifiedbyECOGPS(Oversus1)and USparticipant(YesversusNo)ascovariates. Forbaseline andWeek52.Nis thenumberof subjectsineach treatmentgroupwithnon-missingassessments at thespecific timepoint;forchangefrombaseline.Nisthe numberofsubjectsintheanalysispopulationineachtreatmentgroup. DatabaseCutoffDate:14DEC2020 | BasedonacLDAmodelwiththePROscoresastheresponsevariablewithcovariatesfortreatmentbystudyvisitinteraction,stratificationfactorsmetastasisstatus(MOversus M1NED).andwithinMOgroupfurther stratifiedbyECOGPS(Oversus1)and USparticipant(YesversusNo)ascovariates. Forbaseline andWeek52.Nis thenumberof subjectsineach treatmentgroupwithnon-missingassessments at thespecific timepoint;forchangefrombaseline.Nisthe numberofsubjectsintheanalysispopulationineachtreatmentgroup. DatabaseCutoffDate:14DEC2020 | BasedonacLDAmodelwiththePROscoresastheresponsevariablewithcovariatesfortreatmentbystudyvisitinteraction,stratificationfactorsmetastasisstatus(MOversus M1NED).andwithinMOgroupfurther stratifiedbyECOGPS(Oversus1)and USparticipant(YesversusNo)ascovariates. Forbaseline andWeek52.Nis thenumberof subjectsineach treatmentgroupwithnon-missingassessments at thespecific timepoint;forchangefrombaseline.Nisthe numberofsubjectsintheanalysispopulationineachtreatmentgroup. DatabaseCutoffDate:14DEC2020 | BasedonacLDAmodelwiththePROscoresastheresponsevariablewithcovariatesfortreatmentbystudyvisitinteraction,stratificationfactorsmetastasisstatus(MOversus M1NED).andwithinMOgroupfurther stratifiedbyECOGPS(Oversus1)and USparticipant(YesversusNo)ascovariates. Forbaseline andWeek52.Nis thenumberof subjectsineach treatmentgroupwithnon-missingassessments at thespecific timepoint;forchangefrombaseline.Nisthe numberofsubjectsintheanalysispopulationineachtreatmentgroup. DatabaseCutoffDate:14DEC2020 | BasedonacLDAmodelwiththePROscoresastheresponsevariablewithcovariatesfortreatmentbystudyvisitinteraction,stratificationfactorsmetastasisstatus(MOversus M1NED).andwithinMOgroupfurther stratifiedbyECOGPS(Oversus1)and USparticipant(YesversusNo)ascovariates. Forbaseline andWeek52.Nis thenumberof subjectsineach treatmentgroupwithnon-missingassessments at thespecific timepoint;forchangefrombaseline.Nisthe numberofsubjectsintheanalysispopulationineachtreatmentgroup. DatabaseCutoffDate:14DEC2020 | BasedonacLDAmodelwiththePROscoresastheresponsevariablewithcovariatesfortreatmentbystudyvisitinteraction,stratificationfactorsmetastasisstatus(MOversus M1NED).andwithinMOgroupfurther stratifiedbyECOGPS(Oversus1)and USparticipant(YesversusNo)ascovariates. Forbaseline andWeek52.Nis thenumberof subjectsineach treatmentgroupwithnon-missingassessments at thespecific timepoint;forchangefrombaseline.Nisthe numberofsubjectsintheanalysispopulationineachtreatmentgroup. DatabaseCutoffDate:14DEC2020 |

Table 21 Analysis of Change from Baseline in FKSI-DRS Score to Week 52 (PRO FAS Population)

<!-- image -->

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Week52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Week52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | ChangefromBaselinetoWeek52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ChangefromBaselinetoWeek52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ChangefromBaselinetoWeek52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | N                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | LS Mean (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Pembrolizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 435                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 32.86 (3.50)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 300                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 31.85 (4.69)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 483                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | -1.12(-1.53,-0.71)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | -1.12(-1.53,-0.71)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 447                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 32.79 (3.53)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 328                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 32.51 (4.13)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 492                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.45(-0.84.-0.05)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 0.45(-0.84.-0.05)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Pairwise Comparison                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | DifferenceinLS Means (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | p-Valuea                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Pembrolizumabvs.Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | -0.67(-1.23,-0.12)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.0170                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| BasedonacLDAmodelwiththePROscoresastheresponsevariablewithcovariatesfortreatmentbystudyvisitinteraction,stratificationfactorsmetastasisstatus(MOversus MINED),andwithinMOgroupfurther stratified byECOGPS(Oversus1)andUSparticipant(YesversusNo)ascovariates. Forbaseline andWeek52,Nisthenumberofsubjects in each treatmentgroupwithnon-missingassessments at thespecifictimepoint;forchangefrombaseline,N is the numberofsubjectsintheanalysispopulationineachtreatmentgroup. DatabaseCutoffDate:14DEC2020 | BasedonacLDAmodelwiththePROscoresastheresponsevariablewithcovariatesfortreatmentbystudyvisitinteraction,stratificationfactorsmetastasisstatus(MOversus MINED),andwithinMOgroupfurther stratified byECOGPS(Oversus1)andUSparticipant(YesversusNo)ascovariates. Forbaseline andWeek52,Nisthenumberofsubjects in each treatmentgroupwithnon-missingassessments at thespecifictimepoint;forchangefrombaseline,N is the numberofsubjectsintheanalysispopulationineachtreatmentgroup. DatabaseCutoffDate:14DEC2020 | BasedonacLDAmodelwiththePROscoresastheresponsevariablewithcovariatesfortreatmentbystudyvisitinteraction,stratificationfactorsmetastasisstatus(MOversus MINED),andwithinMOgroupfurther stratified byECOGPS(Oversus1)andUSparticipant(YesversusNo)ascovariates. Forbaseline andWeek52,Nisthenumberofsubjects in each treatmentgroupwithnon-missingassessments at thespecifictimepoint;forchangefrombaseline,N is the numberofsubjectsintheanalysispopulationineachtreatmentgroup. DatabaseCutoffDate:14DEC2020 | BasedonacLDAmodelwiththePROscoresastheresponsevariablewithcovariatesfortreatmentbystudyvisitinteraction,stratificationfactorsmetastasisstatus(MOversus MINED),andwithinMOgroupfurther stratified byECOGPS(Oversus1)andUSparticipant(YesversusNo)ascovariates. Forbaseline andWeek52,Nisthenumberofsubjects in each treatmentgroupwithnon-missingassessments at thespecifictimepoint;forchangefrombaseline,N is the numberofsubjectsintheanalysispopulationineachtreatmentgroup. DatabaseCutoffDate:14DEC2020 | BasedonacLDAmodelwiththePROscoresastheresponsevariablewithcovariatesfortreatmentbystudyvisitinteraction,stratificationfactorsmetastasisstatus(MOversus MINED),andwithinMOgroupfurther stratified byECOGPS(Oversus1)andUSparticipant(YesversusNo)ascovariates. Forbaseline andWeek52,Nisthenumberofsubjects in each treatmentgroupwithnon-missingassessments at thespecifictimepoint;forchangefrombaseline,N is the numberofsubjectsintheanalysispopulationineachtreatmentgroup. DatabaseCutoffDate:14DEC2020 | BasedonacLDAmodelwiththePROscoresastheresponsevariablewithcovariatesfortreatmentbystudyvisitinteraction,stratificationfactorsmetastasisstatus(MOversus MINED),andwithinMOgroupfurther stratified byECOGPS(Oversus1)andUSparticipant(YesversusNo)ascovariates. Forbaseline andWeek52,Nisthenumberofsubjects in each treatmentgroupwithnon-missingassessments at thespecifictimepoint;forchangefrombaseline,N is the numberofsubjectsintheanalysispopulationineachtreatmentgroup. DatabaseCutoffDate:14DEC2020 | BasedonacLDAmodelwiththePROscoresastheresponsevariablewithcovariatesfortreatmentbystudyvisitinteraction,stratificationfactorsmetastasisstatus(MOversus MINED),andwithinMOgroupfurther stratified byECOGPS(Oversus1)andUSparticipant(YesversusNo)ascovariates. Forbaseline andWeek52,Nisthenumberofsubjects in each treatmentgroupwithnon-missingassessments at thespecifictimepoint;forchangefrombaseline,N is the numberofsubjectsintheanalysispopulationineachtreatmentgroup. DatabaseCutoffDate:14DEC2020 | BasedonacLDAmodelwiththePROscoresastheresponsevariablewithcovariatesfortreatmentbystudyvisitinteraction,stratificationfactorsmetastasisstatus(MOversus MINED),andwithinMOgroupfurther stratified byECOGPS(Oversus1)andUSparticipant(YesversusNo)ascovariates. Forbaseline andWeek52,Nisthenumberofsubjects in each treatmentgroupwithnon-missingassessments at thespecifictimepoint;forchangefrombaseline,N is the numberofsubjectsintheanalysispopulationineachtreatmentgroup. DatabaseCutoffDate:14DEC2020 |

## Overall Improvement and Overall Improvement/Stability in FKSI-DRS and EORTC QLQ-C30 Global Health Status/Quality of Life

The percentage of participants with improvement and improvement/stability in FKSI-DRS score was numerically higher in the placebo group (12.2% [95% CI: 9.4, 15.4] and 66.1% [95% CI: 61.8, 70.3], respectively) compared with the pembrolizumab group (7.7% [95% CI: 5.5, 10.4] and 56.9% [95% CI: 52.4, 61.4], respectively). The percentage of participants who experienced deterioration in FKSI-DRS score was 30.6% (95% CI: 26.6, 35.0) in the pembrolizumab group and 23.1% (95% CI: 19.5, 27.1) in the placebo group.

## Ancillary analyses

## Subgroup analyses

Consistent treatment effects were observed for DFS by investigator assessment across the prespecified subgroups with all CIs overlapping the CI for the primary DFS HR.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Dalabase Cutoff Date:14DEC2020

Figure 10 Forest Plot of Disease-Free Survival Hazard Ratio by Subgroup Factors Based on Investigator Assessment (Primary Censoring Rule) (ITT Population)

## PD-L1 expression subgroups

## PD-L1 Expression (CPS&lt;1)

Table 22 Analysis of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment (ITT Population)(CPS&lt;1)

<div style=\"page-break-after: always\"></div>

|                                               | Pembrolizumab (N=124)    | Placebo (N=113)   |
|-----------------------------------------------|--------------------------|-------------------|
| Number of Events (%)                          | 20 (16.1)                | 22 (19.5)         |
| Death                                         | 2 (1.6)                  | 0 (0)             |
| Disease Recurrence                            | 18 (14.5)                | 22 (19.5)         |
| Number of Censored (%)                        | 104 (83.9)               | 91 (80.5)         |
| LastTumorAssessmentShowingNoDiseaseRecurrence | 99 (79.8)                | 91 (80.5)         |
| No Post-Baseline Disease Status Assessment    | 5 (4.0)                  | 0 (0)             |
| Kaplan-Meier Estimates (months)a              |                          |                   |
| Median (95% CI)                               | NR (NR. NR)              | NR (NR, NR)       |
| [Q1,Q3]                                       | [NR, NR]                 | [NR, NR]          |
| person-months                                 | 2566.6                   | 2282.7            |
| Event Rate / 100 person-months                | 0.8                      | 1.0               |
| vs Placebo                                    |                          |                   |
| Hazard Ratio (95% CIb p-valuec                | 0.83 (0.45, 1.51) 0.2678 |                   |
| DFS Rate at month 12 (%)(95% CI)              | 89.8 (82.7, 94.1)        | 85.7 (77.7, 91.0) |
| DFS Rate at month 18 (%) (95% CI)             | 86.0 (78.1, 91.2)        | 82.4 (73.7, 88.4) |
| DFS Rate at month 24 (%) (95% CI)             | 82.7 (73.5, 89.0)        | 78.5 (69.0, 85.4) |

NR = Not reached.

Database CutoffDate:14DEC2020

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 11 Kaplan-Meier Plot of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment (ITT Population)(CPS&lt;1)

Table 23 Analysis of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment (ITT Population)(CPS&lt;1) (updated Data cutoff 14 Jun 2021)

25 (22.1)

1 (0.9)

24 (21.2)

88 (77.9)

88 (77.9)

0 (0)

NR (NR, NR)

[39.2, NR]

2810.7

0.9

85.7 (77.8, 91.0)

83.0 (74.6, 88.8)

78.0 (68.9, 84.7)

|                                                                                                                                                                                                                           | Pembrolizumab (N=124)                                                                            | Placebo                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Number of Events (%) Death Disease Recurrence Number of Censored (%) Last Tumor Assessment Showing No Recurrence No Post-Baseline Disease Status Kaplan-Meier Estimates (months) a Median (95% CI) [Q1, Q3] person-months | 19 (15.3) 2 (1.6) 17 (13.7) 105 (84.7) 100 (80.6) 5 (4.0) NR (NR, NR) [NR, NR] 3130.6 0.6 (0.37, | (N=113) 25 (22.1) 1 (0.9) 24 (21.2) 88 (77.9) 88 (77.9) 0 (0) NR (NR, NR) [39.2, NR] 2810.7 0.9 |
| Disease                                                                                                                                                                                                                   |                                                                                                  |                                                                                                 |
| Assessment                                                                                                                                                                                                                |                                                                                                  |                                                                                                 |
| Event Rate / 100 person-months                                                                                                                                                                                            |                                                                                                  |                                                                                                 |
| vs Placebo                                                                                                                                                                                                                |                                                                                                  |                                                                                                 |
| Hazard Ratio (95% CI) b                                                                                                                                                                                                   | 0.68 1.24)                                                                                       |                                                                                                 |
| p-value c                                                                                                                                                                                                                 | 0.1018                                                                                           |                                                                                                 |
| DFS Rate at month 12 (%) (95% CI)                                                                                                                                                                                         | 89.8 (82.8, 94.1)                                                                                | 85.7 (77.8, 91.0)                                                                               |
| DFS Rate at month 18 (%) (95% CI)                                                                                                                                                                                         | 87.3 (79.8, 92.1)                                                                                | 83.0 (74.6, 88.8)                                                                               |
| DFS Rate at month 24 (%) (95% CI)                                                                                                                                                                                         | 85.3 (77.4, 90.6)                                                                                | 78.0 (68.9, 84.7)                                                                               |

a  From product-limit (Kaplan-Meier) method for censored data.

b  Based on Cox regression model with Efron's method of tie handling with treatment as a covariate.

c  One-sided p-value based on log-rank test.

<div style=\"page-break-after: always\"></div>

Figure 12 Kaplan-Meier Plot of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment (ITT Population)(CPS&lt;1) (updated Data cutoff date 14 Jun 2021)

<!-- image -->

## PD-L1 Expression(CPS&gt;=1)

Table 24 Analysis of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment (ITT Population)(CPS&gt;=1)

|                                                     | Pembrolizumab (N=365)    | Placebo (N=383)   |
|-----------------------------------------------------|--------------------------|-------------------|
| Number of Events (%)                                | 87 (23.8)                | 128 (33.4)        |
| Death                                               | 4(1.1)                   | 2 (0.5)           |
| Disease Recurrence                                  | 83 (22.7)                | 126 (32.9)        |
| Number ofCensored (%)                               | 278 (76.2)               | 255 (66.6)        |
| Last Tumor Assessment Showing No Disease Recurrence | 272 (74.5)               | 252 (65.8)        |
| No Post-Baseline Disease Status Assessment          | 6(1.6)                   | 3 (0.8)           |
| Kaplan-Meier Estimates (months)a                    |                          |                   |
| Median (95% CI)                                     | NR (35.9, NR)            | NR (NR, NR)       |
| [Q1, Q3]                                            | [24.9, NR]               | [11.1, NR]        |
| person-months                                       | 7089.4                   | 6930.7            |
| Event Rate/100 person-months                        | 1.2                      | 1.8               |
| vs Placebo                                          |                          |                   |
| Hazard Ratio (95% CIb p-valuec                      | 0.67 (0.51, 0.88) 0.0019 |                   |
| DFS Rate at month 12 (%) (95% CI)                   | 84.7 (80.5, 88.0)        | 73.5 (68.8, 77.7) |
| DFS Rate at month 18 (%) (95% CI)                   | 80.3 (75.7, 84.1)        | 69.0 (64.1, 73.5) |
| DFS Rate at month 24 (%) (95% CI)                   | 75.7 (70.4, 80.2)        | 65.1 (59.8, 70.0) |

Database Cutoff Date: 14DEC2020

<div style=\"page-break-after: always\"></div>

Figure 13 Kaplan-Meier Plot of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment (ITT Population)(CPS&gt;=1)

<!-- image -->

## Subgroups with different prognosis

## Summary of DFS Results in Baseline Disease Status Subgroups based on updated dataset (14. Jun 2021).

(0.52, 0.89)

(0.33, 1.10)

(0.12, 0.66)

| Baseline Disease Status by Investigator              | Hazard Ratio (95% CI)   |
|------------------------------------------------------|-------------------------|
| Baseline Disease Status of M0                        | 0.68 (0.53, 0.88)       |
| Baseline Disease Status of M0-Intermediate-High Risk | 0.68 (0.52, 0.89)       |
| Baseline Disease Status of M0-High Risk              | 0.60 (0.33, 1.10)       |
| Baseline Disease Status of M1 NED                    | 0.28 (0.12, 0.66)       |

## M1 NED

Table 25 Analysis of Disease-Free Survival (Primary Censoring Rule)  Based on Investigator Assessment (ITT Population)(Baseline Disease Status of M1 NED by Investigator)(updated data cut-off  14JUN2021)

19 (65.5)

1 (3.4)

|                      | Pembrolizumab (N=29)   | Placebo (N=29)   |
|----------------------|------------------------|------------------|
| Number of Events (%) | 7 (24.1)               | 19 (65.5)        |
| Death                | 1 (3.4)                | 1 (3.4)          |

<div style=\"page-break-after: always\"></div>

18 (62.1)

10 (34.5)

10 (34.5)

0 (0)

[5.5, NR]

479.0

4.0

48.3 (29.5, 64.8)

41.4 (23.7, 58.3)

37.9 (20.9, 54.9)

| Disease Recurrence                                                             | 6 (20.7)                                   | 18 (62.1)         |
|--------------------------------------------------------------------------------|--------------------------------------------|-------------------|
| Number of Censored (%)                                                         | 22 (75.9)                                  | 10 (34.5)         |
| Last Tumor Assessment Showing No Disease                                       | 21 (72.4)                                  | 10 (34.5)         |
| No Post-Baseline Disease Status Assessment                                     | 1 (3.4)                                    | 0 (0)             |
| Kaplan-Meier Estimates (months) a Median (95% CI)                              | NR (25.7, NR)                              | 11.6 (5.6, NR)    |
| person-months                                                                  | 665.6                                      | 479.0             |
| Event Rate / 100 person-months                                                 |                                            |                   |
|                                                                                | 1.1                                        | 4.0               |
| vs Placebo Hazard Ratio (95% CI) b p-value c DFS Rate at month 12 (%) (95% CI) | 0.28 (0.12, 0.66) 0.0010 82.1 (62.3, 92.1) | 48.3 (29.5, 64.8) |
| DFS Rate at month 18 (%) (95% CI)                                              | 82.1 (62.3, 92.1)                          | 41.4 (23.7, 58.3) |
| DFS Rate at month 24 (%) (95% CI)                                              | 78.4 (58.1, 89.7)                          | 37.9 (20.9, 54.9) |

NR = Not reached.

Database Cutoff Date: 14JUN2021

| Pembrolizumab   |   29 |   27 |   25 |   23 |   22 |   14 |   6 |   4 | 2 0   |
|-----------------|------|------|------|------|------|------|-----|-----|-------|
| Placebo         |   29 |   24 |   19 |   14 |   12 |    9 |   4 |   2 | 0 0   |

Figure 14 Kaplan-Meier Plot of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment

<!-- image -->

(ITT Population)(Baseline Disease Status of M1 NED by Investigator) 14JUN2021

<div style=\"page-break-after: always\"></div>

M0 DFS by Investigator Assessment in M0

|                                                   | Pembrolizumab (N=467)   | Placebo (N=469)   |
|---------------------------------------------------|-------------------------|-------------------|
| Number of Events (%)                              | 107 (22.9)              | 150 (32.0)        |
| Death                                             | 5 (1.1)                 | 2 (0.4)           |
| Disease Recurrence                                | 102 (21.8)              | 148 (31.6)        |
| Number of Censored (%)                            | 360 (77.1)              | 319 (68.0)        |
| Last Tumor Assessment Showing No Disease          | 349 (74.7)              | 316 (67.4)        |
| No Post-Baseline Disease Status Assessment        | 11 (2.4)                | 3 (0.6)           |
| Kaplan-Meier Estimates (months) a Median (95% CI) | NR (NR, NR)             | NR (40.5, NR)     |
| [Q1, Q3]                                          | [30.2, NR]              | [15.0, NR]        |
| person-months                                     | 11095.7                 | 10594.8           |
| Event Rate / 100 person-months                    | 1.0                     | 1.4               |
| vs Placebo                                        |                         |                   |
| Hazard Ratio (95% CI) b                           | 0.68 (0.53, 0.88)       |                   |
| p-value c                                         | 0.0012                  |                   |
| DFS Rate at month 12 (%) (95% CI)                 | 85.7 (82.2, 88.7)       | 77.8 (73.7, 81.3) |
| DFS Rate at month 18 (%) (95% CI)                 | 82.1 (78.2, 85.3)       | 73.2 (68.9, 77.0) |

NR = Not reached.

Database Cutoff Date: 14JUN2021

Figure 15 Analysis of Disease-Free Survival (Primary Censoring Rule)

Based on Investigator Assessment  (ITT Population)(Baseline Disease Status of M0 by Investigator) updated data cut-off 14JUN2021

150 (32.0)

2 (0.4)

148 (31.6)

319 (68.0)

316 (67.4)

3 (0.6)

NR (40.5, NR)

[15.0, NR]

10594.8

1.4

77.8 (73.7, 81.3)

73.2 (68.9, 77.0)

69.2 (64.7, 73.2)

<div style=\"page-break-after: always\"></div>

Figure 16 Kaplan-Meier Plot of Disease-Free Survival (Primary Censoring Rule Based on Investigator Assessment (ITT Population)(Baseline Disease Status of M0 by Investigator)

<!-- image -->

## DFS by Investigator Assessment in Intermediate-High and High-Risk Subgroups

A post hoc analysis was conducted to evaluate DFS by investigator assessment in subgroups of participants with RCC at M0-intermediate-high risk versus M0-high risk of recurrence.

Table 26 Analysis of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment  (ITT Population) (M0-Intermediate-High Risk by Investigator) Database Cutoff Date: 14DEC2020

3 (0.7)

|                                                     | Pembrolizumab (N=422)   | Placebo (N=433)   |
|-----------------------------------------------------|-------------------------|-------------------|
| Number of Events (%)                                | 83 (19.7)               | 110 (25.4)        |
| Death                                               | 5 (1.2)                 | 1 (0.2)           |
| Disease Recurrence                                  | 78 (18.5)               | 109 (25.2)        |
| Number of Censored (%)                              | 339 (80.3)              | 323 (74.6)        |
| Last Tumor Assessment Showing No Disease Recurrence | 328 (77.7)              | 320 (73.9)        |
| No Post-Baseline Disease Status Assessment          | 11 (2.6)                | 3 (0.7)           |
| Kaplan-Meier Estimates (months) a                   |                         |                   |
| Median (95% CI)                                     | NR (NR, NR)             | NR (NR, NR)       |
| [Q1, Q3]                                            | [30.3, NR]              | [19.5, NR]        |

<div style=\"page-break-after: always\"></div>

83.8)

80.2)

77.3)

| person-months                     | 8425.6            | 8345.5            |
|-----------------------------------|-------------------|-------------------|
| Event Rate / 100 person-months    | 1.0               | 1.3               |
| vs Placebo                        |                   |                   |
| Hazard Ratio (95% CI) b           | 0.75 (0.57, 1.00) |                   |
| p-value c                         | 0.0244            |                   |
| DFS Rate at month 12 (%) (95% CI) | 87.9 (84.3, 90.7) | 80.3 (76.2, 83.8) |
| DFS Rate at month 18 (%) (95% CI) | 83.4 (79.4, 86.8) | 76.4 (72.0, 80.2) |
| DFS Rate at month 24 (%) (95% CI) | 80.1 (75.5, 84.0) | 73.1 (68.3, 77.3) |

Figure 17 Kaplan-Meier Plot of Disease-Free Survival (Primary Censoring Rule)Based on Investigator Assessment (ITT Population) (M0-Intermediate-High Risk by Investigator) Database Cutoff Date: 14DEC2020

<!-- image -->

Table 27 Analysis of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment (ITT Population)(M0-Intermediate-High Risk by Investigator) (updated data cut-off 14JUN2021)

Pembrolizumab

Placebo

<div style=\"page-break-after: always\"></div>

127 (29.3)

2 (0.5)

125 (28.9)

306 (70.7)

303 (70.0)

3 (0.7)

NR (40.5, NR)

[19.1, NR]

10065.0

1.3

80.1 (76.0, 83.6)

75.8 (71.5, 79.6)

72.0 (67.5, 76.1)

|                                                   | (N=422)                  | (N=433)           |
|---------------------------------------------------|--------------------------|-------------------|
| Number of Events (%)                              | 87 (20.6)                | 127 (29.3)        |
| Death                                             | 5 (1.2)                  | 2 (0.5)           |
| Disease Recurrence                                | 82 (19.4)                | 125 (28.9)        |
| Number of Censored (%)                            | 335 (79.4)               | 306 (70.7)        |
| Last Tumor Assessment Showing No Disease          | 324 (76.8)               | 303 (70.0)        |
| No Post-Baseline Disease Status Assessment        | 11 (2.6)                 | 3 (0.7)           |
| Kaplan-Meier Estimates (months) a Median (95% CI) | NR (NR, NR)              | NR (40.5, NR)     |
| [Q1, Q3]                                          | [36.3, NR]               | [19.1, NR]        |
| person-months                                     | 10191.2                  | 10065.0           |
| Event Rate / 100 person-months                    | 0.9                      | 1.3               |
| vs Placebo                                        |                          |                   |
| Hazard Ratio (95% CI) b p-value c                 | 0.68 (0.52, 0.89) 0.0025 |                   |
| DFS Rate at month 12 (%) (95% CI)                 | 87.6 (84.0, 90.5)        | 80.1 (76.0, 83.6) |
| DFS Rate at month 18 (%) (95% CI)                 | 84.1 (80.1, 87.3)        | 75.8 (71.5, 79.6) |
| DFS Rate at month 24 (%) (95% CI)                 | 81.1 (76.8, 84.6)        | 72.0 (67.5, 76.1) |

a  From product-limit (Kaplan-Meier) method for censored data.

b  Based on Cox regression model with Efron's method of tie handling with treatment as a covariate.

c  One-sided p-value based on log-rank test.

NR = Not reached.

Database Cutoff Date: 14JUN2021

<div style=\"page-break-after: always\"></div>

Figure 18 Kaplan-Meier Plot of Disease-Free Survival (Primary Censoring Rule)

<!-- image -->

## Based on Investigator Assessment (ITT Population)(M0-Intermediate-High Risk by Investigator) (14JUN2021)

Table 28 Analysis of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment  (ITT Population) (M0-High Risk by Investigator) Database Cutoff Date: 14DEC2020

22 (61.1)

22 (61.1)

14 (38.9)

14 (38.9)

11.4 (2.9, NR)

[2.9, NR]

|                                                     | Pembrolizumab   | Placebo        |
|-----------------------------------------------------|-----------------|----------------|
| Number of Events (%)                                | 19 (47.5)       | 22 (61.1)      |
| Disease Recurrence                                  | 19 (47.5)       | 22 (61.1)      |
| Number of Censored (%)                              | 21 (52.5)       | 14 (38.9)      |
| Last Tumor Assessment Showing No Disease Recurrence | 21 (52.5)       | 14 (38.9)      |
| Kaplan-Meier Estimates (months) a                   |                 |                |
| Median (95% CI)                                     | 22.4 (11.1, NR) | 11.4 (2.9, NR) |
| [Q1, Q3]                                            | [8.6, NR]       | [2.9, NR]      |

<div style=\"page-break-after: always\"></div>

469.6

4.7

50.0 (32.9, 64.9)

44.4 (28.0, 59.6)

35.6 (19.3, 52.3)

| person-months                     | 676.2             | 469.6             |
|-----------------------------------|-------------------|-------------------|
| Event Rate / 100 person-months    | 2.8               | 4.7               |
| vs Placebo                        |                   |                   |
| Hazard Ratio (95% CI) b           | 0.60 (0.33, 1.11) |                   |
| p-value c                         | 0.0523            |                   |
| DFS Rate at month 12 (%) (95% CI) | 65.0 (48.2, 77.6) | 50.0 (32.9, 64.9) |
| DFS Rate at month 18 (%) (95% CI) | 59.8 (42.9, 73.1) | 44.4 (28.0, 59.6) |
| DFS Rate at month 24 (%) (95% CI) | 48.4 (30.7, 63.9) | 35.6 (19.3, 52.3) |

NR = Not reached.

Database Cutoff Date: 14DEC2020

Figure 19 Kaplan-Meier Plot of Disease-Free Survival (Primary Censoring Rule)Based on Investigator Assessment (ITT Population) (M0-High Risk by Investigator) Database Cutoff Date:14DEC2020

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 29 Analysis of Disease-Free Survival (Primary Censoring Rule)  Based on Investigator Assessment (ITT Population) (pT3, N0, M0, Grade 2-4)  (Database Cutoff Date: 14DEC2020)

99 (24.9)

1 (0.3)

98 (24.6)

299 (75.1)

296 (74.4)

3 (0.8)

NR (NR, NR)

[19.8, NR]

7696.3

1.3

80.6 (76.3, 84.2)

76.9 (72.3, 80.8)

73.7 (68.7, 78.0)

|                                            | Pembrolizumab (N=385)   | Placebo (N=398)   |
|--------------------------------------------|-------------------------|-------------------|
| Number of Events (%)                       | 73 (19.0)               | 99 (24.9)         |
| Death                                      | 4 (1.0)                 | 1 (0.3)           |
| Disease Recurrence                         | 69 (17.9)               | 98 (24.6)         |
| Number of Censored (%)                     | 312 (81.0)              | 299 (75.1)        |
| Last Tumor Assessment Showing No Disease   | 301 (78.2)              | 296 (74.4)        |
| Recurrence                                 |                         |                   |
| No Post-Baseline Disease Status Assessment | 11 (2.9)                | 3 (0.8)           |
| Kaplan-Meier Estimates (months) a          |                         |                   |
| Median (95% CI)                            | NR (NR, NR)             | NR (NR, NR)       |
| [Q1, Q3]                                   | [30.3, NR]              | [19.8, NR]        |
| person-months                              | 7691.6                  | 7696.3            |
| Event Rate / 100 person-months             | 0.9                     | 1.3               |
| vs Placebo                                 |                         |                   |
| Hazard Ratio (95% CI) b                    | 0.74 (0.55, 1.00)       |                   |
| p-value c                                  | 0.0264                  |                   |
| DFS Rate at month 12 (%) (95% CI)          | 88.6 (84.8, 91.4)       | 80.6 (76.3, 84.2) |
| DFS Rate at month 18 (%) (95% CI)          | 84.2 (80.0, 87.7)       | 76.9 (72.3, 80.8) |
| DFS Rate at month 24 (%) (95% CI)          | 80.9 (76.0, 84.9)       | 73.7 (68.7, 78.0) |

Database Cutoff Date: 14DEC2020

<div style=\"page-break-after: always\"></div>

Figure 20 Kaplan-Meier Plot of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment (ITT Population) (pT3, N0, M0, Grade 2-4) (Database Cutoff Date: 14DEC2020)

<!-- image -->

| Pembrolizumab   |   385 |   356 |   325 |   295 |   184 |   121 |   53 |   17 |   1 |
|-----------------|-------|-------|-------|-------|-------|-------|------|------|-----|
| Placebo         |   398 |   358 |   323 |   287 |   175 |   122 |   53 |   16 |   1 |

Table 30 Analysis of Disease-Free Survival (Primary Censoring Rule)  Based on Investigator Assessment (ITT Population) (pT3, N0, M0, Grade 2-4) (Database Cutoff Date: 14JUN2021)

115 (28.9)

2 (0.5)

113 (28.4)

283 (71.1)

280 (70.4)

3 (0.8)

|                                            | Pembrolizumab (N=385)   | Placebo (N=398)   |
|--------------------------------------------|-------------------------|-------------------|
| Number of Events (%)                       | 76 (19.7)               | 115 (28.9)        |
| Death                                      | 4 (1.0)                 | 2 (0.5)           |
| Disease Recurrence                         | 72 (18.7)               | 113 (28.4)        |
| Number of Censored (%)                     | 309 (80.3)              | 283 (71.1)        |
| Last Tumor Assessment Showing No Disease   | 298 (77.4)              | 280 (70.4)        |
| No Post-Baseline Disease Status Assessment | 11 (2.9)                | 3 (0.8)           |
| Kaplan-Meier Estimates (months) a          |                         |                   |

<div style=\"page-break-after: always\"></div>

a  From product-limit (Kaplan-Meier) method for censored data.

| Median (95% CI)                   | NR (NR, NR)       | NR (40.5, NR)     |
|-----------------------------------|-------------------|-------------------|
| [Q1, Q3]                          | [36.3, NR]        | [19.3, NR]        |
| person-months                     | 9301.3            | 9282.1            |
| Event Rate / 100 person-months    | 0.8               | 1.2               |
| vs Placebo                        |                   |                   |
| Hazard Ratio (95% CI) b           | 0.66 (0.49, 0.88) |                   |
| p-value c                         | 0.0024            |                   |
| DFS Rate at month 12 (%) (95% CI) | 88.3 (84.6, 91.2) | 80.4 (76.1, 84.0) |
| DFS Rate at month 18 (%) (95% CI) | 84.9 (80.9, 88.2) | 76.2 (71.7, 80.1) |
| DFS Rate at month 24 (%) (95% CI) | 82.2 (77.8, 85.8) | 72.6 (67.9, 76.8) |

NR = Not reached.

Database Cutoff Date: 14JUN2021

<!-- image -->

[19.3, NR]

9282.1

1.2

80.4 (76.1, 84.0)

76.2 (71.7, 80.1)

72.6 (67.9, 76.8)

<div style=\"page-break-after: always\"></div>

Table 31 Analysis of Disease-Free Survival (Primary Censoring Rule)  Based on Investigator Assessment (ITT Population) (pT3, N0, M0, Grade 1 or pT2 (Grade 4 or sarcomatoid), N0, M0) (Database Cutoff Date: 14DEC2020 )

11 (31.4)

0 (0)

24 (68.6)

24 (68.6)

NR (20.3, NR)

[13.8, NR]

649.2

1.7

0.3360

77.1 (59.5, 87.9)

71.4 (53.4, 83.5)

67.0 (47.8, 80.4)

|                                                                     | Pembrolizumab (N=37)                       | Placebo (N=35)            |
|---------------------------------------------------------------------|--------------------------------------------|---------------------------|
| Number of Events (%)                                                | 10 (27.0) 1 (2.7)                          | 11 (31.4) 0 (0) 11 (31.4) |
| Death                                                               |                                            |                           |
| Disease Recurrence                                                  | 9 (24.3)                                   |                           |
| Number of Censored (%)                                              | 27 (73.0)                                  | 24 (68.6)                 |
| Last Tumor Assessment Showing No Disease Recurrence                 | 27 (73.0)                                  | 24 (68.6)                 |
| Kaplan-Meier Estimates (months) a Median (95% CI) [Q1, Q3]          | NR (NR, NR) [19.2, NR]                     | NR (20.3, NR) [13.8, NR]  |
| person-months                                                       | 734.0                                      | 649.2                     |
| Event Rate / 100 person-months                                      | 1.4                                        | 1.7                       |
| vs Placebo Hazard Ratio (95% CI) b p-value c                        | 0.83 (0.35, 1.95) 0.3360 81.1 (64.4, 90.5) | 77.1 (59.5, 87.9)         |
| DFS Rate at month 12 (%) (95% CI) DFS Rate at month 18 (%) (95% CI) | 75.7 (58.5, 86.5)                          | 71.4 (53.4, 83.5)         |
| DFS Rate at month 24 (%) (95% CI)                                   | 72.4 (54.6, 84.1)                          | 67.0 (47.8, 80.4)         |

Database Cutoff Date: 14DEC2020

<div style=\"page-break-after: always\"></div>

Figure 22 Kaplan-Meier Plot of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment (ITT Population) (pT3, N0, M0, Grade 1 or pT2 (Grade 4 or sarcomatoid), N0, M0) (Database Cutoff Date: 14DEC2020)

<!-- image -->

Table 32 Analysis of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment (ITT Population)(pT3, N0, M0, Grade 1 or pT2 (Grade 4 or sarcomatoid), N0, M0)  (Database Cutoff Date: 14JUN2021 )

12 (34.3)

0 (0)

12 (34.3)

23 (65.7)

23 (65.7)

[13.8, NR]

|                                                     | Pembrolizumab (N=37)   | Placebo (N=35)   |
|-----------------------------------------------------|------------------------|------------------|
| Number of Events (%)                                | 11 (29.7)              | 12 (34.3)        |
| Death                                               | 1 (2.7)                | 0 (0)            |
| Disease Recurrence                                  | 10 (27.0)              | 12 (34.3)        |
| Number of Censored (%)                              | 26 (70.3)              | 23 (65.7)        |
| Last Tumor Assessment Showing No Disease Recurrence | 26 (70.3)              | 23 (65.7)        |
| Kaplan-Meier Estimates (months) a                   |                        |                  |
| Median (95% CI)                                     | NR (NR, NR)            | NR (22.0, NR)    |
| [Q1, Q3]                                            | [19.2, NR]             | [13.8, NR]       |

<div style=\"page-break-after: always\"></div>

782.8

1.5

77.1 (59.5, 87.9)

71.4 (53.4, 83.5)

65.3 (47.1, 78.6)

| person-months                     | 889.9             | 782.8             |
|-----------------------------------|-------------------|-------------------|
| Event Rate / 100 person-months    | 1.2               | 1.5               |
| vs Placebo                        |                   |                   |
| Hazard Ratio (95% CI) b           | 0.84 (0.37, 1.91) |                   |
| p-value c                         | 0.3424            |                   |
| DFS Rate at month 12 (%) (95% CI) | 81.1 (64.4, 90.5) | 77.1 (59.5, 87.9) |
| DFS Rate at month 18 (%) (95% CI) | 75.7 (58.5, 86.5) | 71.4 (53.4, 83.5) |
| DFS Rate at month 24 (%) (95% CI) | 70.1 (52.5, 82.2) | 65.3 (47.1, 78.6) |

Figure 23 Figure 9 Kaplan-Meier Plot of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment (ITT Population) (pT3, N0, M0, Grade 1 or pT2 (Grade 4 or sarcomatoid), N0, M0) (Database Cutoff Date: 14JUN2021)

<!-- image -->

## ECOG-Status

Table 33 Analysis of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment (ITT Population)(ECOG 1)

<div style=\"page-break-after: always\"></div>

|                                                 | Pembrolizumab (N-75)    | Plcebo (N-72)     |
|-------------------------------------------------|-------------------------|-------------------|
| Nunber of Events (%%)                           | 22 (29.3)               | 23 (31.9)         |
| Deah                                            | 3(4.0)                  | 0(0)              |
| Dieare Recumence                                | 19 (25.3)               | 23 (31.9)         |
| Number of Censored (%6)                         | 53 (70.7)               | 49 (68.1)         |
| Last Tunor Awewment Showing NoDisease Recumenca | 48 (61.0)               | 49 (68.1)         |
| No PolBaseline Disense StalusAwwament           | 5(6.7)                  | (0) o             |
| Kaplan Meier Eatimmles (months)                 |                         |                   |
| Medin (9.5% Cl)                                 | 36.3 (25.7, NR)         | NR (222, NR)      |
| [Q1, 03]                                        | [16.8, NR]              | [11.1,NR]         |
| person monhs                                    | 1309.9                  | 1233.2            |
| Event Rale/10 person-monhs                      | 1.7                     | 1.9               |
| vs Plhcebo                                      |                         |                   |
| Harard Ratio (95%C1)b P-valee                   | 0.91 (0.50, 1.3) 0.3699 |                   |
| DFS Rate al m0nth 12(96)(95%6 C1)               | 79.6 (68.0, 87.4)       | 743 (62.3, 82.9)  |
| DFS Rale al momlh 18(%6](95%% L)                | 74.3 (61.8, 83.3)       | 69.0 (563, 78.7)  |
| DFS Rate at month 24(96]195% C1)                | 71.7 (58.4,81.4)        | 61.7 (46.4, 73.8) |

Figure 24 Kaplan-Meier Plot of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment (ITT Population)(ECOG 1)

<!-- image -->

<!-- image -->

## Sarcomatoid (absent/present)

<div style=\"page-break-after: always\"></div>

In a post hoc analysis, DFS by investigator assessment was evaluated in subgroups with and without sarcomatoid features since the presence of sarcomatoid features is considered to be associated with high risk of disease recurrence. Consistent DFS results with pembrolizumab compared with placebo were observed regardless of the presence or absence of sarcomatoid features. The DFS rate at 12 months was 78.2% in the pembrolizumab group and 62.7% in the placebo group in the presence of sarcomatoid features (HR 0.56, 95% CI: 0.29, 1.06) and 86.3% and 78.0%, respectively, in the absence of sarcomatoid features (HR 0.70, 95% CI: 0.53, 0.92).

Table 34 Analysis of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment (ITT Population)(Sarcomatoid Absent at Baseline)

|                                                   | Pembrolizumab (N-117)   | Plhcebo (N-415)   |
|---------------------------------------------------|-------------------------|-------------------|
| Nunber of Events (96)                             | 87 (20.9)               | 118 (28.4)        |
| Dealh                                             | 5(12)                   | 1 (0.2)           |
| Dieie Recumence                                   | 82 (19.7)               | 117 (28.2)        |
| NumberofCensored(6)                               | 330 (79.1)              | 297 (71.6)        |
| Last Tumor Asesihemt Showlng No Disease Recumence | 321 (77.0)              | 294 (70.8)        |
| No PoslBaseline Disease Stalus AMesgnent          | 9(22)                   | 3(0.7)            |
| Kaplan-Meier Estimates (months)                   |                         |                   |
| Medion (9.5%6 C1)                                 | NR (NR, NR)             | NR (NR, NR)       |
| [Q1, 03]                                          | [29.1, NR]              | [16.6, NR]        |
| peron-months                                      | 8325.5                  | 7882.0            |
| Event Rale / 100 person monlhs                    | 1.0                     | 1.5               |
| vs Phcebo                                         |                         |                   |
| Harard Ratio (95% C1)b P-wiluee                   | 0.70 (0.53,0.92) 0.0055 |                   |
| DFS Rale al month 12(26)(9.5% (1)                 | 863 (82 .5,893)         | 78.0 (73.7, 81.7) |
| DFS Rale at m0nh 18(96)(95% CD)                   | 82.6 (78.4, 86.0)       | 74.0 (69.4, 78.0) |
| DFS Rale at month 24(96)(95% C0)                  | 78.5 (73.8,82.5)        | 70.3 (653, 74.6)  |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Datbre OatoffDate:14DEC2020

Figure 25 Kaplan-Meier Plot of Disease-Free Survival (Primary Censoring Rule) Based on Investigator Assessment (ITT Population)(Sarcomatoid Absent at Baseline)

<div style=\"page-break-after: always\"></div>

Table 35Analysis of Disease-FreeSurvival(PrimaryCensoring Rule)Based onInvestigatorAssessment (ITTPopulation)(SarcomatoidPresentedatBaseline)

|                                               | Pembroliznmab (N-52)     | Phcebo (N-59)     |
|-----------------------------------------------|--------------------------|-------------------|
| Number ofEvents (%6)                          | 14 (26.9)                | 26 (44.1)         |
| Dealh                                         | 0(0)                     | 1(1.7)            |
| Disease Recumence                             | 14 (26.9)                | 25 (42.4)         |
| Number ofCensored(%)                          | 38 (73.1)                | 33 (55.9)         |
| Lau Tumor Awesmem Showing No Disnse Recumeice | 38 (73.1)                | 33 (55.9)         |
| Kaplan Meier Estimates (months)               |                          |                   |
| Median (95% CD)                               | NR (25.7, NR)            | NR (113, NR)      |
| [Q1, Q3]                                      | [22.4, NR]               | [7.2, NR]         |
| peron months                                  | 938.1                    | 952.1             |
| Event Rate/ 100 personmonths                  | 1.5                      | 2.7               |
| vs Plcebo                                     |                          |                   |
| Hazard Ratio (95% C1)b p-valuee               | 0.56 (0.29, 1.06) 0.0360 |                   |
| DFS Rate at momth 12(96)(95% C1)              | 78.2 (64.0,87.3)         | 62.7 (49.1, 73.6) |
| DFS Rate at momth 18 (96) (95% Cl)            | 75.9(61.5,85.6)          | 593 (45.7, 70.6)  |
| DFS Rate at month 24(%6) (95% C1)             | 71.5 (54.7, 83.0)        | 53.4 (38.8, 65.9) |

Figure 26Kaplan-MeierPlot of Disease-FreeSurvival(Primary Censoring Rule)Based onInvestigator Assessment(ITTPopulation)(SarcomatoidPresented atbaseline.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Concordance of Disease Recurrence Assessments

## Concordance of Disease Recurrence Assessments pf Investigator vs. BICR in the ITT Population is presented in the Table 36.

Table 36 Concordance of Disease Recurrence Assessments (Investigator vs. BICR)  (ITT Population)

|                                               | Pembrolizumab   | Pembrolizumab   | Placebo   | Placebo   |
|-----------------------------------------------|-----------------|-----------------|-----------|-----------|
|                                               | n               | (%)             | n         | (%)       |
| Participants in population                    | 496             |                 | 498       |           |
| Assessment                                    |                 |                 |           |           |
| Investigator Assessment - Disease Recurred    | 103             |                 | 149       |           |
| Bicr Agreed                                   | 84              | (81.6)          | 129       | (86.6)    |
| Bicr And Investigator Agreed On Time          | 52              | (50.5)          | 86        | (57.7)    |
| Bicr Declared At Earlier Time                 | 32              | (31.1)          | 43        | (28.9)    |
| Bicr Disagreed                                | 19              | (18.4)          | 20        | (13.4)    |
| Investigator Assessment - No Disease Recurred | 379             |                 | 346       |           |
| Bicr Agreed                                   | 351             | (92.6)          | 319       | (92.2)    |
| Bicr Disagreed                                | 28              | (7.4)           | 27        | (7.8)     |
| No Post-Baseline Assessment By Investigator   | 14              |                 | 3         |           |
| No Bicr Assessment                            | 14              | (100.0)         | 3         | (100.0)   |

Number of participants with disease recurred, not recurred and no post-baseline assessments by investigator are used as the denominators for the percentage calculation for the corresponding block of rows.

BICR: Blinded independent central review.

Discrepancy on disease recurrence time is counted when more than 1 imaging assessment timepoint difference is observed.

Database Cutoff Date: 14DEC2020

Differential discordance of disease recurrence based on investigator review versus BICR was estimated and are presented in the table below. The early discrepancy rate was calculated to quantify the frequency with which the investigator review declared disease recurrence early relative to BICR within each treatment group; the late discrepancy rate was calculated to quantify the frequency with which the investigator review declared disease recurrence later than BICR within each treatment group. Based on the criteria in Mannino et al , the estimated difference of early discrepancy rate (0.050) did not cross its threshold value of ≤ -0.05 and the estimated difference of late discrepancy rate (-0.056) also did not cro ss its threshold value of ≥0.075.

Table 37 Differential Discordance of Disease Recurrence Assessments (Investigator vs. BICR)  (ITT Population)

|                                            | Pembrolizumab   | Pembrolizumab   | Placebo   | Placebo   |
|--------------------------------------------|-----------------|-----------------|-----------|-----------|
|                                            | n               | (%)             | n         | (%)       |
| Participants in population                 | 496             |                 | 498       |           |
| Assessment                                 |                 |                 |           |           |
| Investigator Assessment - Disease Recurred | 103             |                 | 149       |           |
| BICR Agreed                                | 84              | (81.6)          | 129       | (86.6)    |
| BICR And Investigator Agreed On Time       | 52              | (50.5)          | 86        | (57.7)    |
| BICR Declared At Earlier Time              | 32              | (31.1)          | 43        | (28.9)    |
| BICR Disagreed                             | 19              | (18.4)          | 20        | (13.4)    |

<div style=\"page-break-after: always\"></div>

| EDR                                  |   0.184 | 0.134   |
|--------------------------------------|---------|---------|
| LDR                                  |   0.627 | 0.683   |
| Difference in EDR (Pembro - Placebo) |   0.05  |         |
| Difference in LDR (Pembro - Placebo) |  -0.056 |         |

Number of participants with disease recurred is used as the denominators for the percentage calculation. BICR: Blinded independent central review. Discrepancy on disease recurrence time is counted when more than 1 imaging assessment timepoint difference is observed.  EDR= Early discrepancy rate, calculated as BICR disagreed / (BICR agreed  + BICR disagreed). LDR= Late discrepancy rate, calculated as BICR declared at earlier time / (BICR declared at earlier time + BICR disagreed). A difference in EDR &lt;=-0.05 or a difference in LDR&gt;=0.075 are suggestive of a systematic bias in the investigator assessment favoring the pembrolizumab arm. Database Cutoff Date: 14DEC2020

In this study, the protocol required radiographic evidence for disease recurrence, while the confirmation by pathological assessments (eg, biopsy) was strongly encouraged. Concordance and discordance of radiographic disease recurrence and local pathological assessment of disease recurrence was analyzed post hoc. Of the 39 participants with disease recurrence determined by investigator review but not by BICR, 17.9% (7 participants, 3 in the pembrolizumab group and 4 in the placebo group) were declared with disease recurrence by investigator review based on both radiographic and pathological evidence, while no disease recurrence was declared by BICR based on imaging only. In addition, of the 55 participants with disease recurrence determined by BICR but not by investigator review, 9.1% (5 participants, 4 in the pembrolizumab group and 1 in the placebo group) were declared with disease recurrence by BICR of imaging, while no disease recurrence was declared by investigator's assessment of imaging plus negative local pathological assessment results. As a result, in the total of 94 participants with discordance of disease recurrence assessments between investigator review and BICR, discordance was generally similar in both groups and 12 (13%) could be explained by the additional local pathological results that were only available for investigator review.

Table 38 Summary of Pathological Assessments for Disease Recurrence (ITT Population)

|                                                                            | Pembrolizumab   | Pembrolizumab   | Placebo   | Placebo   | Total   | Total   |
|----------------------------------------------------------------------------|-----------------|-----------------|-----------|-----------|---------|---------|
|                                                                            | n               | (%)             | n         | (%)       | n       | (%)     |
| Participantsinpopulation                                                   | 496             |                 | 498       |           | 994     |         |
| DiseaserecurrencebyINV,withBICRagreed                                      | 84              |                 | 129       |           | 213     |         |
| Determinedbyimagingwithoutpathological confirmation                        | 68              | (81.0)          | 105       | (81.4)    | 173     | (81.2)  |
| Determinedbyimagingfistwithsubscquent pathological confirmation            | 16              | (19.0)          | 20        | (15.5)    | 36      | (16.9)  |
| Determinedbypathological assessmentfirstwithsubsequent imagingconfirmation |                 |                 | 4         | (3.1)     | +       | (1.9)   |
| Discaserecurrence byINV,withBICRdisagrecd                                  | 19              |                 | 20        |           | 39      |         |
| Determined by imaging without pathological confimmation                    | 16              | (84.2)          | 15        | (75.0)    | 31      | (79.5)  |
| Determined byimagingfistwithsubsequentpathologicalconfirmation             | 3               | (15.8)          | 4         | (20.0)    | 7       | (17.9)  |
| Determinedbypathological assessmentwithoutimagingconfirmation              |                 |                 | 1         | (5.0)     | 1       | (2.6)   |
| Nodisease recuirence byINV,with BICR disagreed                             | 28              |                 | 27        |           | 55      |         |
| Pathological assessmentwastakenwithnegativeresultsbyINV                    | 4               | (14.3)          | 1         | (3.7)     | 5       | (9.1)   |

BICR:Blinded independent central review.INV: Investigator assessment.

Pathological assessment of radiographic disease recurrence by investigator's review is optional. Disease recuirence by BICR is determined by BlCR ofimaging alone, regardless of pathological assessment results.

DatabaseCutoffDate:14DEC2020

Source:[P564V01MK3475:adam-adsl][P564V01MK3475:analysis-biopsy]

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 39 Summary of Efficacy for Trial KEYNOTE-564

<div style=\"page-break-after: always\"></div>

| Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)   | Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)            | Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)            | Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)                                                                                |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                           | KEYNOTE-564; P564V01MK3475 EudraCT: 2016-004351-75 NCT: NCT03142334                                                                                                                                                 | KEYNOTE-564; P564V01MK3475 EudraCT: 2016-004351-75 NCT: NCT03142334                                                                                                                                                 | KEYNOTE-564; P564V01MK3475 EudraCT: 2016-004351-75 NCT: NCT03142334                                                                                                                                                                                                                     |
| Design                                                                                                                                                                                                     | Phase 3, multicenter, efficacy, safety, randomized, double-blind, placebo-controlled, intervention study                                                                                                            | Phase 3, multicenter, efficacy, safety, randomized, double-blind, placebo-controlled, intervention study                                                                                                            | Phase 3, multicenter, efficacy, safety, randomized, double-blind, placebo-controlled, intervention study                                                                                                                                                                                |
|                                                                                                                                                                                                            | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                      | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                      | Approximately 1 year Not applicable Post-treatment follow-up 5 years and beyond                                                                                                                                                                                                         |
| Hypotheses                                                                                                                                                                                                 | Pembrolizumab is superior to placebo with respect to the primary endpoint of disease-free survival (DFS). Pembrolizumab is superior to placebo with respect to the key secondary endpoint of overall survival (OS). | Pembrolizumab is superior to placebo with respect to the primary endpoint of disease-free survival (DFS). Pembrolizumab is superior to placebo with respect to the key secondary endpoint of overall survival (OS). | Pembrolizumab is superior to placebo with respect to the primary endpoint of disease-free survival (DFS). Pembrolizumab is superior to placebo with respect to the key secondary endpoint of overall survival (OS).                                                                     |
| Treatment groups                                                                                                                                                                                           | Pembrolizumab                                                                                                                                                                                                       | Pembrolizumab                                                                                                                                                                                                       | Pembrolizumab 200 mg infusion every 3 weeks (Q3W) for up to 17 cycles (approximately 1 year) 496 participants randomized (Intent-to-Treat [ITT] population) 488 participants treated Discontinued study treatment: 190 participants Most common reason: Adverse event (AE): 104 (21.3%) |
|                                                                                                                                                                                                            | Placebo                                                                                                                                                                                                             | Placebo                                                                                                                                                                                                             | Placebo (saline) infusion Q3W for up to 17 cycles (approximately 1 year) 498 participants randomized (ITT population) 496 participants treated Discontinued study treatment: 130 participants Most common reason: Disease relapse: 101 (20.4%)                                          |
| Endpoints and definitions                                                                                                                                                                                  | Primary endpoint                                                                                                                                                                                                    | DFS by Investigator Assessment                                                                                                                                                                                      | DFS as assessed by the investigator: time from randomization to the first documented local recurrence, or occurrence of distant kidney cancer metastasis(es), or death due to any cause, whichever occurs first                                                                         |
| Endpoints and definitions                                                                                                                                                                                  | Key secondary endpoint                                                                                                                                                                                              | OS                                                                                                                                                                                                                  | OS: time from randomization to death due to any cause                                                                                                                                                                                                                                   |
| Database lock                                                                                                                                                                                              | 26-JAN-2021; data cutoff date for interim analysis 1 (IA1) was 14-DEC-2020.                                                                                                                                         | 26-JAN-2021; data cutoff date for interim analysis 1 (IA1) was 14-DEC-2020.                                                                                                                                         | 26-JAN-2021; data cutoff date for interim analysis 1 (IA1) was 14-DEC-2020.                                                                                                                                                                                                             |
| Results and Analysis                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                    |
| Analysis description                                                                                                                                                                                       | Primary analysis: DFS by Investigator Assessment                                                                                                                                                                    | Primary analysis: DFS by Investigator Assessment                                                                                                                                                                    | Primary analysis: DFS by Investigator Assessment                                                                                                                                                                                                                                        |
| Analysis population and time point description                                                                                                                                                             | ITT (all randomized participants, analyzed in the treatment group to which they were randomized) Event-driven by prespecified number of DFS events                                                                  | ITT (all randomized participants, analyzed in the treatment group to which they were randomized) Event-driven by prespecified number of DFS events                                                                  | ITT (all randomized participants, analyzed in the treatment group to which they were randomized) Event-driven by prespecified number of DFS events                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Descriptive statistics and estimate variability   | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                  | Pembrolizumab                                                                                                                                                                                                                                                                                                                                                                                                                    | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability   | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                               | 496                                                                                                                                                                                                                                                                                                                                                                                                                              | 498                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability   | Death: Disease Recurrence: Kaplan-Meier Estimates: Median, months (95% CI): Q1, Q3:                                                                                                                                                                                                                                                                                                                                              | 6 (1.2%) 103 (20.8%) Not reached (NR, NR) 25.8, NR                                                                                                                                                                                                                                                                                                                                                                               | 2 (0,4%) 149 (29.9%) Not reached (NR, NR) 13.8, NR                                                                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability   | Death: Disease Recurrence: Kaplan-Meier Estimates: Median, months (95% CI): Q1, Q3:                                                                                                                                                                                                                                                                                                                                              | From product-limit (Kaplan-Meier) method for censored data. Primary censoring rule.                                                                                                                                                                                                                                                                                                                                              | From product-limit (Kaplan-Meier) method for censored data. Primary censoring rule.                                                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                    | Primary endpoint: DFS by Investigator Assessment                                                                                                                                                                                                                                                                                                                                                                                 | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                | Pembrolizumab vs. Placebo                                                                                                                                                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison                    | Primary endpoint: DFS by Investigator Assessment                                                                                                                                                                                                                                                                                                                                                                                 | Hazard ratio:                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.68                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Effect estimate per comparison                    | Primary endpoint: DFS by Investigator Assessment                                                                                                                                                                                                                                                                                                                                                                                 | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.53, 0.87                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                                   | Primary endpoint: DFS by Investigator Assessment                                                                                                                                                                                                                                                                                                                                                                                 | Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastasis status (M0 versus M1 NED by investigator) and Eastern Oncology Cooperative Group (ECOG) performance score (PS) (0 versus 1), US participant (Yes vs. No) within M0 group by investigator.                                                                                                               | Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastasis status (M0 versus M1 NED by investigator) and Eastern Oncology Cooperative Group (ECOG) performance score (PS) (0 versus 1), US participant (Yes vs. No) within M0 group by investigator.                                                                                                               |
|                                                   | Primary endpoint: DFS by Investigator Assessment                                                                                                                                                                                                                                                                                                                                                                                 | P-value                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.0010                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                   | Primary endpoint: DFS by Investigator Assessment                                                                                                                                                                                                                                                                                                                                                                                 | One-sided p-value based on log-rank test stratified by metastasis status (M0 versus M1 NED by investigator) and ECOG PS (0 versus 1), US participant (Yes vs. No) within M0 group by investigator.                                                                                                                                                                                                                               | One-sided p-value based on log-rank test stratified by metastasis status (M0 versus M1 NED by investigator) and ECOG PS (0 versus 1), US participant (Yes vs. No) within M0 group by investigator.                                                                                                                                                                                                                               |
| Notes                                             | A total of 260 DFS events (78% of the total planned events at final analysis) were observed in the 2 treatment groups (109 in the pembrolizumab group and 151 in the placebo group). At the prespecified 2.5% overall alpha level (one-sided), pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in DFS compared with placebo (median DFS was not reached in either treatment group). | A total of 260 DFS events (78% of the total planned events at final analysis) were observed in the 2 treatment groups (109 in the pembrolizumab group and 151 in the placebo group). At the prespecified 2.5% overall alpha level (one-sided), pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in DFS compared with placebo (median DFS was not reached in either treatment group). | A total of 260 DFS events (78% of the total planned events at final analysis) were observed in the 2 treatment groups (109 in the pembrolizumab group and 151 in the placebo group). At the prespecified 2.5% overall alpha level (one-sided), pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in DFS compared with placebo (median DFS was not reached in either treatment group). |

<div style=\"page-break-after: always\"></div>

| Analysis description                            | Key secondary endpoint: OS                                                                                                                                                                                                                                                                                                                                                         | Key secondary endpoint: OS                                                                                                                                                                                                                                                                                                                                                         | Key secondary endpoint: OS                                                                                                                                                                                                                                                                                                                                                         |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description  | ITT (all randomized participants, analyzed in the treatment group to which they were randomized) Event-driven by prespecified number of DFS events                                                                                                                                                                                                                                 | ITT (all randomized participants, analyzed in the treatment group to which they were randomized) Event-driven by prespecified number of DFS events                                                                                                                                                                                                                                 | ITT (all randomized participants, analyzed in the treatment group to which they were randomized) Event-driven by prespecified number of DFS events                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                    | Pembrolizumab                                                                                                                                                                                                                                                                                                                                                                      | Placebo                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                                 | 496                                                                                                                                                                                                                                                                                                                                                                                | 498                                                                                                                                                                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability | Number of events                                                                                                                                                                                                                                                                                                                                                                   | 18 (3.6%)                                                                                                                                                                                                                                                                                                                                                                          | 33 (6.6%)                                                                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability | Kaplan-Meier Estimates: Median, months (95% CI): Q1, Q3:                                                                                                                                                                                                                                                                                                                           | NR (NR, NR) NR, NR From product-limit                                                                                                                                                                                                                                                                                                                                              | NR (NR, NR) NR, NR (Kaplan-Meier) method for censored                                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                  | Primary endpoint: DFS by Investigator Assessment                                                                                                                                                                                                                                                                                                                                   | Comparison groups                                                                                                                                                                                                                                                                                                                                                                  | Pembrolizumab vs. Placebo                                                                                                                                                                                                                                                                                                                                                          |
| Effect estimate per comparison                  | Primary endpoint: DFS by Investigator Assessment                                                                                                                                                                                                                                                                                                                                   | Hazard ratio:                                                                                                                                                                                                                                                                                                                                                                      | 0.54                                                                                                                                                                                                                                                                                                                                                                               |
| Effect estimate per comparison                  | Primary endpoint: DFS by Investigator Assessment                                                                                                                                                                                                                                                                                                                                   | 95% CI                                                                                                                                                                                                                                                                                                                                                                             | 0.30, 0.96                                                                                                                                                                                                                                                                                                                                                                         |
| Effect estimate per comparison                  | Primary endpoint: DFS by Investigator Assessment                                                                                                                                                                                                                                                                                                                                   | Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastasis status (M0 versus M1 NED by investigator) and ECOG PS (0 versus 1), US participant (Yes vs. No) within M0 group by investigator.                                                                                                                          | Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastasis status (M0 versus M1 NED by investigator) and ECOG PS (0 versus 1), US participant (Yes vs. No) within M0 group by investigator.                                                                                                                          |
| Effect estimate per comparison                  | Primary endpoint: DFS by Investigator Assessment                                                                                                                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                                                                                                                                                                            | 0.0164037                                                                                                                                                                                                                                                                                                                                                                          |
| Effect estimate per comparison                  | Primary endpoint: DFS by Investigator Assessment                                                                                                                                                                                                                                                                                                                                   | One-sided p-value based on log-rank test stratified by metastasis status (M0 versus M1 NED by investigator) and ECOG PS (0 versus 1), US participant (Yes vs. No) within M0 group by investigator.                                                                                                                                                                                 | One-sided p-value based on log-rank test stratified by metastasis status (M0 versus M1 NED by investigator) and ECOG PS (0 versus 1), US participant (Yes vs. No) within M0 group by investigator.                                                                                                                                                                                 |
| Notes                                           | The OS data were immature at IA1 with 51 deaths (26% of total planned OS events at the final analysis). The p-value did not cross the statistical hypothesis testing p-value boundary of 9.3×10 -6 at IA1. The upper bound of 95% CI for the OS hazard ratio was below 1.0, with nearly twice as many deaths in the placebo group (33) compared with the pembrolizumab group (18). | The OS data were immature at IA1 with 51 deaths (26% of total planned OS events at the final analysis). The p-value did not cross the statistical hypothesis testing p-value boundary of 9.3×10 -6 at IA1. The upper bound of 95% CI for the OS hazard ratio was below 1.0, with nearly twice as many deaths in the placebo group (33) compared with the pembrolizumab group (18). | The OS data were immature at IA1 with 51 deaths (26% of total planned OS events at the final analysis). The p-value did not cross the statistical hypothesis testing p-value boundary of 9.3×10 -6 at IA1. The upper bound of 95% CI for the OS hazard ratio was below 1.0, with nearly twice as many deaths in the placebo group (33) compared with the pembrolizumab group (18). |
| Results and Analysis                            | Results and Analysis                                                                                                                                                                                                                                                                                                                                                               | Results and Analysis                                                                                                                                                                                                                                                                                                                                                               | Results and Analysis                                                                                                                                                                                                                                                                                                                                                               |
| Analysis description                            | Updated analysis (data cut-off 14. Jun 2021): DFS by Investigator Assessment                                                                                                                                                                                                                                                                                                       | Updated analysis (data cut-off 14. Jun 2021): DFS by Investigator Assessment                                                                                                                                                                                                                                                                                                       | Updated analysis (data cut-off 14. Jun 2021): DFS by Investigator Assessment                                                                                                                                                                                                                                                                                                       |
| Analysis population and time point description  | ITT (all randomized participants, analyzed in the treatment group to which they were randomized)                                                                                                                                                                                                                                                                                   | ITT (all randomized participants, analyzed in the treatment group to which they were randomized)                                                                                                                                                                                                                                                                                   | ITT (all randomized participants, analyzed in the treatment group to which they were randomized)                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                    | Pembrolizumab                                                                                                                                                                                                                                                                                                                                                                      | Placebo                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                                 | 496                                                                                                                                                                                                                                                                                                                                                                                | 498                                                                                                                                                                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability | Deaths:                                                                                                                                                                                                                                                                                                                                                                            | 6 (1.2%)                                                                                                                                                                                                                                                                                                                                                                           | 3 (0.6)                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | Disease recurrence:                                                                                                                                                                                                                                                                                                                                                                | 108 (21.8%)                                                                                                                                                                                                                                                                                                                                                                        | 166 (33.3)                                                                                                                                                                                                                                                                                                                                                                         |
| Descriptive statistics and estimate variability | Kaplan-Meier Estimates:                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

0. 0047677

|                                                 |                                                                                                                          | From product-limit (Kaplan-Meier) method for censored data. Primary censoring rule.                                      | From product-limit (Kaplan-Meier) method for censored data. Primary censoring rule.                                      |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| Effect estimate per comparison                  | Primary endpoint: DFS by Investigator Assessment                                                                         | Comparison groups                                                                                                        | Pembrolizumab vs. Placebo                                                                                                |
|                                                 |                                                                                                                          | Hazard ratio:                                                                                                            | 0.63                                                                                                                     |
|                                                 |                                                                                                                          | 95% CI                                                                                                                   | 0.50, 0.80                                                                                                               |
|                                                 |                                                                                                                          | P-value                                                                                                                  | < 0.0001                                                                                                                 |
| Analysis description                            | Updated analysis (14 Jun 2021): Key secondary endpoint: OS                                                               | Updated analysis (14 Jun 2021): Key secondary endpoint: OS                                                               | Updated analysis (14 Jun 2021): Key secondary endpoint: OS                                                               |
| Analysis population and time point description  | ITT (all randomized participants, analyzed in the treatment group to which they were randomized)                         | ITT (all randomized participants, analyzed in the treatment group to which they were randomized)                         | ITT (all randomized participants, analyzed in the treatment group to which they were randomized)                         |
| Descriptive statistics and estimate variability | Treatment group                                                                                                          | Pembrolizumab                                                                                                            | Placebo                                                                                                                  |
|                                                 | Number of subjects                                                                                                       | 496                                                                                                                      | 498                                                                                                                      |
|                                                 | Number of events                                                                                                         | 23 (4.6%)                                                                                                                | 43(8.6%)                                                                                                                 |
|                                                 | Kaplan-Meier Estimates: Median, months (95% CI): Q1, Q3:                                                                 | NR (NR, NR) [NR, NR]                                                                                                     | NR (NR, NR) [NR, NR]                                                                                                     |
|                                                 |                                                                                                                          | From product-limit (Kaplan-Meier) method for censored                                                                    | From product-limit (Kaplan-Meier) method for censored                                                                    |
| Effect estimate per comparison                  | Primary endpoint: DFS by Investigator Assessment                                                                         | Comparison groups                                                                                                        | Pembrolizumab vs. Placebo                                                                                                |
|                                                 |                                                                                                                          | Hazard ratio:                                                                                                            | 0.52                                                                                                                     |
|                                                 |                                                                                                                          | 95% CI                                                                                                                   | 0.31, 0.86                                                                                                               |
|                                                 |                                                                                                                          | P-value                                                                                                                  | 0. 0047677                                                                                                               |
| Notes                                           | The OS data were immature at the updated analysis with 66 deaths (33% of total planned OS events at the final analysis). | The OS data were immature at the updated analysis with 66 deaths (33% of total planned OS events at the final analysis). | The OS data were immature at the updated analysis with 66 deaths (33% of total planned OS events at the final analysis). |

## Clinical studies in special populations

No data in special populations have been provided.

## 2.4.3. Discussion on clinical efficacy

This is an extension of indication for pembrolizumab in the adjuvant treatment of patients at immediate/high and high risk of recurrent renal carcinoma (RCC) post nephrectomy supported by the results from the pivotal phase III study KEYNOTE-564 of pembrolizumab vs. placebo.

<div style=\"page-break-after: always\"></div>

## Design and conduct of clinical studies

KEYNOTE-564 is an international, multicenter, randomized, double-blind, Phase III study of adjuvant pembrolizumab 200 mg Q3W for 17 cycles or 1 year vs. placebo in patients with RCC at intermediatehigh or high risk of recurrence following nephrectomy.

Overall, the population recruited is a so-called 'intermediate-high' and 'high' risk subset. In the literature, there is no clear consensus about the definition for high risk. The MAH definition seems to replicate partially the UCLA Integrated Staging System (UISS) that incorporates the TNM classification, ECOG PS score, and Fuhrman grade. To define the 'intermediate-high' risk group, the MAH included a subset of the UISS intermediate risk criteria and a subset of UISS high risk criteria to select patients with higher risk of recurrence. Considering the outcome in the control arm, the chosen criteria appear to be relevant to determine a more dismal prognosis. Therefore, criteria used to define the proposed target population 'adults with RCC at intermediate-high or high risk of recurrence ' can be considered acceptable.

## Indication wording

KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions (for selection of criteria, please see section 5.1)

Only patients with ECOG PS 0-1 were enrolled. Median age was 60 years, which is younger than the usual age at diagnosis of RCC (64 years (NCI).

Since there are currently no approved adjuvant treatments for RCC, the placebo-controlled design appears appropriate.

DFS according to investigator review could be an acceptable primary endpoint considering the adjuvant treatment setting, the inclusion of OS as secondary endpoint and the double-blind placebo controlled trial. However, in the Scientific Advice (EMEA/H/SA/2437/16/2016/II) the MAH stated that DFS by Blinded independent central review (BICR) was planned to be the primary endpoint of KN564. In the light of the typical safety profile of pembrolizumab, it could be anticipated that the blinding of the investigator could be corrupted and therefore the assessment of the investigator could be biased.

The statistical analysis plan is overall acceptable. The definition of time-to-event variables DFS and OS as time from randomization to the event is supported. The approach to DFS as a composite of objective disease recurrence or death from any cause (whichever occurs first), and an additional analysis of OS as key-secondary endpoint is in line with current guidance (Guideline on multiplicity issues in clinical trials, EMA/CHMP/44762/201). Censoring rules for the primary endpoint DFS are generally supported. The approach to interim analyses is in principle acceptable.

## Efficacy data and additional analyses

The data cut-off for the submitted IA1 was 14th Dec 2020 with a median follow-up of 23.9 months (range 2.5 to 41.5 months). Efficacy analyses were performed on the ITT population. Baseline patients and disease characteristics appeared overall balanced between the two arms. Patients were classified in 'intermediate-high' (pT2, Grade 4 or sarcomatoid, N0, M0 / pT3, any grade, N0, M0) with n=86% of the study population, 'high' (pT4, any grade, N0, M0/ pT any stage, any grade, N+, M0) with n=7.6% and 'M1 NED' RCC participants with n=5.8%. Overall, the population is dominated by a so called 'intermediate - high' risk subset.

In the ITT population pembrolizumab showed a statistically significant advantage over placebo in DFS according to investigator assessment [median DFS not reached; HR 0.68 (95%CI: 0.53, 0.87), p =

<div style=\"page-break-after: always\"></div>

0.001]. The probability of being event free at year 1 and year 2 was 85.7% vs. 76.2% and 77.3% vs. 68.1% for pembrolizumab and placebo, respectively. Data were based on 260 events (78% of final analyses). A high number of censoring after 1 year was noted.

The OS data were immature at IA1 with 51 deaths (26% of total planned OS events at the final analysis). For OS, the HR was 0.54 (95% CI: 0.30, 0.96) and the median OS was not reached in either group.  As OS data were too immature, the MAH provided DRSS1 and DRSS2 data (Disease Recurrence-specific Survival as assessed by the investigator) which could support the assumption that DFS results will translate into OS benefit.  In addition, a post hoc exploratory analysis of PFS2 based on investigator assessment (HR: 0.52; 95% CI: 0.34, 0.81) indicated a reduced risk of disease progression or death on next-line drug therapy in the pembrolizumab group compared with the placebo group based on still limited event rates.

PRO assessments, including FKSI-DRS scale, EORTC QLQ-C30 global health status/QoL scale, EORTC QLQ-C30 functional scales, and EORTC QLQ-C30 symptom scales, generally showed limited differences between treatment groups.

During the procedure the MAH Applicant provided updated efficacy results with additional 6 months of follow up (median duration of follow-up 29.7 months based on a data cutoff date of 14-JUN-2021).

In the ITT population 23 additional DFS events had occurred with 5 additional DFS events in the pembrolizumab arm and 18 additional events in the placebo arm; the higher number of additional events in the placebo arm is considered reassuring. The HR for DFS at the updated analysis was 0.63 (95% CI: 0.50, 0.80) in the ITT population, compared with an HR of 0.68 [95% CI: 0.53, 0.87] at IA1. At the updated data cut-off the DFS event rates were 23% and 33.9% in the pembrolizumab arm vs the placebo arm, respectively, thus representing 85% of the planned events at the final DFS analysis. DFS KM curves do not converge anymore at the updated data cut-off and the curves could suggest a trend towards reaching a plateau. In conclusion, the updated results support the DFS benefit that demonstrated statistical significance in the first IA. Overall survival data in the ITT population are still too immature to draw any reliable conclusions; at the updated analyses only 66 events had occurred (33% of the targeted 200 OS events at the final analysis). However, despite the low absolute event rates, nearly twice as many OS events were reported in the placebo arm compared with the pembrolizumab treatment arm (with 5 vs 10 additional OS events in the pembrolizumab vs the placebo arm at the updated DCO date). Nevertheless, the OS data is still immature and the MAH is recommended to provide updated OS data from study KEYNOTE-564 (REC).

Exploratory results of DFS by independent assessment were provided. The HR for DFS by BICR was 0.78 (95% CI: 0.61, 0.99) as compared to 0.63 (95% CI 0.50, 0.80) for the HR of DFS by investigators, based on the most recent data cut-off of June 2021. In line with the inferior point estimate of the HR by BICR the difference of 24 months DFS rates between both treatment arms was smaller for the independent assessment compared to the investigator assessment (5.8% vs 11% for BICR vs. INV, respectively). The disease recurrence assessments by BICR and investigators cannot be considered highly concordant (rates of 80.6% in the pembrolizumab arm and 86.7% in the placebo arm).

Nonetheless, it should be taken into account that the DFS analysis by investigators is rather reflecting the real practice use in the clinical setting. In addition, since the assessment of EFS is a more comprehensive measure of the treatment effect of pembrolizumab in all study participants (also reflecting a delay of disease progression for patients with baseline disease), the results of the EFS analysis by BICR based on the December 2020 data cutoff can be considered supportive: EFS HR 0.72 (95% CI 0.56, 0.91).

As already outlined above, the proposed eligibility criteria ( intermediate-high /high/M1 ) resulted in a heterogeneous population with regard to prognosis and risk of relapse. While it could be reasonably

<div style=\"page-break-after: always\"></div>

assumed that the absolute anti-tumour activity of pembrolizumab was not so much influenced by the stage of disease, the relative magnitude of the effect, and consequently the B/R, might change depending on the baseline risk of relapse. While a clear DFS benefit was detected in the small groups with high risk (HR of 0.60; 95% CI 0.33, 1.11) and M1NED (HR of 0.29; 95% CI 0.12, 0.69), the benefit/risk in the large group of the intermediate-high risk patients (HR of 0.75; 95% CI 0.57, 1.00) could not be adequately determined with the initial submission given the considerable heterogeneity of this subgroup and the immaturity of OS provided, but reassurance was provided with the updated data where the HR for DFS decreased to 0.68 (95% CI: 0.37, 1.24). Attempts to divide the large heterogeneous 'intermediate-high' risk subgroup further into T3 N0 M0 G2-4 (as classified as high risk by UISS) and the complementary group of intermediate-high group risk did not identify a subgroup that would certainly not benefit from the treatment. Although the results in the complementary subgroup (pT3, N0, M0, Grade 1 or pT2 [Grade 4 or sarcomatoid], N0, M0) appeared inferior compared to the T3 N0 M0 G2-4 subgroup, the patient numbers were too small to draw reliable conclusions and given the observed similar dismal prognosis, there is no rationale to assume a lower treatment effect in one of these subgroups.

With the initial data cutoff, the DFS HR was 0.83 (95% CI: 0.45, 1.51) in participants whose tumours express PD-L1 CPS &lt;1 , for the comparison of pembrolizumab compared to placebo. KM curves indicated no clinically meaningful treatment effect in this subgroup. Cumulative data from both arms suggested that PD-L1 expression could be a negative prognostic marker (also based on published literature), resulting in a better prognosis for PD-L1 negative patients as seen in several other indications, which could influence the relative magnitude of the effect. In addition, there is a strong biological plausibility for PD-L1 being predictive. Considering the association of biomarker status and efficacy outcomes, the treatment benefit of pembrolizumab in the overall study population appeared to be driven by the subgroup of patients with high PD-L1 expression status.

With the updated DFS data (DCO 14-Jun-2021) the point estimate of the HR decreased from 0.83 (95% CI 0.45, 1.51) to 0.68 (0.37, 1.24) in the PD-L1 negative subgroup. Thus, the point estimates of the DFS HRs became very similar between the PD-L1 negative and positive subgroups. Considering the point estimates the concern regarding a smaller (and not clinically relevant) benefit in the PD-L1 negative population appears not valid anymore. Updated DFS KM curve for the CPS&lt;1 subgroup showed a separation (Figure 11).

## 2.4.1. Conclusions on the clinical efficacy

Interim data of Study KEYNOTE-564 showed a statistically significant DFS advantage of pembrolizumab over placebo in the adjuvant treatment of RCC. Updated results with additional 6 months of follow-up supported a clinically meaningful DFS benefit in the overall study population. Although survival data were still immature, OS results indicated a trend in favour of pembrolizumab. Further OS data are expected to be submitted as soon as available (REC). Taking the supportive Disease Recurrence-specific Survival and PFS2 results into consideration, a favourable B/R balance is concluded on for patients with RCC at increased risk of recurrence following nephrectomy.

## 2.5. Clinical safety

## Introduction

The safety data set in support of the new indication of pembrolizumab monotherapy in the adjuvant treatment of RCC post nephrectomy derived from 488 participants in Study KEYNOTE-564 (KN564)

<div style=\"page-break-after: always\"></div>

received pembrolizumab (Indication Dataset) and n=496 received placebo. In addition, safety data from the Pembrolizumab Monotherapy Reference Safety Dataset (RSD, n=5884) were included for comparison.

Table 40 Safety Datasets

| KEYNOTE-564 Pembrolizumab (IndicationDataset) N=488                                          | KEYNOTE-564 Placebo N=496                                                 | Pembrolizumab MonotherapyRSD N=5884                        | CumulativeRunningSafety DatasetforPembrolizumab Monotherapy N=9218                                                                                                                                                                             |
|----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| All participants with target indication in KEYNOTE-564who received pembrolizumab monotherapy | All participants with target indication in KEYNOTE-564who receivedplacebo | Represents the established safety profile of pembrolizumab | Provided todemonstratethat no clinically significant changes from the RSD have occurred, supporting the consistency of the safety data ofpembrolizumabacross indications; this dataset is not used as a comparisonwithKEYNOTE- 564 safety data |

The Pembrolizumab Monotherapy Reference Safety Dataset (RSD) RDS comprises pooled safety data from approved indications in the EU from following studies: KN001, KN002, KN006, KN010, KN012 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, and KN087.

## Patient exposure

The median duration of exposure to pembrolizumab was &gt;2-fold longer for participants in the Indication Dataset compared with the RSD (11.1 months vs 4.9 months, respectively), which is expected for pembrolizumab monotherapy when used as an adjuvant treatment.

Table 41 Summary of Drug Exposure

|                                                                                                                               | Pembrolizumab (N-488)                                                                                                         | Placebo (N-496)                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| Duration on therapy (months)                                                                                                  |                                                                                                                               |                                                                                                                               |
| Mean                                                                                                                          | 9.0                                                                                                                           | 9.8                                                                                                                           |
| Median                                                                                                                        | 11.1                                                                                                                          | 11.1                                                                                                                          |
| SD                                                                                                                            | 3.7                                                                                                                           | 3.1                                                                                                                           |
| Range                                                                                                                         | 0.0 to 14.3                                                                                                                   | 0.0 to 15.4                                                                                                                   |
| Number of Administrations                                                                                                     |                                                                                                                               |                                                                                                                               |
| Mean                                                                                                                          | 13.5                                                                                                                          | 14.7                                                                                                                          |
| Median                                                                                                                        | 17.0                                                                                                                          | 17.0                                                                                                                          |
| SD                                                                                                                            | 5.2                                                                                                                           | tt                                                                                                                            |
| Range                                                                                                                         | 1.0 to 17.0                                                                                                                   | 1.0 to 17.0                                                                                                                   |
| Duration on therapy (months) is calculated as (last dose date - first dose date + 1)/30.4367. Database Cutoff Date: 14DEC2020 | Duration on therapy (months) is calculated as (last dose date - first dose date + 1)/30.4367. Database Cutoff Date: 14DEC2020 | Duration on therapy (months) is calculated as (last dose date - first dose date + 1)/30.4367. Database Cutoff Date: 14DEC2020 |

<div style=\"page-break-after: always\"></div>

|                    | Pembrolizumab (N=488)   | Pembrolizumab (N=488)   | Pembrolizumab (N=488)   | Placebo (N=496)   | Placebo (N=496)   | Placebo (N=496)   |
|--------------------|-------------------------|-------------------------|-------------------------|-------------------|-------------------|-------------------|
|                    |                         | (%)                     | Person-time             |                   | (%)               | Person-time       |
| DurationofExposure |                         |                         |                         |                   |                   |                   |
| >0m                | 488                     | (100.0)                 | 4,371.1                 | 496               | (100.0)           | 4,842.7           |
| >=1m               | 463                     | (94.9)                  | 4357.8                  | 493               | (99.4)            | 4,841.3           |
| >=3m               | 428                     | (87.7)                  | 4,284.2                 | 447               | (90.1)            | 4,732.1           |
| >=6 m              | 370                     | (75.8)                  | 4,012.8                 | 413               | (83.3)            | 4,571.2           |
| >=9 m              | 325                     | (66.6)                  | 3,680.6                 | 386               | (77.8)            | 4,363.3           |
| >=12m              | 32                      | (6.6)                   | 414.9                   | 27                | (5.4)             | 353.3             |

Each subject is counted once on each applicable duration category row.

Duration of exposure is the time from the first dose date to the last dose date.

Person-time is caleulated as person time in months.

Database Cutoff Date: 14DEC2020.

Eachparticipant iscounted once on each applicable duration categoryrow.

Duration of Exposure (months) is calculated as (last dose date - first dose date + 1)/30.4367.

Includes all participantswhoreceived at least one dose of pembrolizumabinKN564.

bIncludes all participants who received at least one dose of placebo in KN564.

- Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3,KN002 (original phase), KN006, KN010,KN012 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087.
- Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2,B3,D, C, F1, F2, F3; KN002 (original phase); KN006; KN010; KN012 Cohorts B and B2 (HNSCC), Cohort C (Urothelial Tract Cancer) and Cohort D (Gastric Cancer); KN013 Cohort 3 (cHL) and Cohort 4A (PMBCL); KN024; KN028 Cohort A4 (Esophageal), Cohort B4 Cohort3;KN061;KN062;KN087;KN158CohortE(Cervical),CohortG(SCLC)andTMB-H;KN164CohortA;KN170; KN177; KN180;KN181;KN204;KN224;KN427 Cohort A :KN564; KN629;P017.
- Database cutoff date for Melanoma (KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054: 020CT2017)
- Database cutoff date for Lung (KN001-NSCLC: 23JAN2015,KN010: 30SEP2015, KN024:10JUL2017, KN042: 04SEP2018)
- DatabasecutoffdateforHNSCC(KN012-HNSCC:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055: 22APR2016)
- DatabasecutoffdateforGastric(KN012-Gastric:26APR2016,KN059-Cohort1 andCohort3:08AUG2018,KN061:26OCT2017, KN062:26MAR2019)
- DatabasecutoffdateforcHL(KN013-Cohort3:28SEP2018,KN087:21MAR2019,KN204:16JAN2020)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015, KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff datefor Colorectal (KN164-Cohort A:03AUG2016,KN177: 19FEB2020)

DatabasecutoffdateforPMBCL(KN013-Cohort4A:04AUG2017.KN170:07MAY2020)

DatabasecutoffdateforCervical(KN028-CohortB4:20FEB2017,KN158-CohortE:27JUN2019)

Databasecutoff dateforHCC(KN224:15MAY2018)

DatabasecutoffdateforMerkelCell(P017:06FEB2018)

Database cutoff date for Esophageal (KN028-Cohort A4: 31JAN2018, KN180: 30JUL2018, KN181: 15OCT2018)

Database cutoffdateforRCC(KN427-CohortA:07SEP2018,KN564:14DEC2020)

DatabasecutoffdateforTMB-H(KN158:27JUN2019)

DatabasecutoffdateforSCLC(KN028-CohortC1:31JUL2018,KN158-Cohort G:27JUN2019)

Databasecutoffdatefor NMIBC(KN057:24MAY2019)

Database cutoff date for cSCC (KN629:29JUL2020)

## Demographic and Other Characteristics of Study Population

The demographics and baseline characteristics were generally similar between the Indication Dataset and the RSD apart from ECOG PS and age (lower rate of ECOG PS 1 and more participants ≤ 65 years of age in the Indication Dataset versus the RSD; see Table 5.5.4). The characteristics of participants were well balanced for the Indication Dataset and the placebo group.

Table 42 Participant Characteristics (APaT Population)

<div style=\"page-break-after: always\"></div>

(57.3)

(29.7)

(11.2)

164

(47.9)

(48.8)

311

(3.4)

|                              | KN564 Data for Pembrolizumab   | KN564 Data for Pembrolizumab   | KN564 Data for Placebo   | KN564 Data for Placebo   | Reference Safety Dataset for Pembrolizumab   | Reference Safety Dataset for Pembrolizumab   | Cumulative Running Safety Dataset for Pembrolizumab   | Cumulative Running Safety Dataset for Pembrolizumab   |
|------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|----------------------------------------------|----------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                              | n                              | (%)                            | n                        | (%)                      | n                                            | (%)                                          | n                                                     | (%)                                                   |
| Age Class (Years)            |                                |                                |                          |                          |                                              |                                              |                                                       |                                                       |
| <65                          | 333                            | (68.2)                         | 324                      | (65.3)                   | 3,385                                        | (57.5)                                       | 5,283                                                 | (57.3)                                                |
| 65-74                        | 137                            | (28.1)                         | 147                      | (29.6)                   | 1,737                                        | (29.5)                                       | 2,742                                                 | (29.7)                                                |
| 75-84                        | 18                             | (3.7)                          | 25                       | (5.0)                    | 663                                          | (11.3)                                       | 1,029                                                 | (11.2)                                                |
| >=85                         | 0                              | (0.0)                          | 0                        | (0.0)                    | 99                                           | (1.7)                                        | 164                                                   | (1.8)                                                 |
| ECOG Performance Scale       |                                |                                |                          |                          |                                              |                                              |                                                       |                                                       |
| [0] Normal Activity          | 416                            | (85.2)                         | 424                      | (85.5)                   | 2,761                                        | (46.9)                                       | 4,413                                                 | (47.9)                                                |
| [1] Symptoms, but ambulatory | 72                             | (14.8)                         | 72                       | (14.5)                   | 2,931                                        | (49.8)                                       | 4,494                                                 | (48.8)                                                |
| Other/Missing                | 0                              | (0.0)                          | 0                        | (0.0)                    | 192                                          | (3.3)                                        | 311                                                   | (3.4)                                                 |

## Adverse events

## Adverse event summary

AEs were coded using MedDRA (Version 23.1). AEs were monitored throughout the study and graded in severity according to the guidelines outlined in the NCI CTCAE Version 4.0.

Table 43 Adverse Event Summary (APaT Population)

|                                                               | KN564 Data for Pembrolizumab   | KN564 Data for Pembrolizumab   | KN564 Data for Placebo   | KN564 Data for Placebo   | Reference Safety Dataset for Pembrolizumab   | Reference Safety Dataset for Pembrolizumab   | Cumulative Running Safety Dataset for Pembrolizumab   | Cumulative Running Safety Dataset for Pembrolizumab   |
|---------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|----------------------------------------------|----------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                               | n                              | (%)                            | n                        | (%)                      | n                                            | (%)                                          | n                                                     | (%)                                                   |
| Participants in population                                    | 488                            |                                | 496                      |                          | 5,884                                        |                                              | 9,218                                                 |                                                       |
| with one or more adverse events                               | 470                            | (96.3)                         | 452                      | (91.1)                   | 5,690                                        | (96.7)                                       | 8,890                                                 | (96.4)                                                |
| with no adverse event                                         | 18                             | (3.7)                          | 44                       | (8.9)                    | 194                                          | (3.3)                                        | 328                                                   | (3.6)                                                 |
| with drug-relateda adverse events                             | 386                            | (79.1)                         | 265                      | (53.4)                   | 4,132                                        | (70.2)                                       | 6,375                                                 | (69.2)                                                |
| with toxicity grade 3-5 adverse events                        | 158                            | (32.4)                         | 88                       | (17.7)                   | 2,829                                        | (48.1)                                       | 4,444                                                 | (48.2)                                                |
| with toxicity grade 3-5 drug- related adverse events          | 92                             | (18.9)                         | 6                        | (1.2)                    | 913                                          | (15.5)                                       | 1,490                                                 | (16.2)                                                |
| with serious adverse events                                   | 100                            | (20.5)                         | 56                       | (11.3)                   | 2,266                                        | (38.5)                                       | 3,449                                                 | (37.4)                                                |
| with serious drug-related adverse events                      | 59                             | (12.1)                         | 1                        | (0.2)                    | 656                                          | (11.1)                                       | 1,049                                                 | (11.4)                                                |
| who died                                                      | 2                              | (0.4)                          | 1                        | (0.2)                    | 312                                          | (5.3)                                        | 484                                                   | (5.3)                                                 |
| who died due to a drug-related adverse event                  | 0                              | (0.0)                          | 0                        | (0.0)                    | 39                                           | (0.7)                                        | 66                                                    | (0.7)                                                 |
| discontinued drug due to an adverse event                     | 101                            | (20.7)                         | 10                       | (2.0)                    | 790                                          | (13.4)                                       | 1,215                                                 | (13.2)                                                |
| discontinued drug due to a drug-related adverse event         | 86                             | (17.6)                         | 3                        | (0.6)                    | 410                                          | (7.0)                                        | 676                                                   | (7.3)                                                 |
| discontinued drug due to a serious adverse event              | 49                             | (10.0)                         | 5                        | (1.0)                    | 572                                          | (9.7)                                        | 855                                                   | (9.3)                                                 |
| discontinued drug due to a serious drug-related adverse event | 37                             | (7.6)                          | 0                        | (0.0)                    | 245                                          | (4.2)                                        | 392                                                   | (4.3)                                                 |

a  Determined by the investigator to be related to the drug.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

(96.4)

328

(3.6)

(69.2)

(48.2)

(16.2)

(37.4)

(11.4)

484

(5.3)

66

(0.7)

(13.2)

676

(7.3)

855

(9.3)

392

(4.3)

<div style=\"page-break-after: always\"></div>

Table 44 Exposure-Adjusted Adverse Event Summary (Including Multiple Occurrences of Events)

9218

74360.62

(123.55)

27860 (37.47)

9827 (13.22)

2250 (3.03)

6089 (8.19)

493 (0.66)

66 (0.09)

734 (0.99)

410 (0.55)

|                                                                                       | Event Count and Rate (Events/100 person-months) a   | Event Count and Rate (Events/100 person-months) a   | Event Count and Rate (Events/100 person-months) a   | Event Count and Rate (Events/100 person-months) a   |
|---------------------------------------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                                                                       | KN564 Data for Pembrolizumab                        | KN564 Data for Placebo                              | Reference Safety Dataset for Pembrolizumab          | Cumulative Running Safety Dataset for Pembrolizumab |
| Number of participants exposed                                                        | 488                                                 | 496                                                 | 5884                                                | 9218                                                |
| Total exposure b in person- months                                                    | 4852.07                                             | 5331.33                                             | 47883.80                                            | 74360.62                                            |
| Total events (rate)                                                                   |                                                     |                                                     |                                                     |                                                     |
| adverse events                                                                        | 4345 (89.55)                                        | 3111 (58.35)                                        | 61600 (128.64)                                      | 91873 (123.55)                                      |
| drug-related adverse events toxicity grade 3-5 adverse events                         | 1760 (36.27) 286 (5.89)                             | 854 (16.02) 121 (2.27)                              | 19283 (40.27) 6162 (12.87)                          | 27860 (37.47) 9827 (13.22)                          |
| toxicity grade 3-5 drug- related adverse events                                       | 139 (2.86)                                          | 6 (0.11)                                            | 1374 (2.87)                                         | 2250 (3.03)                                         |
| serious adverse events                                                                | 137 (2.82)                                          | 75 (1.41)                                           | 4094 (8.55)                                         | 6089 (8.19)                                         |
| serious drug-related adverse events                                                   | 68 (1.40)                                           | 1 (0.02)                                            | 916 (1.91)                                          | 1426 (1.92)                                         |
| adverse events leading to death                                                       | 2 (0.04)                                            | 1 (0.02)                                            | 319 (0.67)                                          | 493 (0.66)                                          |
| drug-related adverse events leading to death                                          | 0 (0.00)                                            | 0 (0.00)                                            | 39 (0.08)                                           | 66 (0.09)                                           |
| adverse events resulting in drug discontinuation                                      | 118 (2.43)                                          | 10 (0.19)                                           | 863 (1.80)                                          | 1316 (1.77)                                         |
| drug-related adverse events resulting in drug                                         | 101 (2.08)                                          | 3 (0.06)                                            | 448 (0.94)                                          | 734 (0.99)                                          |
| discontinuation serious drug-related adverse events resulting in drug discontinuation | 38 (0.78)                                           | 0 (0.00)                                            | 259 (0.54)                                          | 410 (0.55)                                          |

a  Event rate per 100 person-months of exposure=event count *100/person-months of exposure.

b  Drug exposure (months) is defined as the duration between the first dose date and the earlier of the last dose date + 30 or the database cutoff date, which is calculated by (min(last dose date+30, Cutoff date) - first dose date + 1)/30.4367.

c  Determined by the investigator to be related to the drug.

## Most common Adverse Events

Table 45 Participants With Adverse Events (Incidence ≥10% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (APaT Population)

(96.4)

328

(3.6)

(30.3)

(20.3)

(17.3)

(17.3)

(11.2)

|                            | KN564 Data for Pembrolizumab a   | KN564 Data for Pembrolizumab a   | KN564 Data for Placebo b   | KN564 Data for Placebo b   | Reference Safety Dataset for Pembrolizumab c   | Reference Safety Dataset for Pembrolizumab c   | Cumulative Running Safety Dataset for Pembrolizumab d   | Cumulative Running Safety Dataset for Pembrolizumab d   |
|----------------------------|----------------------------------|----------------------------------|----------------------------|----------------------------|------------------------------------------------|------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
|                            | n                                | (%)                              | n                          | (%)                        | n                                              | (%)                                            | n                                                       | (%)                                                     |
| Participants in population | 488                              |                                  | 496                        |                            | 5,884                                          |                                                | 9,218                                                   |                                                         |
| with one or more adverse   | 470                              | (96.3)                           | 452                        | (91.1)                     | 5,690                                          | (96.7)                                         | 8,890                                                   | (96.4)                                                  |
| with no adverse events     | 18                               | (3.7)                            | 44                         | (8.9)                      | 194                                            | (3.3)                                          | 328                                                     | (3.6)                                                   |
| Fatigue                    | 145                              | (29.7)                           | 120                        | (24.2)                     | 1,884                                          | (32.0)                                         | 2,789                                                   | (30.3)                                                  |
| Diarrhoea                  | 124                              | (25.4)                           | 111                        | (22.4)                     | 1,200                                          | (20.4)                                         | 1,870                                                   | (20.3)                                                  |
| Pruritus                   | 111                              | (22.7)                           | 65                         | (13.1)                     | 1,060                                          | (18.0)                                         | 1,591                                                   | (17.3)                                                  |
| Arthralgia                 | 108                              | (22.1)                           | 93                         | (18.8)                     | 1,104                                          | (18.8)                                         | 1,593                                                   | (17.3)                                                  |
| Hypothyroidism             | 103                              | (21.1)                           | 18                         | (3.6)                      | 651                                            | (11.1)                                         | 1,034                                                   | (11.2)                                                  |

<div style=\"page-break-after: always\"></div>

(14.0)

(20.2)

(17.8)

989

(10.7)

435

(4.7)

(11.4)

455

(4.9)

(11.1)

(12.7)

(16.6)

(19.0)

(14.4)

(12.3)

(14.5)

| Rash                       |   98 | (20.1)   |   53 | (10.7)   | 904   | (15.4)   | 1,291   | (14.0)   |
|----------------------------|------|----------|------|----------|-------|----------|---------|----------|
| Nausea                     |   80 | (16.4)   |   48 | (9.7)    | 1,213 | (20.6)   | 1,861   | (20.2)   |
| Cough                      |   76 | (15.6)   |   50 | (10.1)   | 1,148 | (19.5)   | 1,639   | (17.8)   |
| Headache                   |   69 | (14.1)   |   62 | (12.5)   | 711   | (12.1)   | 989     | (10.7)   |
| Hyperthyroidism            |   58 | (11.9)   |    1 | (0.2)    | 247   | (4.2)    | 435     | (4.7)    |
| Asthenia                   |   50 | (10.2)   |   36 | (7.3)    | 666   | (11.3)   | 1,051   | (11.4)   |
| Blood creatinine increased |   50 | (10.2)   |   42 | (8.5)    | 256   | (4.4)    | 455     | (4.9)    |
| Back pain                  |   49 | (10.0)   |   64 | (12.9)   | 662   | (11.3)   | 1,023   | (11.1)   |
| Vomiting                   |   41 | (8.4)    |   28 | (5.6)    | 732   | (12.4)   | 1,173   | (12.7)   |
| Constipation               |   35 | (7.2)    |   40 | (8.1)    | 995   | (16.9)   | 1,530   | (16.6)   |
| Decreased appetite         |   35 | (7.2)    |   10 | (2.0)    | 1,136 | (19.3)   | 1,749   | (19.0)   |
| Dyspnoea                   |   31 | (6.4)    |   27 | (5.4)    | 989   | (16.8)   | 1,323   | (14.4)   |
| Pyrexia                    |   31 | (6.4)    |   23 | (4.6)    | 746   | (12.7)   | 1,135   | (12.3)   |
| Anaemia                    |   20 | (4.1)    |   18 | (3.6)    | 836   | (14.2)   | 1,340   | (14.5)   |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

The most frequently reported AEs (incidence ≥ 20%) in the pembrolizumab arm of study KN564 were fatigue, diarrhoea, pruritus, arthralgia, hypothyroidism, and rash. The AEs with greatest percentage difference (risk difference of approximately ≥10 %) between the pembrolizumab and placebo groups were hypothyroidism, hyperthyroidism, pruritus, and rash (see Figure 28).

The observed incidences of hypothyroidism (21.1% vs 11.1%) and hyperthyroidism (11.9% vs 4.2%) were higher in the Indication Dataset than in the RSD; all hypothyroidism and hyperthyroidism events in the Indication Dataset were Grade 1 and Grade 2 except for 1 participant each with Grade 3 hypothyroidism and Grade 3 hyperthyroidism. Blood creatinine increased (10.2% vs 4.4%) were also higher in the Indication Dataset than in the RSD; however, participants in study KN564 had prior nephrectomy (rate of blood creatinine increase was 8.5% in the placebo arm).

<div style=\"page-break-after: always\"></div>

Figure 27 Betweentreatment Comparisons in AEs; Selected AEs (≥ 10% Incidence) and Sorted by Risk Difference

<!-- image -->

Table 46 Exposure-Adjusted Adverse Events by Observation Period (Including Multiple Occurrences of Events) (Excerpt from Table 14.3-6)

|                              | EventCountandRate(Events/1o0person-months)   | EventCountandRate(Events/1o0person-months)   | EventCountandRate(Events/1o0person-months)   | EventCountandRate(Events/1o0person-months)   | EventCountandRate(Events/1o0person-months)   | EventCountandRate(Events/1o0person-months)   | EventCountandRate(Events/1o0person-months)   | EventCountandRate(Events/1o0person-months)   |
|------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
|                              | Pembrolizumab                                | Pembrolizumab                                | Pembrolizumab                                | Pembrolizumab                                | Placebo                                      | Placebo                                      | Placebo                                      | Placebo                                      |
| Observationperiodofdrug      | 0-3                                          | 3-6                                          | 6-12                                         | Beyond12                                     | 0-3                                          | 3-6                                          | 6-12                                         | Beyond12                                     |
| exposure                     | months                                       | months                                       | months                                       | months                                       | months                                       | months                                       | months                                       | months                                       |
| Numberofsubjectsexposedb     | 488                                          | 453                                          | 390                                          | 278                                          | 496                                          | 488                                          | 425                                          | 347                                          |
| Totalexposureinperson-months | 1422.11                                      | 1262.21                                      | 2041.25                                      | 126.50                                       | 1480.43                                      | 1344.14                                      | 2378.21                                      | 128.55                                       |

The highest AE rates in occurred in the first 3 months of treatment, and AE rates decreased at 3 to 6 months in most cases and continued to decrease through &gt;12 months.

## Treatment-related Adverse Events

Table 47 Participants With DrugRelated Adverse Events (Incidence ≥ 5% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term

(69.2)

|                            | KN564 Data for Pembrolizumab a   | KN564 Data for Pembrolizumab a   | KN564 Data for Placebo b   | KN564 Data for Placebo b   | Reference Safety Dataset for Pembrolizumab c   | Reference Safety Dataset for Pembrolizumab c   | Cumulative Running Safety Dataset for Pembrolizumab d   | Cumulative Running Safety Dataset for Pembrolizumab d   |
|----------------------------|----------------------------------|----------------------------------|----------------------------|----------------------------|------------------------------------------------|------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
|                            | n                                | (%)                              | n                          | (%)                        | n                                              | (%)                                            | n                                                       | (%)                                                     |
| Participants in population | 488                              |                                  | 496                        |                            | 5,884                                          |                                                | 9,218                                                   |                                                         |
| with one or more adverse   | 386                              | (79.1)                           | 265                        | (53.4)                     | 4,132                                          | (70.2)                                         | 6,375                                                   | (69.2)                                                  |

<div style=\"page-break-after: always\"></div>

(30.8)

(18.3)

(13.3)

895

(9.7)

956

(10.4)

957

(10.4)

384

(4.2)

673

(7.3)

748

(8.1)

341

(3.7)

545

(5.9)

657

(7.1)

| with no adverse events   |   102 | (20.9)   |   231 | (46.6)   | 1,752   | (29.8)   | 2,843   | (30.8)   |
|--------------------------|-------|----------|-------|----------|---------|----------|---------|----------|
| Fatigue                  |    99 | (20.3)   |    71 | (14.3)   | 1,170   | (19.9)   | 1,686   | (18.3)   |
| Pruritus                 |    91 | (18.6)   |    57 | (11.5)   | 836     | (14.2)   | 1,230   | (13.3)   |
| Hypothyroidism           |    86 | (17.6)   |    13 | (2.6)    | 565     | (9.6)    | 895     | (9.7)    |
| Diarrhoea                |    77 | (15.8)   |    51 | (10.3)   | 630     | (10.7)   | 956     | (10.4)   |
| Rash                     |    73 | (15.0)   |    36 | (7.3)    | 676     | (11.5)   | 957     | (10.4)   |
| Hyperthyroidism          |    50 | (10.2)   |     0 | (0.0)    | 219     | (3.7)    | 384     | (4.2)    |
| Arthralgia               |    46 | (9.4)    |    43 | (8.7)    | 464     | (7.9)    | 673     | (7.3)    |
| Nausea                   |    39 | (8.0)    |    23 | (4.6)    | 535     | (9.1)    | 748     | (8.1)    |
| Myalgia                  |    30 | (6.1)    |    20 | (4.0)    | 232     | (3.9)    | 341     | (3.7)    |
| Asthenia                 |    28 | (5.7)    |    23 | (4.6)    | 363     | (6.2)    | 545     | (5.9)    |
| Decreased appetite       |    15 | (3.1)    |     2 | (0.4)    | 461     | (7.8)    | 657     | (7.1)    |

## Grade ≥3 Adverse Events

Table 48 Participants With Grade 35 Adverse Events (Incidence ≥ 1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term

(48.2)

(51.8)

152

(1.6)

120

(1.3)

141

(1.5)

129

(1.4)

111

(1.2)

351

(3.8)

32

(0.3)

27

(0.3)

86

(0.9)

17

(0.2)

224

(2.4)

93

(1.0)

133

(1.4)

89

(1.0)

106

(1.1)

75

(0.8)

89

(1.0)

231

(2.5)

109

(1.2)

104

(1.1)

427

(4.6)

108

(1.2)

97

(1.1)

95

(1.0)

120

(1.3)

102

(1.1)

|                                             | KN564 Data for Pembrolizumab   | KN564 Data for Pembrolizumab   | KN564 Data for Placebo   | KN564 Data for Placebo   | Reference Safety Dataset for Pembrolizumab   | Reference Safety Dataset for Pembrolizumab   | Cumulative Running Safety Dataset for Pembrolizumab   | Cumulative Running Safety Dataset for Pembrolizumab   |
|---------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|----------------------------------------------|----------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                             | n                              | (%)                            | n                        | (%)                      | n                                            | (%)                                          | n                                                     | (%)                                                   |
| Participants in population with one or more | 488                            |                                | 496                      |                          | 5,884                                        |                                              | 9,218                                                 |                                                       |
| adverse                                     | 158                            | (32.4)                         | 88                       | (17.7)                   | 2,829                                        | (48.1)                                       | 4,444                                                 | (48.2)                                                |
| with no adverse events                      | 330                            | (67.6)                         | 408                      | (82.3)                   | 3,055                                        | (51.9)                                       | 4,774                                                 | (51.8)                                                |
| Hypertension                                | 14                             | (2.9)                          | 13                       | (2.6)                    | 102                                          | (1.7)                                        | 152                                                   | (1.6)                                                 |
| Alanine aminotransferase increased          | 11                             | (2.3)                          | 1                        | (0.2)                    | 61                                           | (1.0)                                        | 120                                                   | (1.3)                                                 |
| Aspartate aminotransferase increased        | 8                              | (1.6)                          | 1                        | (0.2)                    | 65                                           | (1.1)                                        | 141                                                   | (1.5)                                                 |
| Diarrhoea                                   | 8                              | (1.6)                          | 1                        | (0.2)                    | 79                                           | (1.3)                                        | 129                                                   | (1.4)                                                 |
| Hyperglycaemia                              | 7                              | (1.4)                          | 3                        | (0.6)                    | 64                                           | (1.1)                                        | 111                                                   | (1.2)                                                 |
| Pneumonia                                   | 7                              | (1.4)                          | 1                        | (0.2)                    | 242                                          | (4.1)                                        | 351                                                   | (3.8)                                                 |
| Adrenal insufficiency                       | 6                              | (1.2)                          | 1                        | (0.2)                    | 18                                           | (0.3)                                        | 32                                                    | (0.3)                                                 |
| Lipase increased                            | 6                              | (1.2)                          | 0                        | (0.0)                    | 16                                           | (0.3)                                        | 27                                                    | (0.3)                                                 |
| Acute kidney injury                         | 5                              | (1.0)                          | 0                        | (0.0)                    | 51                                           | (0.9)                                        | 86                                                    | (0.9)                                                 |
| Diabetic ketoacidosis                       | 5                              | (1.0)                          | 0                        | (0.0)                    | 9                                            | (0.2)                                        | 17                                                    | (0.2)                                                 |
| Fatigue                                     | 5                              | (1.0)                          | 0                        | (0.0)                    | 144                                          | (2.4)                                        | 224                                                   | (2.4)                                                 |
| Colitis                                     | 4                              | (0.8)                          | 0                        | (0.0)                    | 60                                           | (1.0)                                        | 93                                                    | (1.0)                                                 |
| Pulmonary embolism                          | 3                              | (0.6)                          | 3                        | (0.6)                    | 91                                           | (1.5)                                        | 133                                                   | (1.4)                                                 |
| Vomiting                                    | 3                              | (0.6)                          | 0                        | (0.0)                    | 42                                           | (0.7)                                        | 89                                                    | (1.0)                                                 |
| Abdominal pain                              | 2                              | (0.4)                          | 1                        | (0.2)                    | 42                                           | (0.7)                                        | 106                                                   | (1.1)                                                 |
| Arthralgia                                  | 2                              | (0.4)                          | 2                        | (0.4)                    | 58                                           | (1.0)                                        | 75                                                    | (0.8)                                                 |
| Hypokalaemia                                | 2                              | (0.4)                          | 1                        | (0.2)                    | 58                                           | (1.0)                                        | 89                                                    | (1.0)                                                 |
| Hyponatraemia                               | 2                              | (0.4)                          | 6                        | (1.2)                    | 153                                          | (2.6)                                        | 231                                                   | (2.5)                                                 |
| Pneumonitis                                 | 2                              | (0.4)                          | 0                        | (0.0)                    | 83                                           | (1.4)                                        | 109                                                   | (1.2)                                                 |
| Urinary tract infection                     | 2                              | (0.4)                          | 3                        | (0.6)                    | 73                                           | (1.2)                                        | 104                                                   | (1.1)                                                 |
| Anaemia                                     | 1                              | (0.2)                          | 0                        | (0.0)                    | 233                                          | (4.0)                                        | 427                                                   | (4.6)                                                 |
| Asthenia                                    | 1                              | (0.2)                          | 1                        | (0.2)                    | 58                                           | (1.0)                                        | 108                                                   | (1.2)                                                 |
| Back pain                                   | 1                              | (0.2)                          | 1                        | (0.2)                    | 64                                           | (1.1)                                        | 97                                                    | (1.1)                                                 |
| Blood alkaline phosphatase increased        | 1                              | (0.2)                          | 0                        | (0.0)                    | 48                                           | (0.8)                                        | 95                                                    | (1.0)                                                 |
| Decreased appetite                          | 1                              | (0.2)                          | 0                        | (0.0)                    | 74                                           | (1.3)                                        | 120                                                   | (1.3)                                                 |
| Dehydration                                 | 1                              | (0.2)                          | 0                        | (0.0)                    | 62                                           | (1.1)                                        | 102                                                   | (1.1)                                                 |

<div style=\"page-break-after: always\"></div>

177

(1.9)

100

| Dyspnoea         | 1 (0.2)   | 0 (0.0)   |   131 | (2.2)   |   177 | (1.9)   |
|------------------|-----------|-----------|-------|---------|-------|---------|
| Pleural effusion | 1 (0.2)   | 1 (0.2)   |    68 | (1.2)   |   100 | (1.1)   |

(1.1)

Figure 28 Between-treatment Comparisons in Grade 35 Adverse Events Selected Adverse Events (≥ 1% Incidence) and Sorted by Risk Difference

<!-- image -->

## Treatmentrelated Grade ≥3 Adverse Events

Table 49 Participants With Grade 3-5 DrugRelated Adverse Events (Incidence ≥ 1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term

(16.2)

(83.8)

68

(0.7)

86

(0.9)

25

(0.3)

69

(0.7)

16

(0.2)

100

(1.1)

103

(1.1)

|                                      | KN564 Data for Pembrolizumab   | KN564 Data for Pembrolizumab   | KN564 Data for Placebo   | KN564 Data for Placebo   | Reference Safety Dataset for Pembrolizumab   | Reference Safety Dataset for Pembrolizumab   | Cumulative Running Safety Dataset for Pembrolizumab   | Cumulative Running Safety Dataset for Pembrolizumab   |
|--------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|----------------------------------------------|----------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                      | n                              | (%)                            | n                        | (%)                      | n                                            | (%)                                          | n                                                     | (%)                                                   |
| Participants in population           | 488                            |                                | 496                      |                          | 5,884                                        |                                              | 9,218                                                 |                                                       |
| with one or more adverse events      | 92                             | (18.9)                         | 6                        | (1.2)                    | 913                                          | (15.5)                                       | 1,490                                                 | (16.2)                                                |
| with no adverse events               | 396                            | (81.1)                         | 490                      | (98.8)                   | 4,971                                        | (84.5)                                       | 7,728                                                 | (83.8)                                                |
| Alanine aminotransferase increased   | 9                              | (1.8)                          | 1                        | (0.2)                    | 35                                           | (0.6)                                        | 68                                                    | (0.7)                                                 |
| Diarrhoea                            | 8                              | (1.6)                          | 0                        | (0.0)                    | 55                                           | (0.9)                                        | 86                                                    | (0.9)                                                 |
| Adrenal insufficiency                | 6                              | (1.2)                          | 0                        | (0.0)                    | 13                                           | (0.2)                                        | 25                                                    | (0.3)                                                 |
| Aspartate aminotransferase increased | 6                              | (1.2)                          | 0                        | (0.0)                    | 35                                           | (0.6)                                        | 69                                                    | (0.7)                                                 |
| Diabetic ketoacidosis                | 5                              | (1.0)                          | 0                        | (0.0)                    | 8                                            | (0.1)                                        | 16                                                    | (0.2)                                                 |
| Fatigue                              | 4                              | (0.8)                          | 0                        | (0.0)                    | 63                                           | (1.1)                                        | 100                                                   | (1.1)                                                 |
| Pneumonitis                          | 2                              | (0.4)                          | 0                        | (0.0)                    | 78                                           | (1.3)                                        | 103                                                   | (1.1)                                                 |

## Serious adverse event/deaths/other significant events

<div style=\"page-break-after: always\"></div>

## Serious Adverse Events (SAEs)

Table 50 Participants With Serious Adverse Events Up to 90 Days of Last Dose (Incidence ≥1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term

(37.4)

(62.6)

95

(1.0)

32

(0.3)

348

(3.8)

88

(1.0)

17

(0.2)

157

(1.7)

84

(0.9)

97

(1.1)

113

(1.2)

99

(1.1)

83

(0.9)

101

(1.1)

102

(1.1)

|                                                            | KN564 Data for Pembrolizumab a   | KN564 Data for Pembrolizumab a   | KN564 Data for Placebo b   | KN564 Data for Placebo b   | Reference Safety Dataset for Pembrolizumab c   | Reference Safety Dataset for Pembrolizumab c   | Cumulative Running Safety Dataset for Pembrolizumab d   | Cumulative Running Safety Dataset for Pembrolizumab d   |
|------------------------------------------------------------|----------------------------------|----------------------------------|----------------------------|----------------------------|------------------------------------------------|------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
|                                                            | n                                | (%)                              | n                          | (%)                        | n                                              | (%)                                            | n                                                       | (%)                                                     |
| Participants in population with one or more adverse events | 488                              |                                  | 496                        |                            | 5,884                                          |                                                | 9,218                                                   |                                                         |
|                                                            | 100                              | (20.5)                           | 56                         | (11.3)                     | 2,266                                          | (38.5)                                         | 3,449                                                   | (37.4)                                                  |
| with no adverse events                                     | 388                              | (79.5)                           | 440                        | (88.7)                     | 3,618                                          | (61.5)                                         | 5,769                                                   | (62.6)                                                  |
| Acute kidney injury                                        | 6                                | (1.2)                            | 0                          | (0.0)                      | 50                                             | (0.8)                                          | 95                                                      | (1.0)                                                   |
| Adrenal insufficiency                                      | 6                                | (1.2)                            | 0                          | (0.0)                      | 18                                             | (0.3)                                          | 32                                                      | (0.3)                                                   |
| Pneumonia                                                  | 6                                | (1.2)                            | 1                          | (0.2)                      | 246                                            | (4.2)                                          | 348                                                     | (3.8)                                                   |
| Colitis                                                    | 5                                | (1.0)                            | 1                          | (0.2)                      | 59                                             | (1.0)                                          | 88                                                      | (1.0)                                                   |
| Diabetic ketoacidosis                                      | 5                                | (1.0)                            | 0                          | (0.0)                      | 9                                              | (0.2)                                          | 17                                                      | (0.2)                                                   |
| Pneumonitis                                                | 3                                | (0.6)                            | 0                          | (0.0)                      | 117                                            | (2.0)                                          | 157                                                     | (1.7)                                                   |
| Diarrhoea                                                  | 1                                | (0.2)                            | 0                          | (0.0)                      | 59                                             | (1.0)                                          | 84                                                      | (0.9)                                                   |
| Dyspnoea                                                   | 1                                | (0.2)                            | 0                          | (0.0)                      | 81                                             | (1.4)                                          | 97                                                      | (1.1)                                                   |
| Pleural effusion                                           | 1                                | (0.2)                            | 1                          | (0.2)                      | 83                                             | (1.4)                                          | 113                                                     | (1.2)                                                   |
| Pulmonary embolism                                         | 1                                | (0.2)                            | 3                          | (0.6)                      | 71                                             | (1.2)                                          | 99                                                      | (1.1)                                                   |
| Urinary tract infection                                    | 1                                | (0.2)                            | 2                          | (0.4)                      | 59                                             | (1.0)                                          | 83                                                      | (0.9)                                                   |
| Anaemia                                                    | 0                                | (0.0)                            | 0                          | (0.0)                      | 59                                             | (1.0)                                          | 101                                                     | (1.1)                                                   |
| Pyrexia                                                    | 0                                | (0.0)                            | 1                          | (0.2)                      | 67                                             | (1.1)                                          | 102                                                     | (1.1)                                                   |

Drug-related Serious Adverse Events (SAEs)

Table 51 Participants With Drugrelated SAEs Up to 90 Days of Last Dose (Incidence ≥ 1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term

(11.4)

(88.6)

26

(0.3)

78

(0.8)

16

(0.2)

150

(1.6)

|                            | KN564 Data for Pembrolizumab a   | KN564 Data for Pembrolizumab a   | KN564 Data for Placebo b   | KN564 Data for Placebo b   | Reference Safety Dataset for Pembrolizumab c   | Reference Safety Dataset for Pembrolizumab c   | Cumulative Running Safety Dataset for Pembrolizumab d   | Cumulative Running Safety Dataset for Pembrolizumab d   |
|----------------------------|----------------------------------|----------------------------------|----------------------------|----------------------------|------------------------------------------------|------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
|                            | n                                | (%)                              | n                          | (%)                        | n                                              | (%)                                            | n                                                       | (%)                                                     |
| Participants in population | 488                              |                                  | 496                        |                            | 5,884                                          |                                                | 9,218                                                   |                                                         |
| with one or more adverse   | 59                               | (12.1)                           | 1                          | (0.2)                      | 656                                            | (11.1)                                         | 1,049                                                   | (11.4)                                                  |
| with no adverse events     | 429                              | (87.9)                           | 495                        | (99.8)                     | 5,228                                          | (88.9)                                         | 8,169                                                   | (88.6)                                                  |
| Adrenal insufficiency      | 6                                | (1.2)                            | 0                          | (0.0)                      | 14                                             | (0.2)                                          | 26                                                      | (0.3)                                                   |
| Colitis                    | 5                                | (1.0)                            | 1                          | (0.2)                      | 51                                             | (0.9)                                          | 78                                                      | (0.8)                                                   |
| Diabetic ketoacidosis      | 5                                | (1.0)                            | 0                          | (0.0)                      | 8                                              | (0.1)                                          | 16                                                      | (0.2)                                                   |
| Pneumonitis                | 3                                | (0.6)                            | 0                          | (0.0)                      | 111                                            | (1.9)                                          | 150                                                     | (1.6)                                                   |

## Deaths

The incidence of deaths (up to 90 days after the last dose of study intervention) due to AEs was 0.4% (n=2) in the Indication Dataset compared with 5.3% in the RSD.

<div style=\"page-break-after: always\"></div>

The two deaths in the Indication Dataset were reported due to AEs with PTs of pneumonia and multiple organ dysfunction syndrome; and 1 death due to AEs was reported in the placebo group (PT: hemorrhage intracranial). None of the deaths were considered treatment related by the investigator.

## Other significant events Adverse Events of Special Interest (AEOSI)

AEOSI are immune-related events and infusion-related reactions associated with pembrolizumab.

Table 52 Adverse Event Summary AEOSI (APaT Population )

|                                                               | KN564 Data for Pembrolizumab   | KN564 Data for Pembrolizumab   | KN564 Data for Placebo   | KN564 Data for Placebo   | Reference Safety Dataset for Pembrolizumab   | Reference Safety Dataset for Pembrolizumab   | Cumulative Running Safety Dataset for Pembrolizumab   | Cumulative Running Safety Dataset for Pembrolizumab   |
|---------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|----------------------------------------------|----------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                               | n                              | (%)                            | n                        | (%)                      | n                                            | (%)                                          | n                                                     | (%)                                                   |
| Participants in population                                    | 488                            |                                | 496                      |                          | 5,884                                        |                                              | 9,218                                                 |                                                       |
| with one or more adverse events                               | 173                            | (35.5)                         | 34                       | (6.9)                    | 1,475                                        | (25.1)                                       | 2,295                                                 | (24.9)                                                |
| with no adverse event                                         | 315                            | (64.5)                         | 462                      | (93.1)                   | 4,409                                        | (74.9)                                       | 6,923                                                 | (75.1)                                                |
| with drug-related adverse events                              | 155                            | (31.8)                         | 22                       | (4.4)                    | 1,282                                        | (21.8)                                       | 2,005                                                 | (21.8)                                                |
| with toxicity grade 3-5 adverse events                        | 44                             | (9.0)                          | 3                        | (0.6)                    | 381                                          | (6.5)                                        | 603                                                   | (6.5)                                                 |
| with toxicity grade 3-5 drug- related adverse events          | 43                             | (8.8)                          | 0                        | (0.0)                    | 331                                          | (5.6)                                        | 532                                                   | (5.8)                                                 |
| with serious adverse events                                   | 41                             | (8.4)                          | 1                        | (0.2)                    | 381                                          | (6.5)                                        | 583                                                   | (6.3)                                                 |
| with serious drug-related adverse events                      | 39                             | (8.0)                          | 1                        | (0.2)                    | 337                                          | (5.7)                                        | 522                                                   | (5.7)                                                 |
| who died                                                      | 0                              | (0.0)                          | 0                        | (0.0)                    | 11                                           | (0.2)                                        | 20                                                    | (0.2)                                                 |
| who died due to a drug-related adverse event                  | 0                              | (0.0)                          | 0                        | (0.0)                    | 11                                           | (0.2)                                        | 20                                                    | (0.2)                                                 |
| discontinued drug due to an adverse event                     | 39                             | (8.0)                          | 0                        | (0.0)                    | 232                                          | (3.9)                                        | 372                                                   | (4.0)                                                 |
| discontinued drug due to a drug-related adverse event         | 38                             | (7.8)                          | 0                        | (0.0)                    | 228                                          | (3.9)                                        | 367                                                   | (4.0)                                                 |
| discontinued drug due to a serious adverse event              | 21                             | (4.3)                          | 0                        | (0.0)                    | 156                                          | (2.7)                                        | 238                                                   | (2.6)                                                 |
| discontinued drug due to a serious drug-related adverse event | 21                             | (4.3)                          | 0                        | (0.0)                    | 154                                          | (2.6)                                        | 236                                                   | (2.6)                                                 |

(24.9)

(75.1)

(21.8)

603

(6.5)

(5.6)

(5.8)

583

(6.3)

(5.7)

(5.7)

20

(0.2)

(0.2)

(0.2)

(3.9)

(4.0)

(3.9)

(4.0)

(2.7)

(2.6)

(2.6)

(2.6)

Table 53 Exposure-Adjusted Adverse Event Summary (Including Multiple Occurrences of Events) AEOSI (APaT Population)

<div style=\"page-break-after: always\"></div>

|                                                                      | Event Count and Rate (Events/100 person-months)*   | Event Count and Rate (Events/100 person-months)*   | Event Count and Rate (Events/100 person-months)*   | Event Count and Rate (Events/100 person-months)*     |
|----------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------|
|                                                                      | KN564 Data for Pembrolizumabd                      | KN564 Data for Placebos                            | Reference Safety Dataset for Pembrolizumab         | Cumulative Running Safety Dataset for Pembrolizumabs |
| Number of participants exposed                                       | 488                                                | 496                                                | 5884                                               | 9218                                                 |
| Total ex posureb in person-months                                    | 4852.07                                            | 5331.33                                            | 47883.80                                           | 74360.62                                             |
| Total events (rate)                                                  |                                                    |                                                    |                                                    |                                                      |
| adverse events                                                       | 292 (6.02)                                         | 39 (0.73)                                          | 2155 (4.50)                                        | 3347 (4.50)                                          |
| drug-related adverse events                                          | 259 (5.34)                                         | 27(0.51)                                           | 1860 (3.88)                                        | 2888 (3.88)                                          |
| toxicity grade 3-5 adverse events                                    | 53 (1.09)                                          | 3 (0.00)                                           | 452 (0.94)                                         | 705 (0.95)                                           |
| toxicity grade 3-5 drug-related adverse events                       | 51 (1.05)                                          | 0 (0.00)                                           | 395 (0.82)                                         | 621 (0.84)                                           |
| serious adverse events                                               | 44 (0.91)                                          | 1 (0.02)                                           | 448 (0.94)                                         | 676 (0.91)                                           |
| serious drug-related adverse events                                  | 42 (0.87)                                          | 1 (0.02)                                           | 400 (0.84)                                         | 606 (0.81)                                           |
| adverse cvents leading to death                                      | 0 (0.00)                                           | 0 (0.00)                                           | 11 (0.02)                                          | 20 (0.03)                                            |
| drug-related adverse events leading to death                         | 0 (0.00)                                           | 0 (0.00)                                           | 11 (0.02)                                          | 20 (0.03)                                            |
| adverse events resulting in drug discontinuation                     | 40 (0.82)                                          | 0 (0.00)                                           | 238 (0.50)                                         | 381 (0.51)                                           |
| drug-related adverse events resulting in drug discontinuation        | 39 (0.80)                                          | 0 (0.00)                                           | 234 (0.49)                                         | 376(0.51)                                            |
| serious adverse events resulting in drug discontinuation             | 22 (0.45)                                          | 0 (0.00)                                           | 161 (0.34)                                         | 245 (0.33)                                           |
| serious dug-related adverse events resulting in drug discontinuation | 22 (0.45)                                          | 0 (0.00)                                           | 159 (0.33)                                         | 243 (0.33)                                           |

Event rate per 100 person-months of exposure=eventcount *100/person months of exposure.

b Drug exposure (months) is defined as the duration between the first dose date and the earlier of the last dose date + 30 or the database cutoff date, which is calculated by (min(last dose date+30, Cutoff date)-- first dose date + 1)/30.4367.

* Determined by the inves tigator to be related to the drug.

Table 54 Participants With AEOSI (Incidence &gt; 0% in One or More Treatment Groups) By AEOSI Category (APaT Population)

(25.1)

(74.9)

47

(0.8)

110

(1.9)

3

(0.1)

4

(0.1)

56

(1.0)

247

(4.2)

36

(0.6)

652

(11.1)

138

(2.3)

3

(0.1)

5

(0.1)

(0.3)

|                                                     | KN564 Data for Pembrolizuma b   | KN564 Data for Pembrolizuma b   | KN564 Data for Placebo   | KN564 Data for Placebo   | Reference Safety Dataset for Pembrolizumab ¶   | Reference Safety Dataset for Pembrolizumab ¶   |
|-----------------------------------------------------|---------------------------------|---------------------------------|--------------------------|--------------------------|------------------------------------------------|------------------------------------------------|
|                                                     | n                               | (%)                             | n                        | (%)                      | n                                              | (%)                                            |
| Participants in population with one or more adverse | 488                             |                                 | 496                      |                          | 5,884                                          |                                                |
| events                                              | 173                             | (35.5)                          | 34                       | (6.9)                    | 1,475                                          | (25.1)                                         |
| with no adverse events                              | 315                             | (64.5)                          | 462                      | (93.1)                   | 4,409                                          | (74.9)                                         |
| Adrenal Insufficiency                               | 10                              | (2.0)                           | 1                        | (0.2)                    | 47                                             | (0.8)                                          |
| Colitis                                             | 8                               | (1.6)                           | 1                        | (0.2)                    | 110                                            | (1.9)                                          |
| Encephalitis                                        | 1                               | (0.2)                           | 0                        | (0.0)                    | 3                                              | (0.1)                                          |
| Guillain-Barre Syndrome                             | 0                               | (0.0)                           | 0                        | (0.0)                    | 4                                              | (0.1)                                          |
| Hepatitis                                           | 5                               | (1.0)                           | 0                        | (0.0)                    | 56                                             | (1.0)                                          |
| Hyperthyroidism                                     | 58                              | (11.9)                          | 1                        | (0.2)                    | 247                                            | (4.2)                                          |
| Hypophysitis                                        | 2                               | (0.4)                           | 0                        | (0.0)                    | 36                                             | (0.6)                                          |
| Hypothyroidism                                      | 103                             | (21.1)                          | 18                       | (3.6)                    | 652                                            | (11.1)                                         |
| Infusion Reactions                                  | 7                               | (1.4)                           | 5                        | (1.0)                    | 138                                            | (2.3)                                          |
| Myasthenic Syndrome                                 | 3                               | (0.6)                           | 0                        | (0.0)                    | 3                                              | (0.1)                                          |
| Myocarditis                                         | 1                               | (0.2)                           | 0                        | (0.0)                    | 5                                              | (0.1)                                          |
| Myositis                                            | 2                               | (0.4)                           | 1                        | (0.2)                    | 19                                             | (0.3)                                          |

<div style=\"page-break-after: always\"></div>

(0.4)

18

(0.3)

264

(4.5)

10

(0.2)

97

(1.6)

58

(1.0)

20

(0.3)

21

| Nephritis                | 3 (0.6)   |   0 | (0.0)   |   23 | (0.4)   |
|--------------------------|-----------|-----|---------|------|---------|
| Pancreatitis             | 0 (0.0)   |   0 | (0.0)   |   18 | (0.3)   |
| Pneumonitis              | 11 (2.3)  |   5 | (1.0)   |  264 | (4.5)   |
| Sarcoidosis              | 4 (0.8)   |   0 | (0.0)   |   10 | (0.2)   |
| Severe Skin Reactions    | 8 (1.6)   |   2 | (0.4)   |   97 | (1.6)   |
| Thyroiditis              | 6 (1.2)   |   1 | (0.2)   |   58 | (1.0)   |
| Type 1 Diabetes Mellitus | 9 (1.8)   |   0 | (0.0)   |   20 | (0.3)   |
| Uveitis                  | 0 (0.0)   |   1 | (0.2)   |   21 | (0.4)   |
| Vasculitis               | 2 (0.4)   |   0 | (0.0)   |    2 | (0.0)   |

(0.4)

Table 55 Exposure-Adjusted AEOSI (Including Multiple Occurrences of Events) By AEOSI Category

| Adrenal Insufficiency    | 10(0.2)   | 1(0.0)   | 54 (0.1)   | 92 (0.1)   |
|--------------------------|-----------|----------|------------|------------|
| Hyperthyroidism          | 60 (1.2)  | 1(0.0)   | 271 (0.6)  | 463 (0.6)  |
| Hypothyroidism           | 111 (2.3) | 20(0.4)  | 730 (1.5)  | 1149 (1.5) |
| Sarcoidosis              | 4 (0.1)   | 0 (0.0)  | 13 (0.0)   | 18 (0.0)   |
| Type 1 Diabetes Mellitus | 11 (0.2)  | 0 (0.0)  | 30 (0.1)   | 58(0.1)    |

Table 56 Participants With AEOSI by Maximum Toxicity Grade

Table 57 Participants With grade 3-4 AEOSI (Incidence &gt;0% in Indication Dataset )

|                                 | KN564 Data for Pembrolizumaba   | KN564 Data for Pembrolizumaba   | KN564 Data for Placebob   | KN564 Data for Placebob   | Reference Safety Dataset for Pembrolizumab*   | Reference Safety Dataset for Pembrolizumab*   | Cumulative Running Safety Dataset for Pembrolizumabd   | Cumulative Running Safety Dataset for Pembrolizumabd   |
|---------------------------------|---------------------------------|---------------------------------|---------------------------|---------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                 | n                               | (%)                             | n                         | (%)                       | n                                             | (%)                                           | n                                                      | (%)                                                    |
| Participants in population      | 488                             |                                 | 496                       |                           | 5,884                                         |                                               | 9,218                                                  |                                                        |
| with one or more adverse events | 173                             | (35.5)                          | 34                        | (6.9)                     | 1,475                                         | (25.1)                                        | 2,295                                                  | (24.9)                                                 |
| Grade 1                         | 26                              | (5.3)                           | 18                        | (3.6)                     | 368                                           | (6.3)                                         | 542                                                    | (5.9)                                                  |
| Grade 2                         | 103                             | (21.1)                          | 13                        | (2.6)                     | 726                                           | (12.3)                                        | 1,150                                                  | (12.5)                                                 |
| Grade 3                         | 39                              | (8.0)                           | 3                         | (0.6)                     | 325                                           | (5.5)                                         | 514                                                    | (5.6)                                                  |
| Grade 4                         | 5                               | (1.0)                           | 0                         | (0.0)                     | 45                                            | (0.8)                                         | 69                                                     | (0.7)                                                  |
| Grade 5                         | 0                               | (0.0)                           | 0                         | (0.0)                     | 11                                            | (0.2)                                         | 20                                                     | (0.2)                                                  |
| with no adverse events          | 315                             | (64.5)                          | 462                       | (93.1)                    | 4,409                                         | (74.9)                                        | 6,923                                                  | (75.1)                                                 |

<div style=\"page-break-after: always\"></div>

(6.3)

(0.4)

(1.1)

(0.0)

(0.7)

(0.1)

(0.3)

(0.1)

(0.2)

(0.1)

(0.3)

(1.4)

(1.3)

(0.0)

(0.3)

|                                                                      | KN564 Data for Pembrolizumab   | KN564 Data for Pembrolizumab   | KN564 Data for Placebo   | KN564 Data for Placebo   | Reference Safety Dataset for Pembrolizumab ¶   | Reference Safety Dataset for Pembrolizumab ¶   |
|----------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|------------------------------------------------|------------------------------------------------|
|                                                                      | n                              | (%)                            | n                        | (%)                      | n                                              | (%)                                            |
| Participants in population with one or more Grade 3-4 adverse events | 488 44                         | (9.0)                          | 496 3                    | (0.6)                    | 5,884 370                                      | (6.3)                                          |
| Adrenal Insufficiency                                                | 6                              | (1.2)                          | 1                        | (0.2)                    | 23                                             | (0.4)                                          |
| Colitis                                                              | 5                              | (1.0)                          | 0                        | (0.0)                    | 67                                             | (1.1)                                          |
| Encephalitis                                                         | 1                              | (0.2)                          | 0                        | (0.0)                    | 2                                              | (0.0)                                          |
| Hepatitis                                                            | 4                              | (0.8)                          | 0                        | (0.0)                    | 44                                             | (0.7)                                          |
| Hyperthyroidism                                                      | 1                              | (0.2)                          | 0                        | (0.0)                    | 7                                              | (0.1)                                          |
| Hypophysitis                                                         | 2                              | (0.4)                          | 0                        | (0.0)                    | 20                                             | (0.3)                                          |
| Hypothyroidism                                                       | 1                              | (0.2)                          | 0                        | (0.0)                    | 7                                              | (0.1)                                          |
| Infusion Reactions                                                   | 2                              | (0.4)                          | 0                        | (0.0)                    | 14                                             | (0.2)                                          |
| Myocarditis                                                          | 1                              | (0.2)                          | 0                        | (0.0)                    | 5                                              | (0.1)                                          |
| Nephritis                                                            | 1                              | (0.2)                          | 0                        | (0.0)                    | 16                                             | (0.3)                                          |
| Pneumonitis                                                          | 4                              | (0.8)                          | 0                        | (0.0)                    | 82                                             | (1.4)                                          |
| Severe Skin Reactions                                                | 8                              | (1.6)                          | 2                        | (0.4)                    | 74                                             | (1.3)                                          |
| Thyroiditis                                                          | 2                              | (0.4)                          | 0                        | (0.0)                    | 1                                              | (0.0)                                          |
| Type 1 Diabetes Mellitus                                             | 9                              | (1.8)                          | 0                        | (0.0)                    | 19                                             | (0.3)                                          |
| Vasculitis                                                           | 1                              | (0.2)                          | 0                        | (0.0)                    | 1                                              | (0.0)                                          |

Table 58 Time to Onset and Duration of AEOSI

|                                                              | KN564 Data for Pembrolizuma b9 11 (%)   | KN564 Data for Placebo\" (%)   | Reference Safety Dataset for Pembrolizima be n (%)   | Cumulative Running Safety Dataset for Pembrolizuma bf n (%)   |
|--------------------------------------------------------------|-----------------------------------------|-------------------------------|------------------------------------------------------|---------------------------------------------------------------|
| Participants in population Participants with AEOSI           | 488 173 (35.5) 100.9 (94.8)             | 496 34 (6.9) 146.4 (89.1)     | 5884 1475 (25.1)                                     | 9218 2295 (24.9)                                              |
| Time to Onset of First AEOSI (days)* Mean (Std) Median Range | 64.0 1 to 426                           | 147.5 1 to 364                | 117.9 (121.0) 79.0 1 to 787 2105                     | 116.5 (123.1) 71.0 1 to 787 3297                              |
| Total episodes of AEOSI Average Episodes per participant     | 292 1.69                                | 39                            |                                                      |                                                               |
| Episode duration (days)b                                     | 101.0                                   | 1.15                          | 1.43 86.0                                            | 1.44                                                          |
| Median Range                                                 | 1 to 1148+                              | 42.0 1 to 1022+               | 1 to 1640+                                           | 88.0 1 to 1640+                                               |

(%) = Number of participants with AEOSI / Number of participants in population.

a Time to onset statistics are based on number of participants with AEOSI.

b From product-limit (Kaplan-Meier) method for censored data. If an adverse event is not resolved at the time of analysis or the participant died without adverse event resolved, the duration is censored at either data cutoff date or date of death, whichever occurred first.

+ indicates the AE episode is not recovered/resolved by the time of the cutoff date or date of death.

Std = Standard Deviation.

Table 59 Summary of Outcome for Participants With AEOSI

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                            |              | KN564Datafor Pembrolizmab   | KN564Datafor Pembrolizmab   | KN564Data for Placebob   | KN564Data for Placebob   | Reference Safety Dataset for Pembrolizumabe   | Reference Safety Dataset for Pembrolizumabe   | Cumulative Running SafetyDataset for Pembrolizumabd   | Cumulative Running SafetyDataset for Pembrolizumabd   |
|----------------------------|--------------|-----------------------------|-----------------------------|--------------------------|--------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                            | Outcome      | n                           | (%)                         | n                        | (%)                      | n                                             | (%)                                           | n                                                     | (%)                                                   |
| Participants in population |              | 488                         |                             | 496                      |                          | 5884                                          |                                               | 9218                                                  |                                                       |
| WithoneormoreAEoSI         | Overall      | 173                         | (35.5)                      | 34                       | (6.9)                    | 1475                                          | (25.1)                                        | 2295                                                  | (24.9)                                                |
| WithoneormoreAEoSI         | Fatal        | 0                           | (0.0)                       | 0                        | (0.0)                    | 11                                            | (0.7)                                         | 20                                                    | (0.9)                                                 |
| WithoneormoreAEoSI         | Not Resolved | 73                          | (42.2)                      | 9                        | (26.5)                   | 692                                           | (46.9)                                        | 1051                                                  | (45.8)                                                |
| WithoneormoreAEoSI         | Resolving    | 32                          | (18.5)                      | 4                        | (11.8)                   | 97                                            | (6.0)                                         | 195                                                   | (8.5)                                                 |
| WithoneormoreAEoSI         | Unknown      | 0                           | (0.0)                       | 0                        | (0.0)                    | 27                                            | (1.8)                                         | 30                                                    | (1.3)                                                 |
| WithoneormoreAEoSI         | Sequelae     | 15                          | (8.7)                       | 0                        | (0:0)                    | 34                                            | (2.3)                                         | 64                                                    | (2.8)                                                 |
| WithoneormoreAEoSI         | Resolved     | 53                          | (30.0)                      | 21                       | (61.8)                   | 614                                           | (41.6)                                        | 935                                                   | (40.7)                                                |

Table 60Summary of OutcomeforParticipants ofAEOSIin theIndicationDataset

| AEOSI                   |   Notresolvedor resolved with sequelae (%) |   Resolving (%) |   Resolved (%) |
|-------------------------|--------------------------------------------|-----------------|----------------|
| Adrenal Insufficiency   |                                       70   |            20   |           10   |
| Colitis                 |                                       25   |             0   |           75   |
| Encephalitis            |                                        0   |             0   |          100   |
| Hepatitis               |                                        0   |             0   |          100   |
| Hyperthyroidism         |                                       13.8 |             5.2 |           81   |
| Hypophysitis            |                                        0   |             0   |          100   |
| Hypothyroidism          |                                       60.2 |            25.2 |           14.6 |
| Infusion Reactions      |                                        0   |             0   |          100   |
| Myasthenic Syndrome     |                                       33.3 |             0   |           66.7 |
| Myocarditis             |                                        0   |           100   |            0   |
| Myositis                |                                      100   |             0   |            0   |
| Nephritis               |                                       33.3 |            33.3 |           33.3 |
| Pneumonitis             |                                        9.1 |             0   |           90.9 |
| Sarcoidosis             |                                       75   |             0   |           25   |
| SevereSkinReactions     |                                       25   |             0   |           75   |
| Thyroiditis             |                                       50   |             0   |           50   |
| Type 1 DiabetesMellitus |                                       88.9 |            11.1 |            0   |
| Vasculitis              |                                        0   |             0   |          100   |

<div style=\"page-break-after: always\"></div>

Table 61 Summary of Concomitant Corticosteroid Use for AEOSI

|                                      | KN564Datafor Pembrolizumab (N=488)   | KN564Datafor Pembrolizumab (N=488)   | KN564Datafor Placebob (N=496)   | KN564Datafor Placebob (N=496)   | ReferenceSafety Datasetfor Pembrolizumab (N=5884)   | ReferenceSafety Datasetfor Pembrolizumab (N=5884)   | Cumulative RunningSafety Datasetfor Pembrolizumabd (N=9218)   | Cumulative RunningSafety Datasetfor Pembrolizumabd (N=9218)   |
|--------------------------------------|--------------------------------------|--------------------------------------|---------------------------------|---------------------------------|-----------------------------------------------------|-----------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                      | n                                    | %                                    | u                               | %                               | n                                                   | %                                                   | n                                                             | %                                                             |
| ParticipantswithoneormoreAEoSI       | 173                                  |                                      | 34                              |                                 | 1475                                                |                                                     | 2295                                                          |                                                               |
| Treatedwithsystemiccorticosteroid    | 52                                   | 30.1                                 | 6                               | 17.6                            | 460                                                 | 31.2                                                | 766                                                           | 33.4                                                          |
| Nottreatedwithsystemiccorticosteroid | 121                                  | 69.9                                 | 28                              | 82.4                            | 1015                                                | 68.8                                                | 1529                                                          | 66.6                                                          |

## Safety data in pooled adjuvant studies

During the procedure the MAH provided safety data for the pembrolizumab adjuvant studies in RCC and melanoma (KEYNOTE-564, KEYNOTE-054, and KEYNOTE-716, n=1480; Adjuvant Dataset) and for the pembrolizumab studies in the advanced/metastatic setting (ie, the pembrolizumab monotherapy dataset without adjuvant study KEYNOTE-054, n=5375; Advanced/Metastatic Dataset).

<div style=\"page-break-after: always\"></div>

Table 62 Adverse Event Summary (APaT population)

|                                                               | KN564 Data for Pembmlizmab   |        | KN564 Data for Placcbos   | KN564 Data for Placcbos   | Reference Safety Dataset for Pembrolizimabd   | Reference Safety Dataset for Pembrolizimabd   | Cumulative Rumning Safety Dataset for Pembroliamab\"   | Cumulative Rumning Safety Dataset for Pembroliamab\"   |
|---------------------------------------------------------------|------------------------------|--------|---------------------------|---------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                               |                              | (%)    |                           | (%)                       | n                                             | (96)                                          | n                                                     | (%6)                                                  |
| Participants in population                                    | 488                          |        | 496                       |                           | 5.884                                         |                                               | 9,218                                                 |                                                       |
| With one or more adverse cvents                               | 470                          | (96.3) | 452                       | (91.1)                    | 5,690                                         | (96.7)                                        | 8.890                                                 | (96.4)                                                |
| with no adverse cvent                                         | 18                           | (3.7)  | 44                        | (8.9)                     | 194                                           | (3.3)                                         | 328                                                   | (3.6)                                                 |
| with dnug-rclated' adverse cvents                             | 386                          | (79.1) | 265                       | (53.4)                    | 4,132                                         | (70.2)                                        | 6.375                                                 | (69.2)                                                |
| with toxicity gmde 3-5 adverse events                         | 158                          | (32.4) | 88                        | (17.7)                    | 2.829                                         | (48.1)                                        | 4,444                                                 | (48.2)                                                |
| with toxicity grade 3-5 dnug-related adverse events           | 92                           | (18.9) | 6                         | (1.2)                     | E16                                           | (15.5)                                        | 1,490                                                 | (16.2)                                                |
| with seripus advcrse events                                   | 100                          | (20.5) | 56                        | (11.3)                    | 2,266                                         | (38.5)                                        | 3,449                                                 | (37.4)                                                |
| with serious drug-related adverse cvcnts                      | 59                           | (12.1) | 1                         | (0.2)                     | 656                                           | (11.1)                                        | 1,049                                                 | (11.4)                                                |
| who died                                                      | 2                            | (0.4)  | 1                         | (0.2)                     | 312                                           | (5.3)                                         | 484                                                   | (5.3)                                                 |
| who died due to a drug-related adverse cvent                  | 0                            | (0.0)  | 0                         | (0.0)                     | 39                                            | (0.7)                                         | 66                                                    | (0.7)                                                 |
| discon tinued drug due to an adverse cvent                    | 101                          | (20.7) | 10                        | (2.0)                     | 790                                           | (13.4)                                        | 1,215                                                 | (13.2)                                                |
| discon tinued drug due to a dnug-related adverse cvent        | 86                           | (17.6) | 3                         | (0.6)                     | 410                                           | (7.0)                                         | 676                                                   | (7.3)                                                 |
| disconinued drug due to a serious ndverse event               | 49                           | (10.0) | 5                         | (o)                       | 572                                           | (9.7)                                         | 855                                                   | (9.3)                                                 |
| discontinued drug due to a serious drug-related adverse event | 37 (7.6)                     | 0      | (0.0)                     | 91                        | (6.1) 223                                     | (4.1)                                         | 245                                                   | (4.2)                                                 |

a Determined by the investigator to be related to the drug.

bIncludes all participants who received at least one dose of pembrolizumab in KN564.

cIncludes all participants who received at least one dose of placebo in KN564.

dIncludes all participants who received at least one dose of pembrolizumab in KN564, KN054 and KN716.

- eIncludes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048,KN052,KN055andKN087.

fIncludes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048,KN052,KN054,KN055 and KN087.

Database Cutoff Date for Melanoma (KN001-Melanoma:18APR2014,KN002: 28FEB2015,KN006:03MAR2015,KN054: 03APR2020/02OCT2017inEURSD,KN716:21JUN2021)

Database Cutoff Date for Lung (KN001-NSCLC:23JAN2015,KN010: 30SEP2015,KN024:10JUL2017,KN042:04SEP2018)

DatabaseCutoffDateforHNSCC(KN012-HNSCC:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055: 22APR2016)

DatabaseCutoffDateforBladder(KN045:26OCT2017,KN052:26SEP2018)

Database cutoff date forRCC (KN564:14DEC2020)

<div style=\"page-break-after: always\"></div>

Table 63 Adverse Event Summary AEOSI

|                                                               | KN564 Data for Pembrolizumabb   | KN564 Data for Pembrolizumabb   | KN564 Data for Placeboc   | KN564 Data for Placeboc   | KN564 + KN054 + KN716 Safety Dataset for Pembrolizumabd   | KN564 + KN054 + KN716 Safety Dataset for Pembrolizumabd   | Safety Dataset for Pembrolizumab in Advanced/Metas tatic Setting   | Safety Dataset for Pembrolizumab in Advanced/Metas tatic Setting   | Reference Safety Dataset for Pembrolizumab'   | Reference Safety Dataset for Pembrolizumab'   |
|---------------------------------------------------------------|---------------------------------|---------------------------------|---------------------------|---------------------------|-----------------------------------------------------------|-----------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                                               | n                               | (%)                             | n                         | (%)                       | n                                                         | (%)                                                       | n                                                                  | (%)                                                                | n                                             | (%)                                           |
| Participants in population                                    | 488                             |                                 | 496                       |                           | 1,480                                                     |                                                           | 5,375                                                              |                                                                    | 5,884                                         |                                               |
| with one or more adverse events                               | 173                             | (35.5)                          | 34                        | (6.9)                     | 534                                                       | (36.1)                                                    | 1,300                                                              | (24.2)                                                             | 1,474                                         | (25.1)                                        |
| with no adverse event                                         | 315                             | (64.5)                          | 462                       | (93.1)                    | 946                                                       | (63.9)                                                    | 4,075                                                              | (75.8)                                                             | 4,410                                         | (74.9)                                        |
| with drug-related? adverse events                             | 155                             | (31.8)                          | 22                        | (4.4)                     | 495                                                       | (33.4)                                                    | 1,118                                                              | (20.8)                                                             | 1,281                                         | (21.8)                                        |
| with toxicity grade 3-5 adverse events                        | 44                              | (9.0)                           | 3                         | (0.6)                     | 132                                                       | (8.9)                                                     | 342                                                                | (6.4)                                                              | 380                                           | (6.5)                                         |
| with toxicity grade 3-5 drug- related adverse events          | 43                              | (8.8)                           | 0                         | (0.0)                     | 125                                                       | (8.4)                                                     | 296                                                                | (5.5)                                                              | 330                                           | (5.6)                                         |
| with serious adverse events                                   | 41                              | (8.4)                           | 1                         | (0.2)                     | 115                                                       | (7.8)                                                     | 337                                                                | (6.3)                                                              | 380                                           | (6.5)                                         |
| with serious drug-related adverse events                      | 39                              | (8.0)                           | 1                         | (0.2)                     | 108                                                       | (7.3)                                                     | 297                                                                | (5.5)                                                              | 336                                           | (5.7)                                         |
| who died                                                      | 0                               | (0.0)                           | 0                         | (0.0)                     | 0                                                         | (0.0)                                                     | 11                                                                 | (0.2)                                                              | 11                                            | (0.2)                                         |
| who died due to a drug-related adverse event                  | 0                               | (0.0)                           | 0                         | (0.0)                     | 0                                                         | (0.0)                                                     | 11                                                                 | (0.2)                                                              | 11                                            | (0.2)                                         |
| discontinued drug due to an adverse event                     | 39                              | (8.0)                           | 0                         | (0.0)                     | 117                                                       | (7.9)                                                     | 199                                                                | (3.7)                                                              | 232                                           | (3.9)                                         |
| discontinued drug due to a drug- related adverse event        | 38                              | (7.8)                           | 0                         | (0.0)                     | 116                                                       | (7.8)                                                     | 195                                                                | (3.6)                                                              | 228                                           | (3.9)                                         |
| discontinued drug due to a serious adverse event              | 21                              | (4.3)                           | 0                         | (0.0)                     | 58                                                        | (3.9)                                                     | 144                                                                | (2.7)                                                              | 156                                           | (2.7)                                         |
| discontinued drug due to a serious drug-related adverse event | 21                              | (4.3)                           | 0                         | (0.0)                     | 58                                                        | (3.9)                                                     | 142                                                                | (2.6)                                                              | 154                                           | (2.6)                                         |

<div style=\"page-break-after: always\"></div>

Table 64 Exposure-Adjusted AE Summary (Including Multiple Occurrences of Events) AEOSI

|                                                                         | Event Count and Rate (Events/100 person-months)a   | Event Count and Rate (Events/100 person-months)a   | Event Count and Rate (Events/100 person-months)a         | Event Count and Rate (Events/100 person-months)a                   | Event Count and Rate (Events/100 person-months)a   |
|-------------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------------------|----------------------------------------------------|
|                                                                         | KN564 Data for Pembrolizum abd                     | KN564 Data for Placeboe                            | KN564 + KN054 + KN716 Safety Dataset for Pembrolizum abf | Safety Dataset for Pembrolizum ab in Advanced/Me tastatic Settings | Reference Safety Dataset for Pembrolizum abh       |
| Number of participants exposed                                          | 488                                                | 496                                                | 1480                                                     | 5375                                                               | 5884                                               |
| Total exposureb in person- months                                       | 4852.07                                            | 5331.33                                            | 14990.36                                                 | 42682.29                                                           | 47883.80                                           |
| Total events (rate)                                                     |                                                    |                                                    |                                                          |                                                                    |                                                    |
| adverse events                                                          | 292 (6.02) 259 (5.34)                              | 39 (0.73) 27 (0.51)                                | 926 (6.18) 850 (5.67)                                    | 1801 (4.22) 1530 (3.58)                                            | 2154 (4.50) 1859 (3.88)                            |
| drug-related adverse events                                             |                                                    |                                                    | 175 (1.17)                                               |                                                                    | 451 (0.94)                                         |
| toxicity grade 3-5 adverse events                                       | 53 (1.09)                                          | 3 (0.06)                                           | 164 (1.09)                                               | 387 (0.91)                                                         | 394 (0.82)                                         |
| toxicity grade 3-5 drug- related adverse events                         | 51 (1.05)                                          | 0 (0.00)                                           | 145 (0.97)                                               | 336 (0.79) 382 (0.89)                                              | 447 (0.93)                                         |
| serious adverse events serious drug-related adverse events              | 44 (0.91) 42 (0.87)                                | 1 (0.02) 1 (0.02)                                  | 137 (0.91)                                               | 339 (0.79)                                                         | 399 (0.83)                                         |
|                                                                         |                                                    |                                                    |                                                          | 11 (0.03)                                                          | 11 (0.02)                                          |
| adverse events leading to death                                         | 0 (0.00) 0 (0.00)                                  | 0 (0.00) 0 (0.00)                                  | 0 (0.00) 0 (0.00)                                        | 11 (0.03)                                                          | 11 (0.02)                                          |
| drug-related adverse events leading to death adverse eventsresulting in | 40 (0.82)                                          | 0 (0.00)                                           | 119 (0.79)                                               | 205 (0.48)                                                         | 238 (0.50)                                         |
| drug discontinuation drug-related adverse                               | 39 (0.80)                                          | 0 (0.00)                                           | 118 (0.79)                                               | 201 (0.47)                                                         | 234 (0.49)                                         |
| events resulting in drug discontinuation serious adverse events         | 22 (0.45)                                          | 0 (0.00)                                           | 59 (0.39)                                                | 149 (0.35)                                                         | 161 (0.34)                                         |
| resulting in drug discontinuation serious drug-related                  |                                                    |                                                    |                                                          |                                                                    |                                                    |
| adverse events resulting in drug discontinuation                        | 22 (0.45)                                          | 0 (0.00)                                           | 59 (0.39)                                                | 147 (0.34)                                                         | 159 (0.33)                                         |

Table 65 Participants With AEOSI by Maximum Toxicity Grade

<div style=\"page-break-after: always\"></div>

Table 66 Participants With AEOSI By Category and Grade 3-4 (Incidence &gt; 0% in KN564)

|                                 | KN564 Data for Pembrolizumaba   | KN564 Data for Pembrolizumaba   | KN564 Data for Placebob   | KN564 Data for Placebob   | KN564 + KN054 + KN716 Safety Dataset for Pembrolizumabc   | KN564 + KN054 + KN716 Safety Dataset for Pembrolizumabc   | Safety Dataset for Pembrolizumab in Advanced/Metas tatic Settingd   | Safety Dataset for Pembrolizumab in Advanced/Metas tatic Settingd   | Reference Safety Dataset for Pembrolizumabe   | Reference Safety Dataset for Pembrolizumabe   |
|---------------------------------|---------------------------------|---------------------------------|---------------------------|---------------------------|-----------------------------------------------------------|-----------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                 | n                               | (%)                             | n                         | (%)                       | n                                                         | (%)                                                       | n                                                                   | (%)                                                                 | n                                             | (%)                                           |
| Participants in population      | 488                             |                                 | 496                       |                           | 1,480                                                     |                                                           | 5,375                                                               |                                                                     | 5,884                                         |                                               |
| with one or more adverse events | 173                             | (35.5)                          | 34                        | (6.9)                     | 534                                                       | (36.1)                                                    | 1,300                                                               | (24.2)                                                              | 1,474                                         | (25.1)                                        |
| Grade 1                         | 26                              | (5.3)                           | 18                        | (3.6)                     | 106                                                       | (7.2)                                                     | 327                                                                 | (6.1)                                                               | 368                                           | (6.3)                                         |
| Grade 2                         | 103                             | (21.1)                          | 13                        | (2.6)                     | 296                                                       | (20.0)                                                    | 631                                                                 | (11.7)                                                              | 726                                           | (12.3)                                        |
| Grade 3                         | 39                              | (8.0)                           | 3                         | (0.6)                     | 119                                                       | (8.0)                                                     | 290                                                                 | (5.4)                                                               | 324                                           | (5.5)                                         |
| Grade 4                         | 5                               | (1.0)                           | 0                         | (0.0)                     | 13                                                        | (0.9)                                                     | 41                                                                  | (0.8)                                                               | 45                                            | (0.8)                                         |
| Grade 5                         | 0                               | (0.0)                           | 0                         | (0.0)                     | 0                                                         | (0.0)                                                     | 11                                                                  | (0.2)                                                               | 11                                            | (0.2)                                         |
| with no adverse events          | 315                             | (64.5)                          | 462                       | (93.1)                    | 946                                                       | (63.9)                                                    | 4,075                                                               | (75.8)                                                              | 4,410                                         | (74.9)                                        |

5,884

1,475

(25.1)

4,409

(74.9)

47

(0.8)

110

(1.9)

3

(0.1)

55

(0.9)

247

(4.2)

36

(0.6)

652

(11.1)

138

(2.3)

3

(0.1)

5

(0.1)

19

(0.3)

|                                                                                   | KN564 Data for Pembrolizumab   | KN564 Data for Pembrolizumab   | KN564 Data for Placebo   | KN564 Data for Placebo   | KN564 + KN054 + KN716 Safety Dataset for Pembrolizumab   | Safety Dataset for Pembrolizumab In Advanced/Meta static Setting   | Reference Safety Dataset for Pembrolizumab ¶   | Reference Safety Dataset for Pembrolizumab ¶   |
|-----------------------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|----------------------------------------------------------|--------------------------------------------------------------------|------------------------------------------------|------------------------------------------------|
|                                                                                   | n                              | (%)                            | n                        | (%)                      | n (%)                                                    | n (%)                                                              | n                                              | (%)                                            |
| Participants in population with one or more adverse events with no adverse events | 488 173 315                    | (35.5) (64.5)                  | 496 34 462               | (6.9) (93.1)             | 1,480 534 (36.1) 946 (63.9)                              | 5,375 1,300 (24.2) 4.075 (75.8)                                    | 5,884 1,475 4,409                              | (25.1) (74.9)                                  |
| Adrenal Insufficiency                                                             | 10                             | (2.0)                          | 1                        | (0.2)                    | 27 (1.8)                                                 | 42 (0.8)                                                           | 47                                             | (0.8)                                          |
| Grade 3-4                                                                         |                                | 6 (1.2)                        |                          | 1 (0.2)                  | 11(0.7)                                                  | 22 (0.4)                                                           |                                                | 23 (0.4)                                       |
| Colitis                                                                           | 8                              | (1.6)                          | 1                        | (0.2)                    | 46 (3.1)                                                 | 91 (1.7)                                                           | 110                                            | (1.9)                                          |
| Grade 3-4                                                                         |                                | 5 (1.0)                        |                          | 0 (0.0)                  | 24 (1.6)                                                 | 57 (1.1)                                                           |                                                | 67 (1.1)                                       |
| Encephalitis                                                                      | 1                              | (0.2)                          | 0                        | (0.0)                    | 1 (0.1)                                                  | 3 (0.1)                                                            | 3                                              | (0.1)                                          |
| Grade 3-4                                                                         |                                | 1(0.2)                         |                          | 0 (0.0)                  | 1 (0.1)                                                  | 2 (0.0)                                                            |                                                | 2 (0.0)                                        |
| Hepatitis                                                                         | 5                              | (1.0)                          | 0                        | (0.0)                    | 25 (1.7)                                                 | 46 (0.9)                                                           | 55                                             | (0.9)                                          |
| Grade 3-4                                                                         |                                | 4 (0.8)                        |                          | 0 (0.0)                  | 20 (1.4)                                                 | 36 (0.7)                                                           |                                                | 43 (0.7)                                       |
| Hyperthyroidism                                                                   | 58                             | (11.9)                         | 1                        | (0.2)                    | 161 (10.9)                                               | 194 (3.6)                                                          | 247                                            | (4.2)                                          |
| Grade 3-4                                                                         |                                | 1 (0.2)                        |                          | 0 (0.0)                  | 2 (0.1)                                                  | 6 (0.1)                                                            |                                                | 7 (0.1)                                        |
| Hypophysitis                                                                      | 2                              | (0.4)                          | 0                        | (0.0)                    | 25 (1.7)                                                 | 25 (0.5)                                                           | 36                                             | (0.6)                                          |
| Grade 3-4                                                                         |                                | 2 (0.4)                        |                          | 0 (0.0)                  | 8 (0.5)                                                  | 17 (0.3)                                                           |                                                | 20 (0.3)                                       |
| Hypothyroidism                                                                    | 103                            | (21.1)                         | 18                       | (3.6)                    | 262 (17.7)                                               | 577 (10.7)                                                         | 652                                            | (11.1)                                         |
| Grade 3-4                                                                         |                                | 1 (0.2)                        |                          | 0 (0.0)                  | 1 (0.1)                                                  | 7 (0.1)                                                            |                                                | 7 (0.1)                                        |
| Infusion Reactions                                                                | 7                              | (1.4)                          | 5                        | (1.0)                    | 21 (1.4)                                                 | 130 (2.4)                                                          | 138                                            | (2.3)                                          |
| Grade 3-4                                                                         |                                | 2 (0.4)                        |                          | 0 (0.0)                  | 4 (0.3)                                                  | 13 (0.2)                                                           |                                                | 14 (0.2)                                       |
| Myasthenic Syndrome                                                               | 3                              | (0.6)                          | 0                        | (0.0)                    | 6 (0.4)                                                  | 2 (0.0)                                                            | 3                                              | (0.1)                                          |
| Grade 3-4                                                                         |                                | 0 (0.0)                        |                          | 0 (0.0)                  | 2 (0.1)                                                  | 1 (0.0)                                                            |                                                | 1 (0.0)                                        |
| Myocarditis                                                                       | 1                              | (0.2)                          | 0                        | (0.0)                    | 2 (0.1)                                                  | 4 (0.1)                                                            | 5                                              | (0.1)                                          |
| Grade 3-4                                                                         |                                | 1 (0.2)                        |                          | 0 (0.0)                  | 2 (0.1)                                                  | 4 (0.1)                                                            |                                                | 5 (0.1)                                        |
|                                                                                   | 2                              | (0.4)                          | 1                        | (0.2)                    | 9 (0.6)                                                  | 18 (0.3)                                                           | 19                                             | (0.3)                                          |
| Myositis                                                                          |                                |                                |                          |                          |                                                          |                                                                    |                                                |                                                |

<div style=\"page-break-after: always\"></div>

23

(0.4)

264

(4.5)

10

(0.2)

97

(1.6)

58

(1.0)

20

(0.3)

21

| Grade 3-4                | 0 (0.0)   | 0 (0.0)   | 4 (0.3)          | 2 (0.0)   |     | 3 (0.1)   |
|--------------------------|-----------|-----------|------------------|-----------|-----|-----------|
| Nephritis                | 3 (0.6)   | 0 (0.0)   | 12 (0.8)         | 21 (0.4)  | 23  | (0.4)     |
| Grade 3-4                | 1         | (0.2) 0   | (0.0) 6 (0.4)    | 14 (0.2)  |     | 16 (0.3)  |
| Pneumonitis              | 11 (2.3)  | 5 (1.0)   | 40 (2.7)         | 247 (4.6) | 264 | (4.5)     |
| Grade 3-4                | 4         | (0.8) 0   | (0.0) 9 (0.6)    | 78 (1.5)  |     | 82 (1.4)  |
| Sarcoidosis              | 4 (0.8)   | 0 (0.0)   | 16 (1.1)         | 3 (0.1)   | 10  | (0.2)     |
| Grade 3-4                | 0         | (0.0) 0   | (0.0) 0 (0.0)    | 0 (0.0)   |     | 0 (0.0)   |
| Severe Skin Reactions    | 8 (1.6)   | 2 (0.4)   | 27 (1.8)         | 92 (1.7)  | 97  | (1.6)     |
| Grade 3-4                | 8 (1.6)   | 2         | (0.4) 26 (1.8)   | 69 (1.3)  |     | 74 (1.3)  |
| Thyroiditis              | 6 (1.2)   | 1 (0.2)   | 28 (1.9)         | 42 (0.8)  | 58  | (1.0)     |
| Grade 3-4                | 2         | (0.4) 0   | (0.0) 2 (0.1)    | 1 (0.0)   |     | 1 (0.0)   |
| Type 1 Diabetes Mellitus | 9 (1.8)   | 0 (0.0)   | 16 (1.1)         | 15 (0.3)  | 20  | (0.3)     |
| Grade 3-4                | 9         | (1.8)     | 0 (0.0) 16 (1.1) | 14 (0.3)  |     | 19 (0.3)  |
| Uveitis                  | 0 (0.0)   | 1 (0.2)   | 3 (0.2)          | 19 (0.4)  | 21  | (0.4)     |
| Grade 3-4                | 0         | (0.0)     | 0 (0.0) 0 (0.0)  | 2 (0.0)   |     | 2 (0.0)   |
| Vasculitis               | 2 (0.4)   | 0 (0.0)   | 2 (0.1)          | 2 (0.0)   | 2   | (0.0)     |
| Grade 3-4                | 1         | (0.2)     | 0 (0.0) 1 (0.1)  | 0 (0.0)   |     | 1 (0.0)   |

(0.4)

Table 68 Summary of Outcome for Participants With AEOSI (Incidence &gt; 0% in One or More Treatment Groups)

|                                                           | KN564 Data for Pembrolizu maba n (%)   | KN564 Data for Placebob n (%)   | KN564 + KN054 + KN716 Safety Dataset for Pembrolizu mabc n (%)   | Safety Dataset for Pembrolizu mab in Advanced/ Metastatic Settingd n (%)   | Reference Safety Dataset for Pembrolizu mabe n (%)   |
|-----------------------------------------------------------|----------------------------------------|---------------------------------|------------------------------------------------------------------|----------------------------------------------------------------------------|------------------------------------------------------|
| Participants in population Participants with AEOSI        | 488 173 (35.5)                         | 496 34 (6.9)                    | 1480 534 (36.1)                                                  | 5375 1300 (24.2)                                                           | 5884 1474 (25.1)                                     |
| Time to Onset of First AEOSI (days)a Mean (Std) Median    | 100.9 (94.8) 64.0                      | 146.4 (89.1) 147.5              | 109.6 (95.8) 78.0                                                | 117.4 (123.6) 75.0                                                         | 118.0 (121.0) 79.5                                   |
| Range Total episodes of AEOSI                             | 1 to 426 292                           | 1 to 364 39 1.15                | 1 to 441 926                                                     | 1 to 787 1751                                                              | 1 to 787 2104                                        |
|                                                           |                                        |                                 |                                                                  | 1.35                                                                       |                                                      |
| Average Episodes per participant Episode duration (days)b | 1.69                                   |                                 | 1.73                                                             |                                                                            | 1.43                                                 |
| Median                                                    | 101.0                                  | 42.0                            | 68.0                                                             | 111.0                                                                      | 86.0                                                 |
| Range                                                     | 1 to 1148+                             | 1 to1022+                       | 1 to 1548+                                                       | 1 to 1640+                                                                 | 1 to 1640+                                           |

<div style=\"page-break-after: always\"></div>

|                            |              | KN564 Data for Pembrolizumab   | KN564 Data for Pembrolizumab   | KN564 Data for Placebo   | KN564 Data for Placebo   | KN564 + KN054 + KN716 Safety Dataset for Pembrolizumab   | KN564 + KN054 + KN716 Safety Dataset for Pembrolizumab   | Safety Dataset for Pembrolizumab in Advanced/Meta- static Setting   | Safety Dataset for Pembrolizumab in Advanced/Meta- static Setting   | Reference Safety Dataset for Pembrolizumab   | Reference Safety Dataset for Pembrolizumab   |
|----------------------------|--------------|--------------------------------|--------------------------------|--------------------------|--------------------------|----------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|----------------------------------------------|----------------------------------------------|
|                            | Outcome      | n                              | (%)                            | n                        | (%)                      | u                                                        | (%)                                                      | n                                                                   | (%)                                                                 | n                                            | (%)                                          |
| Participants in population |              | 488                            |                                | 496                      |                          | 1480                                                     |                                                          | 5375                                                                |                                                                     | 5884                                         |                                              |
| With one or more AEOSI     | Overall      | 173                            | (35.5)                         | 34                       | (6.9)                    | 534                                                      | (36.1)                                                   | 1300                                                                | (24.2)                                                              | 1474                                         | (25.1)                                       |
|                            | Fatal        | 0                              | (0.0)                          | 0                        | (0.0)                    | 0                                                        | (0.0)                                                    | 11                                                                  | (0.8)                                                               | 11                                           | (0.7)                                        |
|                            | Not Resolved | 73                             | (42.2)                         | 9                        | (26.5)                   | 254                                                      | (47.6)                                                   | 581                                                                 | (44.7)                                                              | 692                                          | (46.9)                                       |
|                            | Resolving    | 32                             | (18.5)                         | 4                        | (11.8)                   | 62                                                       | (11.6)                                                   | 97                                                                  | (7.5)                                                               | 97                                           | (6.6)                                        |
|                            | Unknown      | 0                              | (0.0)                          | 0                        | (0.0)                    | 1                                                        | (0.2)                                                    | 27                                                                  | (2.1)                                                               | 27                                           | (1.8)                                        |
|                            | Sequelae     | 15                             | (8.7)                          | 0                        | (0.0)                    | 25                                                       | (4.7)                                                    | 27                                                                  | (2.1)                                                               | 34                                           | (2.3)                                        |
|                            | Resolved     | 53                             | (30.6)                         | 21                       | (61.8)                   | 192                                                      | (36.0)                                                   | 557                                                                 | (42.8)                                                              | 613                                          | (41.6)                                       |

Table 69 Summary of Concomitant Corticosteroid Use for AEOSI

|                                          | KN564Datafor Pembrolizumaba (N=488)   | KN564Datafor Pembrolizumaba (N=488)   | Placebob (N=496)   | Placebob (N=496)   | KN564DataforKN564+KN054 + KN716 Safety Dataset for Pembrolizumabc (N=1480)   | KN564DataforKN564+KN054 + KN716 Safety Dataset for Pembrolizumabc (N=1480)   | Safety Dataset for Pembrolizumab in Advanced/Metast atic Setting? (N=5375)   | Safety Dataset for Pembrolizumab in Advanced/Metast atic Setting? (N=5375)   | Reference Safety Dataset for Pembrolizumab (N=5884)   | Reference Safety Dataset for Pembrolizumab (N=5884)   |
|------------------------------------------|---------------------------------------|---------------------------------------|--------------------|--------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                          | n                                     | %                                     | n                  | %                  | n                                                                            | %                                                                            | n                                                                            | %                                                                            | n                                                     | %                                                     |
| Participants with one or more AEOSI      | 173                                   |                                       | 34                 |                    | 534                                                                          |                                                                              | 1300                                                                         |                                                                              | 1474                                                  |                                                       |
| Treated with systemic corticosteroid     | 52                                    | 30.1                                  | 6                  | 17.6               | 106                                                                          | 19.9                                                                         | 459                                                                          | 35.3                                                                         | 515                                                   | 34.9                                                  |
| Not treated with systemic corticosteroid | 121                                   | 69.9                                  | 28                 | 82.4               | 428                                                                          | 80.1                                                                         | 841                                                                          | 64.7                                                                         | 959                                                   | 65.1                                                  |

Table 70 Summary of Hormone Replacement Therapy Use for AEOSI (

|                                               | Pembrolizumab   | Pembrolizumab   | Placebo   | Placebo   |
|-----------------------------------------------|-----------------|-----------------|-----------|-----------|
|                                               | n               | (%)             | n         | (%)       |
| Subjects in population                        | 488             |                 | 496       |           |
| Subjects with one or more events              | 119             |                 | 20        |           |
| Treated with systemic hormone replacement     | 109             | (91.6)          | 12        | (60.0)    |
| Not treated with systemic hormone replacement | 10              | (8.4)           | 8         | (40.0)    |

## Laboratory findings

The percentage of participants with laboratory abnormalities during the study were higher in the pembrolizumab group compared with the placebo group. The most frequently reported laboratory abnormalities (incidence ≥20%) in the Indication Dataset were general ly consistent with the RSD, and the majority had a CTCAE toxicity Grade of 1 to 2.

Grade 3 to 4 laboratory abnormalities with an incidence of ≥ 2% in the pembrolizumab group were the following: ALT increased (3.8%), AST increased (2.7%), glucose increased (8.0%), lymphocyte decreased (2.5%), phosphate decreased (2.2%), and sodium decreased (3.3%).

<div style=\"page-break-after: always\"></div>

Table 71 Summary of Participants with Increases from Baseline in Laboratory Test Toxicity Grade Based on Highest Post-baseline Toxicity Grade

|                                                                                | KN564 Data for Pembrolizumaba                                              | KN564 Data for Pembrolizumaba                                              | KN564 Data for Placebob                                                    | KN564 Data for Placebob                                                    | Reference Safety Dataset for Pembrolizumabe (N=5884)                       | Reference Safety Dataset for Pembrolizumabe (N=5884)                       | Cumulative Running Safety Dataset for Pembrolizumabd (N=9218)              | Cumulative Running Safety Dataset for Pembrolizumabd (N=9218)              |
|--------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Laboratory Test                                                                | n                                                                          | (N=488) (%)                                                                | (N=496) n                                                                  | (%)                                                                        | n                                                                          | (%)                                                                        | n                                                                          | (%)                                                                        |
| Alanine Aminotransferase Increased (Alanine aminotransferase increased)        | Alanine Aminotransferase Increased (Alanine aminotransferase increased)    | Alanine Aminotransferase Increased (Alanine aminotransferase increased)    | Alanine Aminotransferase Increased (Alanine aminotransferase increased)    | Alanine Aminotransferase Increased (Alanine aminotransferase increased)    | Alanine Aminotransferase Increased (Alanine aminotransferase increased)    | Alanine Aminotransferase Increased (Alanine aminotransferase increased)    | Alanine Aminotransferase Increased (Alanine aminotransferase increased)    | Alanine Aminotransferase Increased (Alanine aminotransferase increased)    |
| Participants with Baseline and Post-baseline                                   | 449                                                                        |                                                                            | 469                                                                        |                                                                            | 4984                                                                       |                                                                            | 8089                                                                       |                                                                            |
| Measurements Grade 3-4                                                         | 17                                                                         | (3.8)                                                                      | 1                                                                          | (0.2)                                                                      | 139                                                                        | (2.8)                                                                      | 285                                                                        | (3.5)                                                                      |
|                                                                                | 90                                                                         |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            | 2043                                                                       |                                                                            |
| All Grades                                                                     |                                                                            | (20.0)                                                                     | 52                                                                         | (11.1)                                                                     | 1261                                                                       | (25.3)                                                                     |                                                                            | (25.3)                                                                     |
| AspartateAminotransferase Increased (Aspartate aminotransferase increased)     | AspartateAminotransferase Increased (Aspartate aminotransferase increased) | AspartateAminotransferase Increased (Aspartate aminotransferase increased) | AspartateAminotransferase Increased (Aspartate aminotransferase increased) | AspartateAminotransferase Increased (Aspartate aminotransferase increased) | AspartateAminotransferase Increased (Aspartate aminotransferase increased) | AspartateAminotransferase Increased (Aspartate aminotransferase increased) | AspartateAminotransferase Increased (Aspartate aminotransferase increased) | AspartateAminotransferase Increased (Aspartate aminotransferase increased) |
| Participants with Baseline and Post-baseline Measurements                      | 448                                                                        |                                                                            | 468                                                                        |                                                                            | 4981                                                                       |                                                                            | 8079                                                                       |                                                                            |
| Grade 3-4                                                                      | 12                                                                         |                                                                            |                                                                            |                                                                            | 146                                                                        |                                                                            | 322                                                                        |                                                                            |
|                                                                                |                                                                            | (2.7)                                                                      | 2                                                                          | (0.4)                                                                      |                                                                            | (2.9)                                                                      |                                                                            | (4.0)                                                                      |
| All Grades                                                                     | 70                                                                         | (15.6)                                                                     | 33                                                                         | (7.1)                                                                      | 1421                                                                       | (28.5)                                                                     | 2325                                                                       | (28.8)                                                                     |
| CreatinineIncreased(Creatinineincreased)                                       | CreatinineIncreased(Creatinineincreased)                                   | CreatinineIncreased(Creatinineincreased)                                   | CreatinineIncreased(Creatinineincreased)                                   | CreatinineIncreased(Creatinineincreased)                                   | CreatinineIncreased(Creatinineincreased)                                   | CreatinineIncreased(Creatinineincreased)                                   | CreatinineIncreased(Creatinineincreased)                                   | CreatinineIncreased(Creatinineincreased)                                   |
| Participants with Baseline and Post-baseline Measurements                      | 448                                                                        |                                                                            | 469                                                                        |                                                                            | 4991                                                                       |                                                                            | 8100                                                                       |                                                                            |
| Grade 3-4                                                                      | 5                                                                          | (1.1)                                                                      | 1                                                                          | (0.2)                                                                      | 70                                                                         | (1.4)                                                                      | 127                                                                        | (1.6)                                                                      |
| All Grades                                                                     | 178                                                                        | (39.7)                                                                     | 130                                                                        | (27.7)                                                                     | 951                                                                        | (19.1)                                                                     | 1701                                                                       | (21.0)                                                                     |
| Glucose Increased (Hyperglycemia) Participants with Baseline and Post-baseline | 449                                                                        |                                                                            | 469                                                                        |                                                                            | 4906                                                                       |                                                                            | 7949                                                                       |                                                                            |
| Measurements Grade 3-4                                                         | 36                                                                         | (8.0)                                                                      | 21                                                                         | (4.5)                                                                      | 247                                                                        | (5.0)                                                                      | 431                                                                        | (5.4)                                                                      |
| All Grades                                                                     | 217                                                                        | (48.3)                                                                     | 212                                                                        | (45.2)                                                                     | 2493                                                                       | (50.8)                                                                     | 3919                                                                       | (49.3)                                                                     |
| Lymphocytes Decreased (Lymphocyte count decreased)                             | Lymphocytes Decreased (Lymphocyte count decreased)                         | Lymphocytes Decreased (Lymphocyte count decreased)                         | Lymphocytes Decreased (Lymphocyte count decreased)                         | Lymphocytes Decreased (Lymphocyte count decreased)                         | Lymphocytes Decreased (Lymphocyte count decreased)                         | Lymphocytes Decreased (Lymphocyte count decreased)                         | Lymphocytes Decreased (Lymphocyte count decreased)                         | Lymphocytes Decreased (Lymphocyte count decreased)                         |
| Participants with Baseline and Post-baseline                                   | 437                                                                        |                                                                            | 456                                                                        |                                                                            | 4673                                                                       |                                                                            | 7739                                                                       |                                                                            |
| Measurements Grade 3-4                                                         | 11                                                                         | (2.5)                                                                      | 3                                                                          | (0.7)                                                                      | 524                                                                        | (11.2)                                                                     | 801                                                                        | (10.4)                                                                     |
|                                                                                | 74                                                                         |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |
| All Grades                                                                     |                                                                            | (16.9)                                                                     | 49                                                                         | (10.7)                                                                     | 1791                                                                       | (38.3)                                                                     | 2846                                                                       | (36.8)                                                                     |
| Phosphate Decreased (Hypophosphatemia)                                         | Phosphate Decreased (Hypophosphatemia)                                     | Phosphate Decreased (Hypophosphatemia)                                     | Phosphate Decreased (Hypophosphatemia)                                     | Phosphate Decreased (Hypophosphatemia)                                     | Phosphate Decreased (Hypophosphatemia)                                     | Phosphate Decreased (Hypophosphatemia)                                     | Phosphate Decreased (Hypophosphatemia)                                     | Phosphate Decreased (Hypophosphatemia)                                     |
| Participants with Baseline and Post-baseline Measurements                      | 449                                                                        |                                                                            | 470                                                                        |                                                                            | 4721                                                                       |                                                                            | 7198                                                                       |                                                                            |
| Grade 3-4                                                                      | 10                                                                         | (2.2)                                                                      | 8                                                                          | (1.7)                                                                      | 260                                                                        | (5.5)                                                                      | 380                                                                        | (5.3)                                                                      |
| All Grades                                                                     | 71                                                                         | (15.8)                                                                     | 74                                                                         | (15.7)                                                                     | 1043                                                                       | (22.1)                                                                     | 1501                                                                       | (20.9)                                                                     |
| Sodium Decreased (Hyponatremia)                                                | Sodium Decreased (Hyponatremia)                                            | Sodium Decreased (Hyponatremia)                                            | Sodium Decreased (Hyponatremia)                                            | Sodium Decreased (Hyponatremia)                                            | Sodium Decreased (Hyponatremia)                                            | Sodium Decreased (Hyponatremia)                                            | Sodium Decreased (Hyponatremia)                                            | Sodium Decreased (Hyponatremia)                                            |
| Participants with Baseline and Post-baseline Measurements                      | 449                                                                        |                                                                            | 469                                                                        |                                                                            | 5332                                                                       |                                                                            | 8438                                                                       |                                                                            |
| Grade 3-4                                                                      | 15                                                                         | (3.3)                                                                      | 9                                                                          | (1.9)                                                                      | 452                                                                        | (8.5)                                                                      | 714                                                                        | (8.5)                                                                      |
| All Grades                                                                     | 94                                                                         | (20.9)                                                                     | 60                                                                         | (12.8)                                                                     | 1932                                                                       | (36.2)                                                                     | 2874                                                                       | (34.1)                                                                     |

## Abnormal liver enzyme and function tests

<div style=\"page-break-after: always\"></div>

A total of 3 participants (0.6%) in the pembrolizumab group and no participant in the placebo group had concurrent increases in aminotransferase to ≥3 x ULN plus bilirubin to ≥2 x ULN plu s ALP to &lt;2 x ULN. In the three cases meeting potential DILI screening laboratory criteria the participants were taking multiple concomitant medications associated with liver toxicity and the MAH concluded that the DILI screening laboratory test results were most likely related to the concomitant application of medications and not related to pembrolizumab.

## Safety in special populations

## Age

The AE profile in the Indication Dataset was generally similar across age groups of &lt;65, 65 to 74, and 75 to 84, although there was a small number of participants in the 75 to 84 years category (n=18; no participant was ≥ 85 years) and generally similar between participants who were &lt;65 years and those ≥ 65 years.

The AE profile for categories of interest (central nervous system confusion/extrapyramidal, AE related to falling, cardiovascular events, cerebrovascular events, and infections) in the Indication Dataset was also generally similar across age groups of &lt;65, 65 to 74, and 75 to 84.

Table 72 Summary by Age Category (&lt;65, ≥65 Years)

|                                                              | KN564DataforPembrolizumab   | KN564DataforPembrolizumab   | KN564DataforPembrolizumab   | KN564DataforPembrolizumab   | KN564Data forPlacebo   | KN564Data forPlacebo   | KN564Data forPlacebo   | KN564Data forPlacebo   | Reference Safety Dataset for Pembrolizumabd   | Reference Safety Dataset for Pembrolizumabd   | Reference Safety Dataset for Pembrolizumabd   | Reference Safety Dataset for Pembrolizumabd   |
|--------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|------------------------|------------------------|------------------------|------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                                              | <65                         | <65                         | >=65                        | >=65                        | <65                    | <65                    | >=65                   | >=65                   | ≤65                                           | ≤65                                           | >=65                                          | >=65                                          |
|                                                              |                             | (%)                         |                             | (%)                         | n                      | (%)                    |                        | (%)                    |                                               | (%)                                           |                                               | (%)                                           |
| Participants in population                                   | 333                         |                             | 155                         |                             | 324                    |                        | 172                    |                        | 3385                                          |                                               | 2,499                                         |                                               |
| with one ormore adverse events                               | 322                         | (96.7)                      | 148                         | (95.5)                      | 294                    | (90.7)                 | 158                    | (91.9)                 | 3.268                                         | (96.5)                                        | 2,422                                         | (96.9)                                        |
| with no adverse event                                        | 11                          | (3.3)                       | 7                           | (4.5)                       | 30.                    | (9.3)                  | 14                     | (8.1)                  | 117                                           | (3.5)                                         | 77                                            | (3.1)                                         |
| with drug-relatedadverse events                              | 270                         | (81.1)                      | 116                         | (74.8)                      | 182                    | (56.2)                 | 83                     | (48.3)                 | 2,366                                         | (69.9)                                        | 1,766                                         | (70.7)                                        |
| with toxicity grade3-5adveise events                         | 104                         | (31.2)                      | 54                          | (34.8)                      | 45                     | (13.9)                 | 43                     | (25.0)                 | 1,505                                         | (44.5)                                        | 1,324                                         | (53.0)                                        |
| with toxicity grade3-5 drug-related adveise events           | 60                          | (18.0)                      | 32                          | (20.6)                      | 4                      | (1.2)                  | 2                      | (1.2)                  | 456                                           | (13.5)                                        | 457                                           | (18.3)                                        |
| with serious adverse events                                  | 62                          | (18.6)                      | 38                          | (24.5)                      | 29                     | (9.0)                  | 27                     | (15.7)                 | 1,182                                         | (34.9)                                        | 1,084                                         | (43.4)                                        |
| withserious drug-related adverse events                      | 36                          | (10.8)                      | 23                          | (14.8)                      | 1                      | (0.3)                  | 0.                     | (0.0)                  | 346                                           | (10.2)                                        | 310                                           | (12.4)                                        |
| whodied                                                      | 1                           | (0.3)                       | 1                           | (0.6)                       | 1                      | (0.3)                  | 0                      | (0.0)                  | 144                                           | (4.3)                                         | 168                                           | (6.7)                                         |
| who died due toa drug-related adverseevent                   | 0                           | (0.0)                       | 0                           | (0.0)                       | 0                      | (0.0)                  | 0                      | (00)                   | 21                                            | (0.6)                                         | 18                                            | (0.7)                                         |
| discontinued drugdue to an adverse event                     | 59                          | (17.7)                      | 42                          | (27.1)                      | 5                      | (1.5)                  | 5                      | (2.9)                  | 399                                           | (811)                                         | 391                                           | (15.6)                                        |
| discontinued drugdue to a drug-related adverse event         | 49                          | (14.7)                      | 37                          | (23.9)                      | 2                      | (0.6)                  |                        | (0.6)                  | 207                                           | (6.1)                                         | 203                                           | (8.1)                                         |
| discontinued drug due to a serious adverse event             | 29                          | (8.7)                       | 20                          | (12.9)                      | 2                      | (0.6)                  | 3                      | (1.7)                  | 287                                           | (8.5)                                         | 285                                           | (11.4)                                        |
| discontinued drug due to a serious drug-related adverseevent | 21                          | (6.3)                       | 16                          | (10.3)                      | 0                      | (0.0)                  | 0                      | (0.0)                  | 123                                           | (3.6)                                         | 122                                           | (4.9)                                         |

<!-- image -->

|                                                      | KN564 Dath for Pembnlirimabb   | KN564 Dath for Pembnlirimabb   | KN564 Dath for Pembnlirimabb   | KN564 Dath for Pembnlirimabb   | KN564 Dath for Pembnlirimabb   | KN564 Dath for Pembnlirimabb   | KN564 Dath for Pembnlirimabb   | KN564 Duta for Placebo   | KN564 Duta for Placebo   | KN564 Duta for Placebo   | KN564 Duta for Placebo   | KN564 Duta for Placebo   | KN564 Duta for Placebo   | KN564 Duta for Placebo   |
|------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                      | 65                             | 65                             | 65.74                          | 65.74                          | 75.84                          | 75.84                          | 285                            | 65                       | 65                       | 65-74                    | 65-74                    | 75.84                    | 75.84                    | 85                       |
|                                                      |                                | (66)                           |                                | ()                             |                                | ()                             | (W)                            |                          | (M)                      |                          | (%)                      |                          | (%)                      | (W)                      |
| Partidpants inpopulation                             | 333                            |                                | 137                            |                                | 18                             |                                | 0                              | 324                      |                          | 147                      |                          | 25                       |                          | 0                        |
| with one or more dverse cvents                       | 322                            | (96.7)                         | IEI                            | (95.6)                         | 17                             | (94.4)                         | (0.0)                          | 294                      | (90.7)                   | 133                      | (506)                    | 25                       | (100.0)                  | (0.0)                    |
| withno dvarseevent                                   | I1                             | (3.3)                          | 6                              | (4.4)                          | 1                              | (5.0)                          | 0 (0.0)                        | 30                       | (9.3)                    | 14                       | (9.5)                    |                          | (00)                     | 0 (0.0)                  |
| with dnug-reltedadverse events                       | 270                            | (81.1)                         | 102                            | (74.5)                         | 14                             | (77.8) 0                       | (0.0)                          | 182                      | (56.2)                   | 72                       | (49.0)                   |                          | (44.0)                   | (0.0)                    |
| with toxicily gnde3-5 ndverse events                 | 104                            | (31.2)                         | 44                             | (32.1)                         | 10                             | (55.6)                         | 0 (0.0)                        | 45                       | (13.9)                   | 35                       | (23.0)                   | 8                        | (32.0)                   | 0 (0.0)                  |
| withwxicily gnde35 dug-rdatedadvere evenls           | 60                             | (18.0)                         | 27                             | (19.7)                         |                                | (27.8)                         | 0 (0.0)                        | 4                        | (1.2)                    | 2                        | (1.4)                    |                          | (0'0)                    | 0 (0.0)                  |
| withserious adverse ewents                           | 62                             | (18.6)                         |                                | (21.9)                         | 8                              | (44.4)                         | (0.0)                          | 29                       | (0r6)                    |                          | (13.6)                   | 7                        | (28.0)                   | 0 (0.0)                  |
| with serious drug-related adverse evemts             | 36                             | (10.8)                         | 18                             | (13.1)                         |                                | (27.8)                         | (0.0)                          |                          | (0.3)                    | 0                        | (o0)                     | 0                        | (0.0)                    | 0 (0.0)                  |
| who died                                             |                                | (0.3)                          |                                | (0.7)                          | 0                              | (00)                           | 0 (0.0)                        |                          | (0.3)                    | 0                        | (o0)                     |                          | (0'0)                    | (0.0)                    |
| who died dueto a drug-rdated adverse eyamt           |                                | (0.0)                          |                                | (0.0)                          |                                | (0.0)                          | (0.0)                          |                          | (0.0)                    | 0                        | (o0)                     |                          | (00)                     | (0.0)                    |
| disoontinued drug due toan adverse evemt             | 59                             | (17.7)                         | 34                             | (24.8)                         |                                | (44.4) 0                       | (0.0)                          | 5                        | (1.5)                    | 5                        | 0.4)                     | 0                        | (00)                     | 0 (0.0)                  |
| disoontinued drug due toa drug-related adverse eveml | 49                             | (14.7)                         |                                | (21.9)                         | 7                              | (38.9)                         | (0.0)                          | 2                        | (0.6)                    | I                        | (0.7)                    | 0                        | (00)                     | (0.0)                    |
| disoonfimued dnug due to n serious adverse evem      | 29                             | (8.7)                          | 15                             | (10.9)                         | 5                              | (21.8)                         | (0.0)                          | 2                        | (0.0)                    | 3                        | (2.0)                    |                          | (0.0)                    | (0.0)                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| discontinued drugdue toaseriousdrug-related adverseevent    | 21                                       | (6.3)                                    | 12                                       | (8.8)                                    | 4                                        | (22.2)                                   | 0                                        | (0.0)                                    | 0                                                   | (0.0)                                               | 0                                                   | (0.0)                                               | 0                                                   | (0.0)                                               | 0                                                   | (0.0)                                               |
|-------------------------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                                             | Reference Safety Duaset for Pembroliamab | Reference Safety Duaset for Pembroliamab | Reference Safety Duaset for Pembroliamab | Reference Safety Duaset for Pembroliamab | Reference Safety Duaset for Pembroliamab | Reference Safety Duaset for Pembroliamab | Reference Safety Duaset for Pembroliamab | Reference Safety Duaset for Pembroliamab | Cumulative Rumning Safety Dataset for Pemhrolizumab | Cumulative Rumning Safety Dataset for Pemhrolizumab | Cumulative Rumning Safety Dataset for Pemhrolizumab | Cumulative Rumning Safety Dataset for Pemhrolizumab | Cumulative Rumning Safety Dataset for Pemhrolizumab | Cumulative Rumning Safety Dataset for Pemhrolizumab | Cumulative Rumning Safety Dataset for Pemhrolizumab | Cumulative Rumning Safety Dataset for Pemhrolizumab |
|                                                             | 65                                       | 65                                       | 65.74                                    | 65.74                                    | 75.84                                    | 75.84                                    | >=85                                     | >=85                                     | -65                                                 | -65                                                 | 65.74                                               | 65.74                                               | 75.84                                               | 75.84                                               | 85                                                  | 85                                                  |
|                                                             |                                          | ()                                       |                                          | ()                                       |                                          | ()                                       |                                          |                                          |                                                     | ()                                                  |                                                     | ()                                                  |                                                     | ()                                                  |                                                     | (6)                                                 |
| Partidipans in population                                   | 3,385                                    |                                          | 1,737                                    |                                          | 663                                      |                                          | 99                                       |                                          | 5,283                                               |                                                     | 2,742                                               |                                                     | 1,029                                               |                                                     | 164                                                 |                                                     |
| withone ormore dvereevents                                  | 3,268                                    | (96.5)                                   | 1,678                                    | (996)                                    | 646                                      | (97.4)                                   | 98                                       | (066)                                    | 5,096                                               | (596)                                               | 2,635                                               | (96.1)                                              | 998                                                 | (0 L6)                                              | 161                                                 | (98.2)                                              |
| with no advarseevent                                        | 117                                      | (3.5)                                    | 59                                       | (3.4)                                    | 17                                       | (2.6)                                    | 1                                        | (01)                                     | 187                                                 | (.5)                                                | 107                                                 | 0.9)                                                | 31                                                  | (3.0)                                               | 3                                                   | (81)                                                |
| with drug-relited advarse events                            | 2,366                                    | (69.9)                                   | 1,224                                    | (70.5)                                   | 467                                      | (70.4)                                   | 75                                       | (75.8)                                   | 3,622                                               | (989)                                               | 1,921                                               | (70.1)                                              | 714                                                 | (69.4)                                              | 118                                                 | (72.0)                                              |
| wilh toxicity grde3.5 dverse events                         | 1,505                                    | (44.5)                                   | 891                                      | (51.3)                                   | 373                                      | (56.3)                                   | 60                                       | (60.6)                                   | 2,413                                               | (45.7)                                              | 1,366                                               | (49.8)                                              | 571                                                 | (55.5)                                              | 94                                                  | (57.3)                                              |
| wilh toxicity grde3.5 dnig-rdated ndvene svens              | 456                                      | (13.5)                                   | 311                                      | (17.9)                                   | 128                                      | (19.3)                                   | 18                                       | (18.2)                                   | 764                                                 | (14.5)                                              | 493                                                 | (18.0)                                              | 200                                                 | (19.4)                                              | 33                                                  | (20.1)                                              |
| with serious adverse eyents                                 | 1,182                                    | (34.9)                                   | 719                                      | (41.4)                                   | 315                                      | (47.5)                                   | 50                                       | (50.5)                                   | 1,815                                               | (34.4)                                              | 1,081                                               | (β9.4)                                              | 476                                                 | (46.3)                                              | 77                                                  | (47.0)                                              |
| with serious dng-relhted adverse eyents                     | 346                                      | (10.2)                                   | 213                                      | (12.3)                                   | 85                                       | (12.8)                                   | 12                                       | (12.1)                                   | 547                                                 | (10.4)                                              | 346                                                 | (12.0)                                              | 135                                                 | (13.1)                                              | 21                                                  | (12.8)                                              |
| who died                                                    | 144                                      | (4.3)                                    | 103                                      | (5.9)                                    | 54                                       | (8.1)                                    | I                                        | (11.1)                                   | 214                                                 | (4.1)                                               | 164                                                 | (6.0)                                               | 86                                                  | (8.4)                                               | 20                                                  | (12.2)                                              |
| who died dneton dnig-rdated ndvetse ewont                   | 21                                       | (0.0)                                    | 12                                       | (0.7)                                    | 5                                        | (80)                                     | 1                                        | (1.0)                                    | 29                                                  | (0.5)                                               | 24                                                  | (6'0)                                               | I                                                   | (1.1)                                               | 2                                                   | (1.2)                                               |
| disoontimed drug due toanndvase event                       | 399                                      | (11.8)                                   | 246                                      | (14.2)                                   | IEI                                      | (19.8)                                   | 14                                       | (14.1)                                   | 605                                                 | (11.5)                                              | 385                                                 | (14.0)                                              | 196                                                 | (19.0)                                              | 29                                                  | (17.7)                                              |
| disoontinued drug due toa dug-related adverse event         | 207                                      | (6.1)                                    | 135                                      | (7.8)                                    | 62                                       | (9.4)                                    | 6                                        | (6.1)                                    | 336                                                 | (6.4)                                               | 225                                                 |                                                     | 102                                                 | (9.9)                                               | 13                                                  | (7.9)                                               |
| disoonfimed drug due toa serious aidverse event             | 287                                      | (8.5)                                    | 174                                      | (10.0)                                   | 100                                      | (15.1)                                   | I1                                       | (11.1)                                   | 425                                                 | (8.0)                                               | 26                                                  | (9.6)                                               | 145                                                 | (14.1)                                              | 22                                                  | (13.4)                                              |
| discontinued drug due toa seriousdrug-related adverse event | 123                                      | (3.6)                                    | 81                                       | (4.7)                                    | 38                                       | (5.7)                                    | 3                                        | (3.0)                                    | t61                                                 | (3.7)                                               | 130                                                 | (4.7)                                               | 62                                                  | (6.0)                                               | 6                                                   | (3.7)                                               |

Table 74 Adverse Event Summary 'for Categories of Interest' in Elderly Subjects by Age

|                                 | Age (Ycars)   | Age (Ycars)   | Age (Ycars)   | Age (Ycars)   | Age (Ycars)   | Age (Ycars)   | Age (Ycars)   | Age (Ycars)   | Age (Ycars)   | Age (Ycars)   | Age (Ycars)   | Age (Ycars)   |
|---------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
|                                 | Pembrolizumab | Pembrolizumab | Pembrolizumab | Pembrolizumab | Pembrolizumab | Pembrolizumab | Placebo       | Placebo       | Placebo       | Placebo       | Placebo       | Placebo       |
|                                 | <65           | <65           | 65-74         | 65-74         | 75-84         | 75-84         | <65           | <65           | 65-74         | 65-74         | 75-84         | 75-84         |
|                                 | n             | (%)           | n             | (%)           | n             | (%)           | n             | (%)           |               | (%)           | n             | (%)           |
| SubjectsinPopulation            | 333           |               | 137           |               | 18            |               | 324           |               | 147           |               | 25            |               |
| withoneormoreadverseevents      | 322           | (96.7)        | 131           | (95.6)        | 17            | (94.4)        | 294           | (90.7)        | 133           | (90.5)        | 25            | (100.0)       |
| whodied                         | 1             | (0.3)         | 1             | (0.7)         | 0             | (0.0)         | 1             | (0.3)         | 0             | (0.0)         | 0             | (0.0)         |
| withseriousadverseevents        | 62            | (18.6)        | 30            | (21.9)        | 8             | (44.4)        | 29            | (9.0)         | 20            | (13.6)        | 7             | (28.0)        |
| discontinuedduetoanadverseevent | 59            | (17.7)        | 34            | (24.8)        | 8             | (44.4)        | 5             | (1.5)         | 5             | (3.4)         | 0             | (0.0)         |
| CNS(confusion/extrapyramidal)   | 25            | (7.5)         | 6             | (4.4)         | 2             | (11.1)        | 18            | (5.6)         | 10            | (6.8)         | 1             | (4.0)         |
| AErelated tofalling             | 21            | (6.3)         | 8             | (5.8)         | 0             | (0.0)         | 24            | (7.4)         | 13            | (8.8)         |               | (20.0)        |
| CVevents                        | 59            | (17.7)        | 17            | (12.4)        | 5             | (27.8)        | 45            | (13.9)        | 22            | (15.0)        | 3             | (12.0)        |
| Cerebrovascularevents           | 3             | (0.9)         | 0             | (0.0)         | 0             | (0.0)         | 3             | (0.9)         | 1             | (0.7)         | 1             | (4.0)         |
| Infections                      | 154           | (46.2)        | 52            | (38.0)        | 9             | (50.0)        | 117           | (36.1)        | 55            | (37.4)        | 10            | (40.0)        |

## ECOG Performance Status

The AE profile was generally similar between participants with an ECOG PS of 0 and ECOG PS of 1 in the Indication Dataset, although there was a small number of participants with ECOG PS of 1 (n=72).

Table 75 Adverse Event Summary by ECOG Status Category (0, 1)

| discontinueddrugduetoaseriousdrug-related adverseevent   | 32 (7.7)   | (6.9)   | 0 (0.0)   | 0 (0.0)   | 106   | (3.8)   | 130   | (4.4)   |
|----------------------------------------------------------|------------|---------|-----------|-----------|-------|---------|-------|---------|

## Gender

Table 76 AE Summary by Gender (Male, Female)

<div style=\"page-break-after: always\"></div>

|                                                              | KN564DataforPembrolizumabb   | KN564DataforPembrolizumabb   | KN564DataforPembrolizumabb   | KN564DataforPembrolizumabb   | KN564DataforPlacebo   | KN564DataforPlacebo   | KN564DataforPlacebo   | KN564DataforPlacebo   | ReferenceSafetyDatasetfor Pembrolizumabd   | ReferenceSafetyDatasetfor Pembrolizumabd   | ReferenceSafetyDatasetfor Pembrolizumabd   | ReferenceSafetyDatasetfor Pembrolizumabd   |
|--------------------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
|                                                              | M                            | M                            | F                            | F                            | M                     | M                     | F                     | F                     | M                                          | M                                          |                                            |                                            |
|                                                              | n                            | (%)                          | n                            | (%)                          | n                     | (%)                   | n                     | (%)                   | u                                          | (%)                                        | n                                          | (%)                                        |
| Participantsinpopulation                                     | 340                          |                              | 148                          |                              | 357                   |                       | 139                   |                       | 3,887                                      |                                            | 1,997                                      |                                            |
| withoneormore adverseevents                                  | 322                          | (94.7)                       | 148                          | (100.0)                      | 323                   | (90.5)                | 129                   | (92.8)                | 3,756                                      | (96.6)                                     | 1,934                                      | (96.8)                                     |
| withnoadverseevent                                           | 18                           | (5.3)                        | 0                            | (0.0)                        | 34                    | (9.5)                 | 10                    | (7.2)                 | 131                                        | (3.4)                                      | 63                                         | (3.2)                                      |
| withdrug-related”adverseevents                               | 265                          | (77.9)                       | 121                          | (81.8)                       | 196                   | (54.9)                | 69                    | (49.6)                | 2,710                                      | (69.7)                                     | 1,422                                      | (71.2)                                     |
| with toxicitygrade3-5adverse events                          | 106                          | (31.2)                       | 52                           | (35.1)                       | 67                    | (18.8)                | 21                    | (15.1)                | 1,894                                      | (48.7)                                     | 935                                        | (46.8)                                     |
| with toxicitygrade3-5drug-relatedadverse events              | 67                           | (19.7)                       | 25                           | (6:91)                       | 5                     | (1.4)                 | 1                     | (0.7)                 | 630                                        | (16.2)                                     | 283                                        | (14.2)                                     |
| with seriousadverseevents                                    | 69                           | (20.3)                       | 31                           | (20.9)                       | 46                    | (12.9)                | 10                    | (7.2)                 | 1,534                                      | (39.5)                                     | 732                                        | (36.7)                                     |
| withserious drug-related adverseevents                       | 46                           | (13.5)                       | 13                           | (8.8)                        | 1                     | (0.3)                 | 0                     | (0.0)                 | 448                                        | (11.5)                                     | 208                                        | (10.4)                                     |
| whodied                                                      | 1                            | (0.3)                        | 1                            | (0.7)                        | 1                     | (0.3)                 | 0                     | (0.0)                 |                                            | (5.7)                                      | 91                                         | (4.6)                                      |
| whodiedduetoa drug-related adverseevent                      | 0                            | (0.0)                        | 0                            | (0.0)                        | 0                     | (0.0)                 | 0                     | (0.0)                 | 25                                         | (0.6)                                      | 14                                         | (0.7)                                      |
| discontinueddrugdueto anadverseevent                         | 69                           | (20.3)                       | 32                           | (21.6)                       | 6                     | (1.7)                 | 4                     | (2.9)                 | 529                                        | (13.6)                                     | 261                                        | (13.1)                                     |
| discontinued drugdue toa drug-related adverse event          | 61                           | (17.9)                       | 25                           | (16.9)                       | 1                     | (0.3)                 | 2                     | (1.4)                 | 278                                        | (7.2)                                      | 132                                        | (6.6)                                      |
| discontinueddrugduetoaseriousadverseevent                    | 33                           | (9.7)                        | 16                           | (10.8)                       | 5                     | (1.4)                 | 0                     | (0.0)                 | 386                                        | (9.9)                                      | 186                                        | (9.3)                                      |
| discontinued drug due to a serious drug-related adverseevent | 28                           | (8.2)                        | 9                            | (6.1)                        | 0                     | (0.0)                 | 0                     | (0.0)                 | 167                                        | (4.3)                                      | 78                                         | (3.9)                                      |

The AE profile was generally similar between male and female participants in the Indication Dataset.

## Geographic Region

Table 77 Adverse Event Summary by Region (EU, Ex-EU)

|                                                               | KN564 Data for Pembrolizumab   | KN564 Data for Pembrolizumab   | KN564 Data for Pembrolizumab   | KN564 Data for Pembrolizumab   | KN564 Data for Placebo   | KN564 Data for Placebo   | KN564 Data for Placebo   | KN564 Data for Placebo   | Reference Safety Dataset for Pembrolizumab   | Reference Safety Dataset for Pembrolizumab   | Reference Safety Dataset for Pembrolizumab   | Reference Safety Dataset for Pembrolizumab   |
|---------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
|                                                               | EU                             | EU                             | Ex-EU                          | Ex-EU                          | EU                       | EU                       | Ex-EU                    | Ex-EU                    | EU                                           | EU                                           | Ex-EU                                        | Ex-EU                                        |
|                                                               | n                              | (%)                            | n                              | (%)                            | n                        | (%)                      | n                        | (%)                      | n                                            | (%)                                          | n                                            | (%)                                          |
| Participants in population                                    | 184                            |                                | 304                            |                                | 187                      |                          | 309                      |                          | 2,092                                        |                                              | 3,792                                        |                                              |
| with one or more adverse events                               | 174                            | (94.6)                         | 296                            | (97.4)                         | 172                      | (92.0)                   | 280                      | (90.6)                   | 2,014                                        | (96.3)                                       | 3,676                                        | (96.9)                                       |
| with no adverse event                                         | 10                             | (5.4)                          | 8                              | (2.6)                          | 15                       | (8.0)                    | 29                       | (9.4)                    | 78                                           | (3.7)                                        | 116                                          | (3.1)                                        |
| with drug-related a adverse events                            | 147                            | (79.9)                         | 239                            | (78.6)                         | 111                      | (59.4)                   | 154                      | (49.8)                   | 1,430                                        | (68.4)                                       | 2,702                                        | (71.3)                                       |
| with toxicity grade 3-5 adverse events                        | 62                             | (33.7)                         | 96                             | (31.6)                         | 36                       | (19.3)                   | 52                       | (16.8)                   | 960                                          | (45.9)                                       | 1,869                                        | (49.3)                                       |
| with toxicity grade 3-5 drug-related adverse events           | 36                             | (19.6)                         | 56                             | (18.4)                         | 2                        | (1.1)                    | 4                        | (1.3)                    | 317                                          | (15.2)                                       | 596                                          | (15.7)                                       |
| with serious adverse events                                   | 45                             | (24.5)                         | 55                             | (18.1)                         | 25                       | (13.4)                   | 31                       | (10.0)                   | 796                                          | (38.0)                                       | 1,470                                        | (38.8)                                       |
| with serious drug-related adverse events                      | 26                             | (14.1)                         | 33                             | (10.9)                         | 0                        | (0.0)                    | 1                        | (0.3)                    | 241                                          | (11.5)                                       | 415                                          | (10.9)                                       |
| who died                                                      | 1                              | (0.5)                          | 1                              | (0.3)                          | 0                        | (0.0)                    | 1                        | (0.3)                    | 109                                          | (5.2)                                        | 203                                          | (5.4)                                        |
| who died due to a drug-related adverse event                  | 0                              | (0.0)                          | 0                              | (0.0)                          | 0                        | (0.0)                    | 0                        | (0.0)                    | 12                                           | (0.6)                                        | 27                                           | (0.7)                                        |
| discontinued drug due to an adverse event                     | 46                             | (25.0)                         | 55                             | (18.1)                         | 6                        | (3.2)                    | 4                        | (1.3)                    | 267                                          | (12.8)                                       | 523                                          | (13.8)                                       |
| discontinued drug due to a drug- related adverse event        | 39                             | (21.2)                         | 47                             | (15.5)                         | 1                        | (0.5)                    | 2                        | (0.6)                    | 151                                          | (7.2)                                        | 259                                          | (6.8)                                        |
| discontinued drug due to a serious adverse event              | 23                             | (12.5)                         | 26                             | (8.6)                          | 4                        | (2.1)                    | 1                        | (0.3)                    | 193                                          | (9.2)                                        | 379                                          | (10.0)                                       |
| discontinued drug due to a serious drug-related adverse event | 16                             | (8.7)                          | 21                             | (6.9)                          | 0                        | (0.0)                    | 0                        | (0.0)                    | 89                                           | (4.3)                                        | 156                                          | (4.1)                                        |

## Safety related to drug-drug interactions and other interactions

As pembrolizumab is an IgG antibody that is administered parenterally and cleared by catabolism, food and DDI are not anticipated to influence exposure. Drugs that affect the cytochrome P450 enzymes, and other metabolizing enzymes, are not expected to interfere with the metabolism of an IgG antibody. The IgG antibodies, in general, do not directly regulate the expression of cytochrome P450 enzymes, other

(96.9)

(3.1)

(71.3)

(49.3)

(15.7)

(38.8)

(10.9)

(5.4)

(0.7)

(13.8)

(6.8)

(10.0)

(4.1)

<div style=\"page-break-after: always\"></div>

enzymes, or transporters involved in drug elimination. Therefore, no dedicated DDI studies have been performed which is considered acceptable.

## Discontinuation due to adverse events

Table 78 Participants With AEs Resulting in Treatment Discontinuation Excerpt: (AE in ≥ 2 participants in the Indication Dataset) By Decreasing Frequency of Preferred Term (APaT Population)

|                                                                                   | KN564 Data for Pembrolizumaba   | KN564 Data for Pembrolizumaba   | KN564 Data for Placebob   | KN564 Data for Placebob   | Reference Safety Dataset for Pembrolizumabc   | Reference Safety Dataset for Pembrolizumabc   | Cumulative Running Safety Dataset for Pembrolizumabd   | Cumulative Running Safety Dataset for Pembrolizumabd   |
|-----------------------------------------------------------------------------------|---------------------------------|---------------------------------|---------------------------|---------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                                                   | n                               | (%)                             | n                         | (%)                       | n                                             | (%)                                           | n                                                      | (%)                                                    |
| Participants in population with one or more adverse events with no adverse events | 488 101 387                     | (20.7) (79.3)                   | 496 10 486                | (2.0) (98.0)              | 5,884 790 5,094                               | (13.4) (86.6)                                 | 9,218 1,215 8,003                                      | (13.2) (86.8)                                          |
| Alanine aminotransferase increased                                                | 8                               | (1.6)                           | 0                         | (0.0)                     | 19                                            | (0.3)                                         | 35                                                     | (0.4)                                                  |
| Adrenal insufficiency                                                             | 5                               | (1.0)                           | 0                         | (0.0)                     | 4                                             | (0.1)                                         | 12                                                     | (0.1)                                                  |
| Colitis                                                                           | 5                               | (1.0)                           | 0                         | (0.0)                     | 27                                            | (0.5)                                         | 44                                                     | (0.5)                                                  |
| Acute kidney injury                                                               | 4                               | (0.8)                           | 0                         | (0.0)                     | 6                                             | (0.1)                                         | 15                                                     | (0.2)                                                  |
| Aspartate aminotransferase increased                                              | 4                               | (0.8)                           | 0                         | (0.0)                     | 19                                            | (0.3)                                         | 29                                                     | (0.3)                                                  |
| Blood creatinine increased                                                        | 4                               | (0.8)                           | 1                         | (0.2)                     | 1                                             | (0.0)                                         | 10                                                     | (0.1)                                                  |
| Arthritis                                                                         | 3                               | (0.6)                           | 0                         | (0.0)                     | 2                                             | (0.0)                                         | 6                                                      | (0.1)                                                  |
| Diarrhoea                                                                         | 3                               | (0.6)                           | 0                         | (0.0)                     | 13                                            | (0.2)                                         | 22                                                     | (0.2)                                                  |
| Pneumonia                                                                         | 3                               | (0.6)                           | 0                         | (0.0)                     | 31                                            | (0.5)                                         | 46                                                     | (0.5)                                                  |
| Pneumonitis                                                                       | 3                               | (0.6)                           | 0                         | (0.0)                     | 96                                            | (1.6)                                         | 130                                                    | (1.4)                                                  |
| Rash                                                                              | 3                               | (0.6)                           | 0                         | (0.0)                     | 6                                             | (0.1)                                         | 9                                                      | (0.1)                                                  |
| Sarcoidosis                                                                       | 3                               | (0.6)                           | 0                         | (0.0)                     | 3                                             | (0.1)                                         | 6                                                      | (0.1)                                                  |
| Type I diabetes mellitus                                                          | 3                               | (0.6)                           | 0                         | (0.0)                     | 4                                             | (0.1)                                         | 9                                                      | (0.1)                                                  |
| Arthralgia                                                                        | 2                               | (0.4)                           | 1                         | (0.2)                     | 10                                            | (0.2)                                         | 12                                                     | (0.1)                                                  |
| Diabetes mellitus Diabetic ketoacidosis                                           | 2 2                             | (0.4) (0.4)                     | 0 0                       | (0.0) (0.0)               | 1 2                                           | (0.0) (0.0)                                   | 3 4                                                    | (0.0) (0.0)                                            |
| Hypothyroidism                                                                    |                                 | (0.4)                           | 0                         |                           | 2                                             |                                               |                                                        | (0.1)                                                  |
|                                                                                   | 2                               |                                 |                           | (0.0)                     |                                               | (0.0)                                         | 5                                                      |                                                        |
| Immune-mediated pneumonitis                                                       | 2                               | (0.4)                           | 0                         | (0.0)                     | 0                                             | (0.0)                                         | 2                                                      | (0.0)                                                  |
| Myocardial infarction                                                             | 2                               | (0.4)                           | 0                         | (0.0)                     | 6                                             | (0.1)                                         | 10                                                     | (0.1)                                                  |
| Nephritis                                                                         | 2                               | (0.4)                           | 0                         | (0.0)                     | 1                                             | (0.0)                                         | 4                                                      | (0.0)                                                  |
| Pulmonary embolism                                                                | 2                               | (0.4)                           | 0                         | (0.0)                     | 12                                            | (0.2)                                         | 15                                                     | (0.2)                                                  |
| Sjogren's syndrome                                                                | 2                               | (0.4)                           | 0                         |                           | 1                                             | (0.0)                                         | 3                                                      | (0.0)                                                  |
| Thrombocytopenia                                                                  | 2                               | (0.4)                           | 0                         | (0.0) (0.0)               | 3                                             | (0.1)                                         | 7                                                      | (0.1)                                                  |

<div style=\"page-break-after: always\"></div>

Table 79 Participants With AEs Resulting in Treatment Discontinuation By SOC and PTs

|                                                                                   | KN564 Data for Pembrolizumaba   | KN564 Data for Pembrolizumaba   | KN564 Data for Placebob   | KN564 Data for Placebob   | Reference Safety Dataset for Pembrolizumabc   | Reference Safety Dataset for Pembrolizumabc   | Cumulative Running Safety Dataset for Pembrolizumabd   | Cumulative Running Safety Dataset for Pembrolizumabd   |
|-----------------------------------------------------------------------------------|---------------------------------|---------------------------------|---------------------------|---------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                                                   | n                               | (%)                             | n                         | (%)                       | n                                             | (%)                                           | n                                                      | (%)                                                    |
| Participants in population with one or more adverse events with no adverse events | 488 101 387                     | (20.7) (79.3)                   | 496 10 486                | (2.0) (98.0)              | 5,884 790 5,094                               | (13.4) (86.6)                                 | 9,218 1,215 8,003                                      | (13.2) (86.8)                                          |
| Blood and lymphatic system disorders                                              | 2                               | (0.4)                           | 0                         | (0.0)                     | 12                                            | (0.2)                                         | 18                                                     | (0.2)                                                  |
| Cardiac disorders                                                                 | 5                               | (1.0)                           | 0                         | (0.0)                     | 37                                            | (0.6)                                         | 56                                                     | (0.6)                                                  |
| Endocrine disorders                                                               | 11                              | (2.3)                           | 0                         | (0.0)                     | 17                                            | (0.3)                                         | 34                                                     | (0.4)                                                  |
| Eye disorders                                                                     | 2                               | (0.4)                           | 1                         | (0.2)                     | 3                                             | (0.1)                                         | 5                                                      | (0.1)                                                  |
| Gastrointestinaldisorders                                                         | 12                              | (2.5)                           | 0                         | (0.0)                     | 83                                            | (1.4)                                         | 149                                                    | (1.6)                                                  |
| Generaldisordersandadministration site conditions                                 | 3                               | (0.6)                           | 1                         | (0.2)                     | 86                                            | (1.5)                                         | 109                                                    | (1.2)                                                  |
| Hepatobiliary disorders                                                           | 4                               | (0.8)                           | 2                         | (0.4)                     | 30                                            | (0.5)                                         | 71                                                     | (0.8)                                                  |
| Immune system disorders                                                           | 4                               | (0.8)                           | 0                         | (0.0)                     | 9                                             | (0.2)                                         | 13                                                     | (0.1)                                                  |
| Infections andinfestations                                                        | 4                               | (0.8)                           | 0                         | (0.0)                     | 81                                            | (1.4)                                         | 113                                                    | (1.2)                                                  |
| Investigations                                                                    | 16                              | (3.3)                           | 1                         | (0.2)                     | 45                                            | (0.8)                                         | 89                                                     | (1.0)                                                  |
| Metabolismandnutritiondisorders                                                   | 7                               | (1.4)                           | 0                         | (0.0)                     | 25                                            | (0.4)                                         | 42                                                     | (0.5)                                                  |
| Musculoskeletalandconnectivetissue disorders                                      | 8                               | (1.6)                           | 1                         | (0.2)                     | 38                                            | (0.6)                                         | 54                                                     | (0.6)                                                  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)               | 3                               | (0.6)                           | 2                         | (0.4)                     | 45                                            | (0.8)                                         | 60                                                     | (0.7)                                                  |
| Nervoussystemdisorders                                                            | 6                               | (1.2)                           | 1                         | (0.2)                     | 50                                            | (0.8)                                         | 74                                                     | (0.8)                                                  |
| Renal and urinary disorders                                                       | 9                               | (1.8)                           | 0                         | (0.0)                     | 24                                            | (0.4)                                         | 46                                                     | (0.5)                                                  |
| Respiratory,thoracicandmediastinal disorders                                      | 8                               | (1.6)                           | 0                         | (0.0)                     | 188                                           | (3.2)                                         | 255                                                    | (2.8)                                                  |
| Skin and subcutaneous tissue disorders                                            | 5                               | (1.0)                           | 0                         | (0.0)                     | 28                                            | (0.5)                                         | 38                                                     | (0.4)                                                  |
| Vasculardisorders                                                                 | 1                               | (0.2)                           | 0                         | (0.0)                     | 11                                            | (0.2)                                         | 13                                                     | (0.1)                                                  |

Table 80 Participants With Adverse Events Resulting in Treatment Discontinuation by Maximum Toxicity Grade

|                              | KN564Datafor Pembrolizumaba   | KN564Datafor Pembrolizumaba   | KN564Datafor Placebob   | KN564Datafor Placebob   | Reference Safety Dataset for Pembrolizumabe   | Reference Safety Dataset for Pembrolizumabe   | Cumulative RunningSafety Dataset for Pembrolizumabd   | Cumulative RunningSafety Dataset for Pembrolizumabd   |
|------------------------------|-------------------------------|-------------------------------|-------------------------|-------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                              |                               | (%)                           | n                       | (%)                     | n                                             | (%)                                           | n                                                     | (%)                                                   |
| Participantsinpopulation     | 488                           |                               | 496                     |                         | 5,884                                         |                                               | 9,218                                                 |                                                       |
| with oneormore adverseevents | 101                           | (20.7)                        | 10                      | (2.0)                   | 790                                           | (13.4)                                        | 1,215                                                 | (13.2)                                                |
| Grade 1                      | 5                             | (1.0)                         | 0                       | (0.0)                   | 33                                            | (0.6)                                         | 43                                                    | (0.5)                                                 |
| Grade 2                      | 28                            | (5.7)                         | 3                       | (0.6)                   | 152                                           | (2.6)                                         | 239                                                   | (2.6)                                                 |
| Grade3                       | 55                            | (11.3)                        | 6                       | (1.2)                   | 309                                           | (5.3)                                         | 484                                                   | (5.3)                                                 |
| Grade 4                      | 11                            | (2.3)                         | 1                       | (0.2)                   | 83                                            | (1.4)                                         | 127                                                   | (1.4)                                                 |
| Grade 5                      | 2                             | (0.4)                         | 0                       | (0.0)                   | 213                                           | (3.6)                                         | 322                                                   | (3.5)                                                 |
| withnoadverseevents          | 387                           | (79.3)                        | 486                     | (98.0)                  | 5,094                                         | (86.6)                                        | 8.003                                                 | (86.8)                                                |

<div style=\"page-break-after: always\"></div>

## Post marketing experience

The safety profile of pembrolizumab was summarized in the Periodic Safety Update Report covering the period 04-SEP-2019 through 03-SEP-2020. There are no records of any pembrolizumab registration being revoked or withdrawn for safety reasons in any country.

## 2.5.1. Discussion on clinical safety

The safety data set in support of the new indication of pembrolizumab monotherapy in the adjuvant treatment of RCC post nephrectomy derived from 488 participants in Study KEYNOTE-564 (KN564) received pembrolizumab (Indication Dataset) and n=496 received placebo. In addition, safety data from the Pembrolizumab Monotherapy Reference Safety Dataset (RSD, n=5884) were included for comparison.

The median duration of exposure to pembrolizumab was &gt;2-fold longer for participants in the Indication Dataset compared with the RSD (11.1 months vs 4.9 months, respectively), which is expected for pembrolizumab monotherapy when used as an adjuvant treatment. Although the median duration on therapy was the same for both treatment arms of study KN564, drug exposure by duration was lower in the pembrolizumab arm reflecting the higher discontinuation rates of pembrolizumab.

The adverse event summary showed higher incidences across all AE categories for the Indication Dataset versus the placebo group, as expected for the comparison of an active treatment versus placebo. Regarding the comparison of the Indication Dataset versus the RSD, participants in the KN564 pembrolizumab group had fewer overall SAEs and Grade 3 to 5 AEs compared with the RSD (20.5% vs 38.5% and 32.4% vs 48.1%), which is likely attributed to participants in the KN564 Safety Dataset being generally younger, without evidence of metastatic disease, but with better ECOG performance status at study entry. Incidences of drug-related AEs (79.1% vs 70.2%), related Grade 3 to 5 AEs (18.9% vs. 15.5%) and related SAEs (12.1% vs 11.1%) were numerically higher or similar in the Indication Dataset compared to the RSD.

Incidences of treatment discontinuations due to AEs were higher in the Indication Dataset compared with the RSD (AEs: 20.7% vs 13.4%; drug-related AEs: 17.6% vs 7.0%) and remained numerically higher also after adjustment for duration of exposure (all-cause AEs: 2.43 vs 1.80; drug-related AEs: 2.08 vs 0.94 events/100 person-months in the Indication Dataset vs RSD).

The same pattern was observed when pooled safety data from adjuvant pembrolizumab studies were compared with study data from the advanced/metastatic setting.

The most common ly reported AEs (incidence ≥20%) in the pembrolizumab arm of study KN564 were fatigue, diarrhea, pruritus, arthralgia, hypothyroidism, and rash. Most common adverse events of pembrolizumab in study KN564 were generally consistent with the RSD apart from notably higher incidences of hypothyroidism (21.1% vs 11.1%) and hyperthyroidism (11.9% vs 4.2%). The higher rate of blood creatinine observed in the Indication Dataset compared to the RSD (10.2% vs 4.4%) is likely partly associated with the prior nephrectomy (rate of blood creatinine increased 8.5% in the placebo arm). In addition, diarrhoea, pruritus, arthralgia and rash were reported with numerically slightly higher frequencies in the Indication Dataset compared with the RSD (Table 43).

Most frequently reported Grade 3 to 5 AEs (incidence ≥1.6%) were hyper tension, alanine aminotransferase increased, aspartate aminotransferase increased and diarrhoea. Higher incidences for related Grade 3 to 5 AEs in the Indication Dataset compared to the RSD were reported for ALT and AST

<div style=\"page-break-after: always\"></div>

increased (1.8% vs 0.6% and 1.2% vs 0.6%), diarrhoea (1.6% vs. 0.9%), adrenal insufficiency (1.2% vs. 0.2%) and diabetic ketoacidosis (1.0% vs. 0.1%).

The most frequently reported SAEs (incidence ≥1%) in the Indication Dataset were acute kidney injury, adrenal insufficiency, pneumonia, colitis, and diabetic ketoacidosis. Though the incidences of these SAEs were low (≤1.2%), higher rates for adrenal insufficiency and diabetic ketoacidosis (both drug -related) were observed in the Indication Dataset compared to the RSD (1.2% vs 0.3% and 1.0% vs 0.2%). Some clinically relevant SAEs with frequency &lt;1% are notable: meningitis aseptic (0.4% [2 events] in the Indication Dataset vs. 0% [no event] in the RSD; both AEs drug-related); Stevens-Johnson syndrome (0.2% vs. 0% [2 events overall in the RSD]); vasculitis (0.2% vs. 0% in the RSD; AE drug-related); type 1 diabetes (0.8% vs. 0.2%), and myocardial infarction (0.6% vs 0.3%; 2 events [0.4%] drug-related).

Two deaths due to AEs (0.4%) were observed in the Indication Dataset (multiple organ dysfunction after accident and pneumonia) compared to 0.2% in the placebo group and 5.3% in the RSD.

The incidence of AEOSI was higher in the Indication Dataset compared with the RSD (any 35.5% vs 25.1%; drug-related 31.8% vs 21.8%); higher incidences were also reported for any and drug-related grade 3-5 AEOSI, serious AEOSI and AEOSI leading to discontinuations (see Table 52). After adjustment for different exposure higher rates of all-cause and drug-related AEs and AEs resulting in drug discontinuations remained, whereas grade 3-5 and serious AEs were comparable between both datasets.

The higher incidence of any AEOSI in the Indication Dataset compared with the RSD was primarily driven by the increased incidences of hypothyroidism (21.1% vs 11.1%) and hyperthyroidism (11.9% vs 4.2%). However, numerically higher frequencies in the Indication Dataset versus the RSD were also observed for adrenal insufficiency (2% vs 0.8%), type 1 diabetes mellitus (1.8% vs. 0.3%) and sarcoidosis (0.8% vs 0.2%), which also remained higher after adjustment by exposure.

Regarding severity of AEOSI, Grade 2 events were observed in 21.1% vs 12.3% in the Indication Dataset vs the RSD while Grade ≥3 of were observed in 9.0% in the Indication Dataset versus 6.5% in RSD. Of note were e.g. higher rates of Grade 3-4 type 1 diabetes mellitus (1.8% vs. 0.3%) or adrenal insufficiency (1.2% vs. 0.4), although slightly higher rates were observed across most categories.

Summary of outcome of AEOSI at a cutoff at June 2021 (with 6 months of longer follow-up) showed that in both, the Indication Dataset and the RSD, approximately half of the patients had AEOSI reported as not resolved or with sequelae.  The proportion of resolving AEOSI was higher in study KN564 (17.8% vs 6.6% in the RSD); according to the MAH the resolving AEOSI in KN564 were primarily low grade hypothyroidism AEs which are likely to require ongoing long-term hormone replacement therapy. Therefore overall, the proportion of resolved AEOSI is slightly lower in study KN564 compared to the RSD (33.9% vs. 41.6%).

To better characterize the safety profile in the adjuvant setting and identify possible differences compared to the established toxicity profile of pembrolizumab in the metastatic setting pooled safety analyses for the adjuvant studies were submitted.

Side-by-side presentation showed that the safety profile of pembrolizumab in KEYNOTE-564 was overall consistent with that of the pooled pembrolizumab adjuvant monotherapy dataset and the observed differences compared to the RSD were mainly confirmed.

The incidence of AEOSI was higher in the Adjuvant Dataset compared with the Advanced/Metastatic Dataset (all 36.1% vs 24.2%, drug-related AEOSI 33.4% vs 20.8%, respectively). Although these differences were again primarily driven by the increased incidences of low-grade hypothyroidism and hyperthyroidism, also Grade 3-5 and serious AEOSI were reported with numerically slightly higher incidences in the adjuvant compared to the metastatic setting (exposure adjusted events/100 person

<div style=\"page-break-after: always\"></div>

months: drug-related Grade 3-5 AEs 1.09 vs. 0.79; drug-related SAEs 0.91 vs 0.79 in adjuvant vs metastatic studies, respectively); besides colitis and hepatitis, numerically higher rates were also observed for endocrine AEOSI of adrenal insufficiency, hypophysitis, thyroiditis and type 1 diabetes mellitus. Discontinuations due to AEOSI were 7.9% vs 3.7%, respectively. The higher incidences of AEOSI in the adjuvant vs the metastatic setting is reflected in the SmPC

Incidences of treatment discontinuations due to AEs were higher in the Indication Dataset compared with the RSD. The most frequent (incidence ≥1%) AEs resulting in treatment discontinuation (any and drug-related) in the Indication Dataset were ALT increased, adrenal insufficiency, and colitis; all occurred at higher frequencie s than in the RSD. AEs with incidences ≥0.6% with higher incidences in the Indication Dataset compared to the RSD were aspartate aminotransferase increased, acute kidney injury, blood creatinine increased, arthritis, diarrhoea, rash, sarcoidosis and type 1 diabetes mellitus. 5 participants (1%) discontinued due to cardiac disorders which were all considered drug-related (2 participants due to myocardial infarction and 1 each for atrial fibrillation, cardiac failure and pleuropericarditis).

The severity and time to onset of AE resulting in treatment discontinuation in the Indication Dataset did not show relevant differences compared to the dataset in the metastatic setting. The higher frequency of drug discontinuation due to AEs reported in KEYNOTE-564 as compared with the RSD is likely attributed to the lower rate of treatment discontinuation due to disease progression in KEYNOTE-564 (10.5% in KEYNOTE-564 vs &gt;=34% in the RSD) that resulted in a longer duration of exposure, which contributes to a higher likelihood for treatment discontinuation due to AEs.

## Safety in special populations

The AE profiles showed a general trend towards higher rates of toxicities with increasing age . Comparing the age groups below and above 65 years, the largest difference was notable for discontinuations due to AEs in the Indication Dataset (17.7% vs 27.1%). This was even more emphasized in the age group of 7584 years with discontinuation rates of 44.4% (for comparison discontinuation rates of 19.8% for the same age group in the RSD).

In addition, large increases of grade 3-5 AEs and SAEs were notable for patients with 75-84 years compared to younger age groups in the Indication Dataset (see Table 5.4.26). These data suggest a worse tolerability of pembrolizumab in the adjuvant setting for elderly patients beyond 75 years (even though conclusions are limited by the small sample size of the age group 75-84 years, n=43).

For patients with ECOG PS 1, higher incidences of grade 3-4 and SAEs were generally observed in study KN564 and the RSD. Of note, high rates of discontinuation due to AEs were reported for patients with ECOG PS of 1 in the Indication Dataset (27.8% compared to 19.5% for patients with good PS in the Indication Dataset and 15.4% for patients with PS 1 in the RSD).

## 2.5.2. Conclusions on clinical safety

The safety data of pembrolizumab in Study KEYNOTE-564 were generally consistent with the established safety profile of pembrolizumab; however, higher rates of discontinuations due to AEs and higher incidences of AEOSI were observed in the Indication Dataset compared with the RSD. The differences were driven by increased low-grade incidences of hypothyroidism and hyperthyroidism but included also

<div style=\"page-break-after: always\"></div>

higher rates of grade 3-4 and serious AEs such as type 1 diabetes mellitus. The higher rates of AEOSI were confirmed in the pooled safety data for the pembrolizumab adjuvant studies in comparison to the dataset in the advanced/metastatic setting. For half of the participants AEOSI were not resolved or resolved with sequelae. The proportion of resolving AEOSI which likely requires ongoing long-term hormone replacement therapy was higher in the adjuvant than the metastatic studies. Since long-term toxicities are of special clinical relevance in the adjuvant setting, these differences in the rate of AEOSI are reflected in the SmPC.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted/was requested to submit an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 34 is acceptable.

The CHMP endorsed the Risk Management Plan version 34 with the following content:

## Safety concerns

Table SVIII.1:  Summary of Safety Concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                        |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-related adverse reactions (including immune related pneumonitis, colitis, hepatitis, nephritis, and endocrinopathies)                                                                                                                                                                                      |
| Important potential risks    | For hematologic malignancies: increased risk of severe complications of allogeneic stem cell transplantation (SCT) in patients who have previously received pembrolizumab Graft versus host disease (GVHD) after pembrolizumab administration in patients with a history of allogeneic stem cell transplant (SCT) |
| Missing information          | None                                                                                                                                                                                                                                                                                                              |

## Pharmacovigilance plan

There are no ongoing or planned additional pharmacovigilance studies that are required for pembrolizumab.

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

Table V.3.1: Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                                                               | Risk minimisation Measures                                                                                                                                                                                                                                                                                                                             | Pharmacovigilance Activities                                                                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks: Immune-Related Adverse Reactions                                                                 | Important Identified Risks: Immune-Related Adverse Reactions                                                                                                                                                                                                                                                                                           | Important Identified Risks: Immune-Related Adverse Reactions                                                                                                                                                          |
| Immune-related adverse reactions (including immune- related pneumonitis, colitis, hepatitis, nephritis and endocrinopathies) | Routine risk minimisation measures: • The risk of the immune- related adverse reactions (including immune-related pneumonitis colitis, hepatitis, nephritis, and endocrinopathies) associated with the use of pembrolizumab is described in the SmPC, Section 4.2, 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. | Routine pharmacovigilance activities Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted questionnaire for spontaneous postmarketing reports of all adverse events |
|                                                                                                                              | Additional risk minimisation measures: Patient educational materials                                                                                                                                                                                                                                                                                   | Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumor types                                                                     |

<div style=\"page-break-after: always\"></div>

Table V.3.1: Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                                                                                | Risk minimisation Measures                                                                                                                                                                                                                                                                                                                                       | Pharmacovigilance Activities                                                                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risks                                                                                                                     | Important Potential Risks                                                                                                                                                                                                                                                                                                                                        | Important Potential Risks                                                                                                                                                              |
| For hematologic malignancies: increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab | Routine risk minimisation measures: • For Hematologic malignancies: the increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab is described in the SmPC, Section 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted | Routine pharmacovigilance activities Additional pharmacovigilance including: • Safety monitoring in the ongoing HL trials (KN087, KN204).                                              |
| GVHD after pembrolizumab administration in patients with a history of allogeneic SCT                                                          | Routine risk minimisation measures: • GVHD after pembrolizumab administration in patients with a history of allogeneic SCT is described in the SmPC, Section 4.4 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted                                                                   | Routine pharmacovigilance activities Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumor types |

## 2.7. Update of the Product information

As a result of this variation, sections 4.1, 4.2 and 5.1 of the SmPC are being updated. The Package Leaflet (PL) is updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons: The proposed changes in the context of this extension of indication do not involve a relevant impact on the PIL.

The design, layout and format of the package leaflet will not be affected.

<div style=\"page-break-after: always\"></div>

## 2.7.2. Additional monitoring

Pursuant to Article 23(3) of Regulation No (EU) 726/2004, Keytruda (pembrolizumab) has been removed from the additional monitoring list with the renewal procedure five years after the Union reference date.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

The claimed indication is for pembrolizumab (Keytruda) as monotherapy for the adjuvant treatment of adults  with  renal  cell  carcinoma  (RCC)  at  intermediate-high  or  high  risk  of  recurrence  following nephrectomy, or following nephrectomy and resection of metastatic lesions.

During the procedure, the indication was updated as follows:

Keytruda as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at intermediate high or high increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions (for selection criteria, please see section 5.1).

## 3.1.1. Disease or condition

Renal cell carcinoma (RCC) represents the sixth most common cancer in men and the eighth most common cancer in women, accounting for 3%-4% of all adult malignancies in the US (Siegel et al. CA A Cancer J Clin. 2019). In 2020, an estimated 138,611 new cases of kidney cancer were expected to be diagnosed in Europe with approximately 54,054 people expected to die from the disease (GLOBOCAN, 2020).

Well-known risk factors for RCC are cigarette smoking, obesity and hypertension (Chow et al. 2010).

Renal cell carcinoma generally resists both traditional chemotherapy and radiation therapy. Surgical resection can be curative for patients presenting with localized disease. However, one third of patients present with regional or distant metastases and the 5-year survival rate for metastatic disease is approximately 12%. Of patients with localized RCC treated with nephrectomy with curative intent, approximately one quarter relapse at distant sites. The prognosis in these cases is poor (Choueiri and Motzer 2017). Advanced RCC entails both locally advanced disease that is not amenable to local therapy, i.e. curative surgery or radiation therapy, as well as metastatic disease. Advanced RCC thus requires systemic treatment. There are currently no approved adjuvant treatments for RCC and observation remains the standard of care after nephrectomy.

## 3.1.2. Available therapies and unmet medical need

The treatment of choice for localized RCC (Stage I-III) is surgical resection, which is the only curative therapy. After nephrectomy, observation remains the standard of care, and no treatment is currently approved in the adjuvant setting in the EU.

<div style=\"page-break-after: always\"></div>

## 3.1.3. Main clinical studies

The main evidence for efficacy and safety to support the present extension of indication is the Phase III study KEYNOTE-564, an international, multicenter, randomized, double-blind trial of adjuvant pembrolizumab vs. placebo. The ITT population includes 994 patients (496 in pembrolizumab arm and 498 in the placebo arm).

## 3.2. Favourable effects

The primary efficacy outcome measure was investigator-assessed disease-free-survival (DFS) in the ITT population. At the pre-specified interim analysis with a median follow-up time of 23.9 months, the study showed a statistically significant improvement in DFS (HR  0.68; 95% CI 0.53, 0.87; p-Value = 0.0010) for patients randomised to the pembrolizumab arm compared with placebo.  Median DFS was not reached in both arms. The probability of being event free at year 1 and year 2 was 85.7% and 77.3% for pembrolizumab vs. 76.2% and 68.1% for placebo. Data were based on 260 events (78% of final analyses).  With an additional 6 months of follow up (median duration of follow-up 29.7 months based on a data cutoff date of 14-JUN-2021) the HR for DFS was 0.63 (95% CI: 0.50, 0.80) in the ITT population.

A clear DFS benefit was observed in patients with high risk of recurrence (MO high) (HR 0.60; 95% CI 0.33, 1.11) and M1 NED (HR 0.29; 95% CI 0.12, 0.69).

Regarding OS, in the pre-specified interim analysis the HR was 0.54 (95% CI: 0.30, 0.96) (p=0.016) and the median OS was not reached in either group. With an additional 6 months of follow up (cut-off date 14-JUN-2021) the HR for OS was 0.52 (95% CI: 0.31, 0.86) in the ITT population.

For Disease Recurrence-specific Survival the cumulative incidences of the event of interest (local and distant recurrence) were lower over time in the pembrolizumab group compared with the placebo group.

Thirty participants in the pembrolizumab group and 56 participants in placebo group experienced a PFS2 event (HR: 0.52; 95% CI: 0.34, 0.81; nominal p-value 0.0018 at IA1), indicating a reduced risk of disease progression or death on next-line drug therapy in the pembrolizumab group compared with the placebo group.

## 3.3. Uncertainties and limitations about favourable effects

At the pre-defined data cut-off date 14 DEC 2020 the OS was events were largely immature with approximately 26% of the total events. With the updated analyses the OS events passed from 51 to 66 which is still considered immature but showed a trend in favour of pembrolizumab. Further OS data are expected to be submitted as soon as available (REC).

## 3.4. Unfavourable effects

The incidence of AEOSI was higher in the Indication Dataset compared with the RSD with any AEOSI been 35.5% vs 25.1% and the drug-related AEOSI been 31.8% vs 21.8%, including higher grade 3-5 AEOSI, serious AEOSI and AEOSI leading to discontinuation. For half of the participants the AEOSI were not resolved or resolved with sequelae at the time of data cutoff.

The higher rates of AEOSI were confirmed in the pooled safety data for the pembrolizumab adjuvant studies in comparison to the dataset in the advanced/metastatic setting (all 36.1% vs 24.2%, drugrelated AEOSI 33.4% vs 20.8%, respectively).

<div style=\"page-break-after: always\"></div>

Theincidencesof treatment discontinuations due toAEswerehigherin theIndicationDatasetcompared with the RSD (AEs: 20.7% vs 13.4%; drug-related AEs: 17.6% vs 7.0%) and remained numerically higheralsoafteradjustmentfordurationofexposure（all-causeAEs:2.43vs1.80;drug-relatedAEs: 2.08 vs 0.94 events/100 person-months in the Indication Dataset vs RSD).

## 3.5.Uncertaintiesandlimitationsaboutunfavourableeffects

Therewerenouncertaintiesthatarekeytothedescriptionoftheharmsoftheproduct.

## 3.6.Effects Table

Table81EffectsTableforKeytrudainKN564fortheadjuvanttreatmentofRcc

| Effect                                    | Short description                         | Unit                                      | Pembro                                    | Placebo                                   | Uncertainties/ Strengthofevidence                                                                                                                            |
|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| FavourableEffectsDatacut-off14DEC2020)    | FavourableEffectsDatacut-off14DEC2020)    | FavourableEffectsDatacut-off14DEC2020)    | FavourableEffectsDatacut-off14DEC2020)    | FavourableEffectsDatacut-off14DEC2020)    | FavourableEffectsDatacut-off14DEC2020)                                                                                                                       |
| DFS by investigator                       | Median (95% CI)                           | years                                     | NR                                        | NR                                        | noindependentradiologic assessment Effect in subgroups difficult to interpret in view of the large heterogeneitywithregardto prognosis andriskofrelapse.     |
|                                           | HR (95% CI)                               |                                           | 0.68 (0.53, 0.87) P=0.0010                | 0.68 (0.53, 0.87) P=0.0010                | noindependentradiologic assessment Effect in subgroups difficult to interpret in view of the large heterogeneitywithregardto prognosis andriskofrelapse.     |
| OS                                        | Median (95% CI)                           | years                                     | NR                                        | NR                                        | Secondary endpoint; immature data                                                                                                                            |
|                                           | HR (95% CI)                               |                                           | 0.54 (0.30, 0.96) P=0.0164037             | 0.54 (0.30, 0.96) P=0.0164037             | Secondary endpoint; immature data                                                                                                                            |
| FavourableEffectsDatacut-off14JUNE2021)   | FavourableEffectsDatacut-off14JUNE2021)   | FavourableEffectsDatacut-off14JUNE2021)   | FavourableEffectsDatacut-off14JUNE2021)   | FavourableEffectsDatacut-off14JUNE2021)   | FavourableEffectsDatacut-off14JUNE2021)                                                                                                                      |
| DFS by investigator                       | Median (95% CI)                           | years                                     | NR                                        | NR                                        | no independent radiologic assessment Effectinsubgroupsdifficultto interpret in view of the large heterogeneity with regard to prognosis and risk of relapse. |
|                                           | HR (95% CI)                               |                                           | 0.63 (0.5, 0.8) P<0.0001                  | 0.63 (0.5, 0.8) P<0.0001                  | no independent radiologic assessment Effectinsubgroupsdifficultto interpret in view of the large heterogeneity with regard to prognosis and risk of relapse. |
| UnfavourableEffects(Datacut-off14DEC2020) | UnfavourableEffects(Datacut-off14DEC2020) | UnfavourableEffects(Datacut-off14DEC2020) | UnfavourableEffects(Datacut-off14DEC2020) | UnfavourableEffects(Datacut-off14DEC2020) | UnfavourableEffects(Datacut-off14DEC2020)                                                                                                                    |
|                                           |                                           |                                           | Indication data set                       | RSD*                                      |                                                                                                                                                              |
| Safety                                    | Drug-related AEs                          | %                                         | 79.1                                      | 70.2                                      | Higher rates of AEOSI and discontinuations due toAEsfor IndicationDatasetvsRSD* Data suggest worse tolerability for elderly beyond 75 years.                 |
|                                           | Drug-related G 3-5 AEs                    | %                                         | 18.9                                      | 15.5                                      | Higher rates of AEOSI and discontinuations due toAEsfor IndicationDatasetvsRSD* Data suggest worse tolerability for elderly beyond 75 years.                 |
|                                           | Drug-related SAEs                         | %                                         | 12.1                                      | 11.1                                      | Higher rates of AEOSI and discontinuations due toAEsfor IndicationDatasetvsRSD* Data suggest worse tolerability for elderly beyond 75 years.                 |
|                                           | Discontinuatio n due to drug- related AEs | %                                         | 17.6                                      | 7.0                                       | Higher rates of AEOSI and discontinuations due toAEsfor IndicationDatasetvsRSD* Data suggest worse tolerability for elderly beyond 75 years.                 |
|                                           | All-cause AEOSI                           | %                                         | 35.5                                      | 25.1                                      | Higher rates of AEOSI and discontinuations due toAEsfor IndicationDatasetvsRSD* Data suggest worse tolerability for elderly beyond 75 years.                 |
|                                           | Drug-related AEOSI                        | %                                         | 31.8                                      | 21.8                                      | Higher rates of AEOSI and discontinuations due toAEsfor IndicationDatasetvsRSD* Data suggest worse tolerability for elderly beyond 75 years.                 |

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Pembrolizumab showed a statistically significant advantage over placebo in DFS according to investigator assessment in the ITT population. Secondary and explorative analyses for OS, DRSS1 and PFS2 are overall supportive; but data are still immature with a median follow-up duration of 29.7 months (updated analysis). The MAH is recommended to provide updated OS data from study KEYNOTE-564.

Although the safety profile of pembrolizumab is well established in the metastatic setting, higher incidences of AEOSI (including grade 3-4 AEs, SAEs) and higher rates of discontinuations due to AEs were observed in the adjuvant treatment compared to the established safety dataset. Long-term toxicities are of special clinical relevance in the adjuvant setting and are reflected in the SmPC.

## 3.7.2. Balance of benefits and risks

Updated results provided support for a beneficial treatment effect of pembrolizumab over placebo in the adjuvant setting of adults with renal cell carcinoma at increased risk of recurrence.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable

## 3.8. Conclusions

The overall benefit/risk balance of Keytruda is considered positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include the adjuvant treatment in monotherapy of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. As a consequence, sections 4.1, 4.2, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 34.0 of the RMP has also been submitted.

<div style=\"page-break-after: always\"></div>

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I and IIIB and to the Risk Management Plan are recommended.